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Forskolin 7)$-acetoxy-8,13 -epoxy- la ,6j3,9^-trihy droxy- 
labdl4-ene-ll-one
Gi inhibitory G-protein of adenylyl cyclase 
regulation
Go G-protein of unknown function
Gs stimulatory G-protein of adenylyl cyclase 
regulation
Gpp(NH)p guanylyl 5'- imidodiphosphate
G - protein Guanine nucleotide - binding protein
GTP guanosine 5'- triphosphate
GDP guanosine 5 '-diphosphate
GDPpS guanosine 5 '-(2-O-thiodiphosphate)
GTPyS guanosine 5'-(3-0-thiotriphosphate)
HAT hypoxanthine-aminopterin-thymidine
Ig immunoglobulin
kDa kilodaltons
KLH keyhole limpet haemocyanin
mA milliamps
mRNA messenger RNA
NAD+ nicotinamide adenine dinucleotide
NEM N - ethylmaleimide
N-terminus amino terminus
PAGE polyacrylamide gel electrophoresis
PBS phosphate - buffered saline
PGEi prostaglandin El
PLC phospholipase C
PLD phospholipase D
rpm revolutions per minute
SDS sodium dodecyl sulphate
TBS tris - buffered saline
TCA trichloroacetic acid
Td transducin
TEMED N ,N, N', Nf - tetramethylethylenediamine
Tris tris (hydroxymethyl) aminomethane
Tween 20 polyoxyethylenesorbitan monolaurate
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SUMMARY
A wide variety of hormones and neurotransmitters have been shown 
to produce intracellular signals mediated by guanine-nucleotide binding 
proteins (G-proteins). These have been shown to form a link between 
receptors on the extracellular face of the cell membrane, and their 
intracellular second-message-generating effectors, such as phospholipase C 
and adenylyl cyclase. An increasing number of different heterotrimeric G- 
proteins have been isolated, with varying degrees (50-95%) of sequence 
homology. This similarity of sequence has raised questions of specificity of 
interaction of G-proteins: do individual G-proteins interact only with 
specific receptors and effectors, or are they more promiscuous in their 
interaction? This question has been addressed by examining the specificity 
of coupling of G-proteins to 0C2 -adrenergic receptors in two model 
systems.
The NG108-15 cell line is known to express an adrenergic receptor 
coupled to inhibition of adenylyl cyclase via a pertussis toxin sensitive G- 
protein. The identity of this G-protein has been determined by utilising 
antisera raised against synthetic peptides corresponding to the carboxy- 
terminal sequence of various G-proteins: the C-terminus of the G-protein 
a-subunit has been implicated as the site of receptor interaction. These 
antisera were used to show that NG108-15 cells expressed Gi2, Gi3, Go 
and Gs. G il was not detected. The adrenergic receptor in NG108-15 cells 
was shown to bind the adrenergic antagonist, pH]-yohimbine with high
affinity (Kd=2.3nM). Displacement of pH]-yohimbine binding indicated
\
that the receptor had a high affinity for both prazosin and oxymetazoline, 
which is characteristic of an 0C2B receptor. The poorly hydrolysable GTP
xiv
analogue G pp(NH)p caused a reduction in the affinity of the receptor for 
the agonist (-)noradrenaline. This change in the affinity of receptors for 
agonists is thought to be the result of uncoupling of the G-protein from the 
receptor, and this was used as an assay to identify the G-protein coupling to 
the 0C2B receptor in NG108-15 cells. Preincubation of membranes from 
NG108-15 cells with antisera raised against the C-terminal sequences of Gs, 
Go, and Gi3 did not affect the affinity of the receptor for (-)noradrenaline, 
however preincubation with the antisemm AS7, which recognises Gi2 in 
NG108-15 cells, caused a reduction in affinity of the receptor for (-) 
noradrenaline. These results suggested that the 0C2B receptor in the NG108- 
15 cells was coupled specifically to Gi2.
In order to examine the factors which govern specificity of 
interaction between G-proteins and receptors, the coupling of G-proteins to 
the OC2-C10 receptor transfected into Rat-1 fibroblasts was assessed. One 
clone was isolated which was shown to express a high level of OC2-C10 
receptor, as defined by pH]-yohimbine binding. Clone 1C bound pH]- 
yohimbine with high affinity (Kd=lnM), and displacement of yohimbine 
binding indicated that the receptor possessed a high affinity for 
oxymetazoline and a low affinity for prazosin, which is typical of an 0C2A 
receptor.
The coupling of the (X2-C10 receptor to G-proteins in clone 1C cells 
was examined by using anti-G-protein antisera. The 0C2 -adrenergic agonist 
UK14,304 was shown to stimulate a pertussis toxin-sensitive high affinity 
GTPase activity in membranes from clone 1C cells. Preincubation of 
membranes from clone 1C with anti-G-protein antisera raised against the 
C-termini of G il, Gi2, and Gi3 attenuated the UK14,304 stimulated 
GTPase activity. Preincubation with antisera against Gs or Go did not have 
this effect. These data suggest that the (X2A receptor in clone 1C cells
xv
couples to G il, Gi2, and Gi3, although the relative levels of expression of 
the G-proteins suggest that the role of Gil may be minimal.
The 0C2A receptor in the human platelet has been shown to mediate 
adrenergic inhibition of adenylyl cyclase via Gi2. It was therefore of 
interest to assess the 0C2A receptor in clone 1C cells for inhibition of 
adenylyl cyclase. UK14,304 was shown to inhibit forskolin-amplified 
adenylyl cyclase activity in membranes from clone 1C cells. This inhibition 
was pertussis toxin sensitive. Incubation of membranes from clone 1C cells 
with the antiserum AS7 completely attenuated the adrenergic inhibition of 
forskolin stimulated adenylyl cyclase, indicating that the 0C2A receptor in 
clone 1C cells was coupled to inhibition of adenylyl cyclase activity via 
;G il and Gi2. Hence, although the 0C2A receptor in clone 1C cells clearly 
activated Gil, Gi2 and Gi3 (as assessed by GTPase uncoupling), only 
Gil and' Gi2 mediate inhibition of adenylyl cyclase.
These results indicate a high degree of specificity of G-protein 
coupling to the 0C2B receptor in NG108-15 cells, but a loss of specificity in 
the case of the (X2A receptor when transfected into the Rat-1 fibroblast. The 
implications are discussed, and the suggestion is made that G-protein 
specificity of interaction with receptors and intracellular effectors depends 
on factors other than the identity of the G-protein. It is proposed that 
factors such as tissue-specific expression of G-proteins and G-protein 
compartmentalisation within the cell membrane all play a part in 
determining the specificity of interaction of G-proteins.
xvi
Chapter 1
CHAPTER 1 
INTRODUCTION
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Chapter 1
HISTORICAL
It is now axiomatic that most hormones and neurotransmitters 
interact with cell-surface receptors, and that this interaction generates an 
intracellular signal which ultimately results in the appropriate cellular 
response. These ideas were established in the late 1950s and early 1960s, 
and have become refined over the last twenty years (for review, see 
Bimbaumer, 1990). The field of signal transduction research began with 
the discovery of a ‘heat stable factor’ which was generated in response to 
catecholamine hormones and which could activate liver phosphorylase.
(Rail et al. 1957). This factor was later identified as 3',5'-cyclic AMP 
(cAMP), and the agent of its generation as the enzyme adenylyl cyclase, 
which was localised to the cell membrane (Rail and Sutherland, 1961). It 
was initially thought that the cyclase enzyme itself contained the site for 
binding hormone, albeit through a separate regulatory subunit referred to 
as the ‘discriminator’ (Robison et al. 1967). However it was shown in the 
1960s that different hormones could stimulate adenylyl cyclase activity in a 
non-additive fashion, implying that hormones, by combining with separate 
and independent binding sites, could activate a single adenylyl cyclase 
(Rodbell et al. 1969). Finally, the distinction between receptor and adenylyl 
cyclase was made clear when the p-adrenergic binding site of frog 
erythrocytes was separated from the enzyme by gel exclusion 
chromatography (Limbird and Lefkowitz, 1977). The full purification of 
the P-adrenergic receptor was not achieved until 1981 (Shorr et al. 1981) 
and purification of adenylyl cyclase itself was achieved in 1985 (Pfeuffer et 
al. 1985).
It was during 1970 that the discovery was made that receptor and 
ligand alone were insufficient to activate adenylyl cyclase. Martin Rodbell
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and his group found that glucagon stimulation of adenylyl cyclase was 
dependant on the presence of the guanine nucleotide, guanosine 
triphosphate (GTP) (Rodbell et al. 1971). Curiously, this discovery was 
made because the batches of ATP they had used as the substrate for 
adenylyl cyclase were substantially contaminated with GTP, and when new, 
purer batches of ATP were used, their assays stopped working!
Subsequently it was found that nonhydrolysable analogues of GTP 
such as guanylylimidodiphosphate (GppNHp) caused a persistent activation 
of adenylyl cyclase (Schramm and Rodbell, 1975). This contrasted with the 
transient activation due to GTP and suggested the presence of a GTP 
binding site which could both bind the guanine nucleotide and cleave it to 
GDP, ie that the GTP regulatory component of adenylyl cyclase stimulation 
was the active site of a GTPase. The demonstration that a high affinity 
GTPase activity in turkey erythrocytes was stimulated by the presence of 
catecholamine hormones which activated adenylyl cyclase confirmed this 
idea (Cassel and Selinger, 1976). Cassel and Selinger, by observing the 
kinetics of [3H]-GDP release from the regulatory subunit, further showed 
that receptor occupancy increased the rate of release of GDP (Cassel and 
Selinger, 1978). They also demonstrated that a protein product of the 
bacterium Vibrio cholerae, cholera toxin, inhibited catecholamine 
stimulated GTPase activity in turkey erythrocytes, and that this resulted in 
an enhanced activation of adenylyl cyclase (Cassel and Selinger, 1977).
They suggested that GTP hydrolysis at the regulatory GTP binding subunit 
constituted an essential ‘turn-off’ mechanism for activation of adenylyl 
cyclase.
Thus the framework for the role of G-proteins in activation of 
adenylyl cyclase was laid. A GTPase regulatory cycle was proposed, in 
which GDP bound to a regulatory subunit of adenylyl cyclase and was 
driven off and replaced by GTP following the binding of a hormone to its
3
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receptor. In the GTP bound state, the regulatory component could activate 
adenylyl cyclase. This activation of adenylyl cyclase would then be 
terminated by a GTPase activity .
The isolation of the GTP binding factor from adenylyl cyclase was 
achieved by using GTP-Sepharose to isolate a 42kDa protein identified by a 
GTP-photoaffinity probe from detergent-solubilised pigeon erythrocyte 
membrane preparations (Pfeuffer, 1977). At the same time a report 
appeared which noted a mutant murine lymphoma cell line, S49 AC" (now 
called cyc ~), in which the communication between receptor and adenylyl 
cyclase appeared to be disrupted. Initially, it was thought that these cells 
lacked the cyclase enzyme, however it was shown by Ross and Gilman 
(Ross and Gilman, 1977) that addition of a detergent extract from wild- 
type membranes which had their adenylyl cyclase inactivated could restore 
(3-adrenergic stimulated cyclase activity. Ross and Gilman showed that the 
eye - cells possessed adenylyl cyclase, but were lacking the GTP-binding 
protein (Ross et al. 1978). They called this component G/F, as it mediated 
both guanine nucleotide and fluoride ion stimulation of adenylyl cyclase, 
but it is known today as Gs, the stimulatory G-protein of adenylyl cyclase.
Identification of Gs
The eye - strain proved to be an invaluable tool for the study of 
interaction between adenylyl cyclase and its G-protein. Gilman’s group 
were able to purify Gs essentially to homogeneity from rabbit liver plasma 
membranes by assaying for reconstitution of eye - adenylyl cyclase 
stimulation (Northup et al. 1980). Cassel and Pfeuffer, while investigating 
the mechanism of action of cholera toxin, had used radiolabelled [32P] 
NAD+ as a substrate for the toxin, and had shown that this caused 
incorporation of a radiolabelled [32P] ADP-ribose group into a 42 kDa
4
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protein in turkey erythrocytes (Cassel and Pfeuffer, 1978). Using the same 
approach, Gilman’s group had found incorporation of [32P]-ADP-ribose 
into two proteins of Mr 52 and 45 kDa. In addition, they purified a protein 
of 35kDa with their factor G/F. They suggested that Gs was a dimer 
consisting of either the 52 or 45 kDa protein, associated with the 35kDa 
protein. It was later shown that Gs was in fact a heterotrimer composed of 
a, |3, and y  subunits of Mr 45, 35 and 8 kDa (Hildebrandt et al. 1984).
Why, then, were there two apparent substrates for cholera toxin in rat liver 
membranes ? It was only in 1986 that the answer was found: the mRNA for 
Gsa was shown to be differentially spliced, resulting in expression of two 
proteins, different forms of GSa> one with apparent Mr 45kDa, the other
with apparent Mr 52kDa (Robishaw et al. 1986).
Discovery of Gi
It became clear quite early on that hormonal inhibition of adenylyl 
cyclase also showed a requirement for guanine nucleotides. Rodbell and 
colleagues showed that, in a rat adipocyte preparation, inhibition of 
adenylyl cyclase occured in the absence of a stimulatory hormone and in 
the presence of low concentrations of GTP (Harwood et al. 1973). In an 
influential review in 1980, Rodbell formulated the concept of different 
forms of G-proteins (or N-proteins, as they were called); Gs, responsible 
for stimulation of adenylyl cyclase, and Gi, responsible for its inhibition. 
He also suggested that different receptors would have different G-proteins 
to transduce their various intracellular effects (Rodbell, 1980).
Several lines of investigation suggested that the GTP-binding site 
coupling inhibitory receptors to adenylyl cyclase was different from that 
coupling to stimulatory receptors, notably the observations that the 
inhibitory site was preferentially susceptible to sulfhydryl alkylation with
5
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iV-ethylmaleimide (Aktories et al. 1982) and to trypsin (Yamamura et al. 
1977). The work of Katada and Ui on pertussis toxin showed conclusively 
that “Gi” existed, and that it was a distinct moiety from Gs. They had 
shown that (X2 -adrenergic receptors inhibited adenylyl cyclase in pancreatic 
islet cells, and that this inhibition was attenuated by a toxin from the 
bacterium Bordetella pertussis, the causative organism of whooping cough 
(Katada and Ui, 1979). They further showed that the target of pertussis 
toxin was a membrane protein of 41 kDa, which was the substrate for the 
toxin’s ADP-ribosyl -transferase activity (Katada and Ui, 1982a), and that 
this protein was distinct from Gs (Katada and Ui, 1982b). Studies using 
the eye - cell line showed that receptor-mediated inhibition of adenylyl 
cyclase occurred even in the absence of Gs, and that pertussis toxin could 
prevent this inhibition, indicating that the 41 kDa protein identified by 
Katada and Ui was “Gi”, the inhibitory G-protein of adenylyl cyclase 
(Hildebrandt and Bimbaumer, 1983; Hildebrandt et al. 1983). It was also in 
1983 that the first reports of “Gi” purification appeared, showing it to be a 
multisubunit protein with the a-subunit being the site for pertussis toxin 
catalysed ADP-ribosylation. Bokoch et al. purified “Gi” from rabbit liver, 
and found it to be a 41 kDa protein (Bokoch et al. 1983), however Codina 
et al. purified it from human erythrocytes, and found it to be a 39kDa 
protein (Codina et al. 1983). This was the first suggestion of G-protein 
heterogeneity; that there might be multiple forms of “Gi”.
Actions of cholera and pertussis toxin
The study of the identity and function of G-proteins has been greatly 
aided by the use of bacterial exotoxins. In particular, the roles of cholera 
and pertussis toxin have already been mentioned. Both toxins are 
oligomeric proteins with an A-B structure (Gill, 1977), in which a B-
6
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oligomer binds to particular cell-surface receptors, enabling penetration of 
the cell by the A-oligomer, wherein it acts as an ADP-ribosyltransferase, 
catalysing the transfer of ADP-ribose from NAD+ to the membrane G- 
proteins which are its substrates. Cholera toxin action requires the presence 
of a cofactor, ARF (ADP-Ribosylation Factor), which itself binds GTP 
(Kahn and Gilman, 1984).
To early investigators into the action of adenylyl cyclase their 
effects appeared to be similar in that both toxins resulted in elevated 
cAMP levels, and both toxins rendered receptors insensitive to hormones 
(stimulatory hormones, in the case of cholera toxin, and inhibitory 
hormones, in the case of pertussis toxin). We now know that these effects 
are due to their actions on “Gi” and Gs, which work in opposition on the 
activation of adenylyl cyclase. Exposure of cells to cholera toxin results in 
ADP-ribosylation of an arginine (Arg 2°1) residue near the GTP binding 
site of Gs (Van Dop et al. 1984). This modification prevents the cleavage 
of the terminal phosphate of GTP to GDP, thus Gs becomes constitutively 
activated, and adenylyl cyclase activity in cholera toxin treated cells is 
elevated (Cassel and Pfeuffer, 1978).
In contrast, treatment of cells with pertussis toxin resulted in loss of 
the ability to inhibit adenylyl cyclase: it was shown that pertussis toxin 
ADP-ribosylated a cysteine residue four amino acids from the C-terminus 
of the “Gi”- a-subunit and that this prevented functional interaction 
between the G-protein and its receptor (Ui et al. 1984; West et al. 1985). 
This is often referred to as “uncoupling” the G-protein from its receptor. 
Unlike cholera toxin catalysed ADP-ribosylation of Gs, where Gsa is the
substrate, pertussis toxin will only ADP-ribosylate the GDP-liganded a(3y 
heterotrimer of “Gi” ( Mattera et al. 1987).
Thus it became possible to distinguish and identify Gs and Gi by use 
of cholera and pertussis toxin, and for a number of years this was the only
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method of detection of G-proteins. However, the realisation that G-proteins 
were more heterogenous than had at first been suspected, and also the 
finding that some receptors, particularly those coupled to 
phosphpJptf£  ^ (  \  were immune to the effects of both toxins,
led to the development of new and more specific methods of G-protein 
detection (see below).
G-PROTEIN STRUCTURE 
1. Alpha Subunit
a: sites for guanine nucleotide binding and GTPase activity
The elucidation of the structure of G-protein alpha subunits has been 
greatly aided by the X-ray crystallographic analysis of two GTP binding- 
proteins related to the heterotrimeric G-protein family, namely the 
bacterial elongation factor involved in ribosomal protein synthesis, EF-Tu 
(Jumak, 1985; La Cour et al. 1985), and the product of the Ras gene, 
p2 lras (de Vos et al. 1988). Similarities in the 3-dimensional structures of 
both of these proteins has allowed extrapolation of structural features, 
particularly with regard to GTP-binding domains and GTPase activity to 
members of the heterotrimeric G-protein family.
The primary sequences of EF-Tu and p21ras were first compared by 
Halliday, who identified four conserved stretches (designated A,C,E, and 
G) which, she predicted, would form part of the guanine-nucleotide 
binding domain (Halliday, 1984). Comparison of the primary amino-acid 
sequences of seven G-protein a-subunits aligned with a hypothetical a avg 
by Masters et al. (Masters et al. 1986) also revealed a remarkable degree of 
conservation of sequence, confirming that these same regions were present
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in the heterotrimeric G-protein a-subunits. From their comparisons of oc- 
subunits, and using the 3-dimensional structure of EF-Tu as a model, 
Masters et al. were able to predict the 3D structure of their a avg (Figure 
1.1). Halliday region A lies in a region important for the regulation or 
hydrolysis of bound GTP. Mutation of this region in ras proteins results in 
a reduced GTPase activity (Barbacid, 1987). Region C also appears to be 
important in the hydrolysis of GTP, lying as it does near the terminal 
phosphate of the guanine nucleotide and in close proximity to the Mg2+ 
ion. Regions E and G contain conserved hydrophobic amino-acids, 
suggesting that they form a hydrophobic pocket to facilitate binding of the 
guanine ring. Again, mutations in this region of p21ras results in lowered 
binding affinity for guanine nucleotides (Sigal et al. 1986).
The crystal structures for EF-Tu and p21ras were obtained for the 
GDP bound proteins. Of major interest, however, is the conformational 
change brought about by the exchange of GTP for GDP, since it is this 
event which activates the G-protein a-subunit. Recently the structure of the 
Gpp(NH)p-activated Haras p21 protein has been analysed (Pai et al. 1989). 
There appeared to be two major conformational changes upon activation. 
Firstly, a putative effector loop between He21-Gly48 (in Halliday region A) 
appeared to have shifted, consistent with an interaction with the terminal 
phosphate of GTP (Jumak et al. 1990). The second, and most dramatic, 
conformational change occurred in a polypeptide sequence of 20 amino 
acids in Halliday region C, beginning with Asp57, the side chain of which is 
thought to be important in coordination of the Mg2+ ion. This segment 
appears to turn through 120 on activation, bringing the amido- group of 
Gly60 into close proximity to the y-phosphate of GTP (Jumak et al. 1990).
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Figure 1.1
The predicted GDP-binding domain of q avp
Adapted from Iyengar R and Bimbaumer L, Eds. “G-proteins”, page 26,
Academic Press 1990.
NH pY Binding
225;
COOH
H21a
228'
;229;
Trypsin
Hinge
I Diagram of the predicted GDP-binding domain of aavg (Masters et al., 1986), 
based on the crystal structure of the corresponding domain of EF-Tu (Jumak, 1985). The 
GDP molecule (G, guanine ring; R, ribose; P, phosphoryl) nestles into a binding siie bounded * 
by turns between p  strands and a  helices; these turns are located in the stippled regions, 
designated A, C, E, and G, which corresDond to _the . four stretches of similar amino-acid 
sequence first noted by Halliday (1984) j
| Key amino -acid residues, numbered in accord with a ,vg, are indicated by single letters . 
(D, Asp; G, Gly; Q, Gin). The predicted hinge region where flexion is thought to be blocked 
by the H2 la mutation at Gly228 is indicated by an arrow, as is the site where tryptic cleavage is 
prevented by activation of the a  chain.
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While these structural observations have been obtained for p21ras and EF- 
Tu, the conservation of sequence across the range of guanine-nucleotide 
binding proteins makes it likely that similar conformational changes will be 
found to occur in the heterotrimeric G-proteins.
b: Sites for interaction with receptor, effector and py
Comparison of the primary sequences of G-protein a-chains reveals three 
major regions of sequence divergence (Regions I, n , and III ill Figure 1.1). 
As the specificity of a-subunits depends upon their ability to interact with 
distinct effector and receptor combinations, one would expect that these 
regions of dissimilarity might encode the receptor- and effector- coupling 
regions, while the regions of sequence similarity would represent regions 
common to the function of all G-proteins, ie. guanine nucleotide binding 
and cleavage.
There is now substantial evidence that the carboxy-terminal region 
of the a-subunit is the site for receptor coupling (Region m , Figure 1.1). 
Firstly, pertussis toxin catalysed ADP-ribosylation of a cysteine residue 
(which is conserved in the various forms of Gi, Go, and transducin) four 
amino acids from the C-terminus blocks receptor interaction with G- 
proteins (Ui et al. 1984), and prevents binding of transducin to rhodopsin 
(Van Dop et al. 1984). A mutant of the S49 murine lymphoma cell line, 
called unc , which does not show hormonal stimulation of adenylyl cyclase 
(Haga et al. 1977) was shown to contain a mutated form of Gs, in which a 
single amino acid substitution six amino acids from the C-terminus 
(Arg—>Pro) accounted for the lack of interaction with receptor (Sullivan 
et al. 1987).
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Bourne’s group also showed that construction of a chimaeric a- 
subunit composed of the N-terminal 60% of murine Gi2 and the C-terminal 
40% of murine Gs when expressed in eye - cells resulted in P-adrenergic 
stimulation of adenylyl cyclase (mediated by Gs), but not somatostatin 
inhibition of cyclase (mediated by Gi) (Masters et al. 1988). The 
implication of this result was that the C-terminal portion of Gs conferred 
on the a-subunit its ability to interact with the P-adrenoceptor, however 
the chimaeric a-subunit would not couple to the somatostatin receptor 
because it contained only the N-terminal part of Gi, and not the C-terminal 
portion important for receptor coupling.
Finally, it has been shown by two groups that a-subunit specific 
antisera raised against the C-terminal decapeptide sequence are capable of 
uncoupling G-proteins from their receptors. McKenzie and Milligan used 
antiserum AS7, raised against the C-terminal sequence of Gi2, to block 8 - 
opioid receptor mediated inhibition of forskolin stimulated adenylyl cyclase 
(McKenzie and Milligan, 1990) and Simonds and Spiegel showed that the 
adrenergic receptor in human platelets was coupled to adenylyl cyclase via 
Gi2 by using the same antisemm, AS7, to prevent norepinephrine 
inhibition of PGEi stimulated cyclase (Simonds et al. 1989a).
By contrast, the region which couples the a-subunit to its effector is 
not known. Bourne suggested that Region II (Figure 1.1) might be 
responsible (Masters et al. 1986), however the later results from Bourne’s 
group, discussed above (Masters et al. 1988) tend to refute this idea, since 
the Gi2/Gs chimaera they constmcted contained Region II from Gi2, yet 
this a-subunit did not behave like “Gi”, being unable to mediate 
somatostatin induced inhibition of cyclase, and instead behaved like Gs. 
Osawa et al. have recently constructed their own Gs/Gi2 chimaeras and 
expressed them in COS cells to examine the site for effector-G-protein 
contact (Osawa et al. 1990). They varied the proportions of Gs and Gi and
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were able to identify a region of 122 amino acids (Ile235-Arg336) which 
was involved in interaction of Gs with adenylyl cyclase.
The region responsible for a-subunit interaction with Py subunits 
appears to be the N-terminus. Tryptic cleavage of the 21 N-terminal 
amino-acids from rod cell transducin destroyed its ability to bind to py 
(Navon and Fung, 1987). The Gi2/Gs chimasras constructed by Osawa also 
threw some light on the py interaction site. They found that mutation of the 
N-terminus prevented regulation of the rate of guanine nucleotide release - 
one of the functions ascribed to the py subunit. They also suggested that the 
C-terminus and N-terminus of Ga must be spatially close together, since 
one of their chimasras with a mutated N-terminus inhibited the pertussis 
toxin catalysed ADP-ribosylation of the C-terminal cysteine of Gi2 (Osawa 
et al. 1990).
C: Membrane Attachment
The hydrophilic nature of much of the a-subunit would suggest that it can 
readily be extracted from the membrane. In fact, most G-proteins require 
the use of a detergent before they can be removed from the membrane.
This begs the question: are the a-subunits attached in some way to the 
membrane? It has been well documented that the protein products of ras 
genes have C-terminus-linked palmitate groups (Barbacid, 1987), and the 
src oncogene product is N-myristylated (Schultz et al. 1985). Both of these 
lipids have hydrophobic properties which would allow the formation of a 
membrane anchor. It appears that G-protein a-subunits may be similarly 
acylated. Schultz et al. used reverse-phase HPLC to detect myristate in Goa 
( Schultz et al. 1987). At the same time, Gilman’s group demonstrated the 
incorporation of [3H]-myristic acid into Go, Ga40 and Ga4 i a-subunits -
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but not into Gs or the (3-subunit (Buss et al. 1987). A variety of N- 
myristylated proteins share a consensus sequence (Met-Gly-X-X-X-Ser) 
which also appears in the sequence of Go, “Gi”,and transducin a-subunits, 
but is lacking in Gsa, (336 and P35 and transducin y (Schultz et al., 1987). 
One form of post-translational modification which seems to be lacking in 
a-subunits is C-terminal isoprenylation. Despite possessing the “CAAX 
box” sequence required for cysteine-linked isoprenylation (see below, in 
discussion of Py-subunit structure) it appears that none of the Gi or Go 
subunits are modified in this way (Sanford et al. 1991). It has also been 
shown that Gil can only become a substrate for such a modification if the 
carboxy terminus is mutated (Jones and Spiegel, 1990).
2 . py subunit
Although the P and y subunits are not covalently linked, they clearly 
form a single functional unit, as they cannot be dissociated without 
denaturing the proteins. Also, it is not known whether the functions of the 
Py subunit are due to one or other of the proteins alone.
Their are two major forms of p-subunit, with molecular weights of 
35- and 36-kDa, (Stemweis and Robishaw, 1984) with the 36kDa form 
predominating in most tissues (Woolkalis and Manning, 1987). These two 
forms, sometimes denoted pi and p2 appear to be the products of two 
separate genes located on chromosomes 1 and 7 respectively (Lochrie and 
Simon, 1988). The cDNAs for the two forms share 90% homology (Fong 
et al. 1987). Neither sequence suggests membrane spanning domains, 
special hydrophobic regions or signal sequences for glycosylation, etc, 
although the sequences for Pi and p2  are strictly conserved across a
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number of mammalian species, suggesting that the two forms may have 
distinct functions (Neer and Clapham, 1990). Both forms of p subunit show 
similarities to the C-terminal region of the yeast cell division cycle gene 
CDC4, although the significance of this fact is not yet clear (Fong et al.
1986).
If less is known about the structure of the P-subunit than the a-, then 
the y-subunit is even more mysterious. There do appear to be different 
forms of y-subunit, and there is evidence that the y-subunit from transducin 
is different to that in brain or erythrocyte G-proteins (Hildebrandt et al.
1985). The cDNA for transducin y-subunit has been cloned and shown to 
encode a hydrophilic protein (Van Dop et al. 1984; Yatsunami et
al. 1985). It has recently been shown that the y-subunit is capable of being 
isoprenylated. The carboxy terminus of brain y-subunit was shown to 
contain the Cys-A-A-X sequence (Cysteine, A=aliphatic, X= any amino 
acid) which occurs as the signal for cysteine thioester isoprenylation in 
p21ras. Mutant forms of p21ras which lack this “CAAX box” have been 
shown not to associate with the membrane, and hence are not transforming, 
suggesting that this modification is important in locating the protein at the 
membrane (Willumsen et al. 1984). The heterotrimeric G-protein y- 
subunit, trans k-beJ, in reticulocyte lysate was shown to be labelled with 
the isoprenoid precursor pH]-mevalonate (Maltese and Robishaw, 1990). A 
number of other groups have also demonstrated C-terminal isoprenylation 
of y-subunits (see Mumby et al. 1990; Lai et al. 1990; Sanford et al. 1991).
The hydrophilic character of the a-subunits, together with the 
relative hydrophobicity of the py subunit has led to the suggestion that the 
Py subunit forms a membrane anchor for the a-subunit (Stemweis, 1986). 
Stemweis observed that purified a-subunits did not associate with 
phospholipid vesicles unless in the presence of Py-subunits. It is clear 
however, that many a-subunits are myristoylated, or at least are capable of
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myristoylation, which makes it a less than compelling argument that this is 
the only role of the (3y subunit (see below).
G-PROTEIN HETEROGENEITY
It became clear that there were more than two G-proteins, Gs and 
“Gi”, in 1984, when the search for “Gi” led to the finding of multiple 
pertussis toxin substrates in bovine brain, where a 39kDa protein was 
found in addition to the familiar 41kDa pertussis toxin substrate (Stemweis 
and Robishaw, 1984). This was simply the beginning of a flood of new G- 
protein discoveries. Initially, G-proteins were detected by virtue of their 
susceptibility to modification by pertussis or cholera toxin, and because of 
their differential positioning on SDS-polyacrylamide gels, but nowadays 
they appear as the result of molecular biology studies. This has allowed the 
detection of G-protein a-subunits for which there are, as yet, no functions 
(eg. Strathmann et al. 1989: Libert et al. 1989). Table 1.1 shows the 
variety of G-protein forms and functions. The diversity of G-protein 
subunits has recently been reviewed (Simon, et al. 1991).
It was noted earlier that there are at least two forms of Gs*(52 and 
45kDa) responsible for the stimulation of adenylyl cyclase. To date four 
very similar cDNAs for Gsa have been detected in human brain (Bray et 
al. 1986). It seems likely that all four cDNAs are produced from a single 
gene by differential splicing (Kozasa et al. 1988). In addition to stimulation 
of adenylyl cyclase, Gs has also been shown to activate dihydropyridine- 
sensitive Ca2+ channels (Yatani et al. 1987). A form of Gs, known as
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“Golf” is expressed only in olfactory tissues, and presumably mediates 
stimulation of adenylyl cyclase in response to smell (Jones and Reed, 1989; 
Lancet and Pace, 1987).
The nature of “Gi” , the pertussis toxin sensitive inhibitory G-protein 
for adenylyl cyclase is less clear. Three closely related forms of Gi were 
cloned from rat C6  glioma cells and a human genomic library (Itoh et al.
1988). These forms, classified as G il, Gi2, and Gi3, appeared from Itoh’s 
study to be the products of different genes, and have since been detected in 
a variety of species and tissues (see Lochrie and Simon, 1988 for review). 
The three forms of “G £ show a remarkable degree of sequence homology, 
the overall level being -90%, with Gi^and Gi^sharing 95% homology. 
Theirymolecular masses are ~40kDa (Gi2) and ~41kDa (Gil and Gi3).
Their functions, despite this homology, seem to vary. All three have been 
shown, in the purified, recombinant form, to open atrial K+ channels 
(Yatani et al. 1988). Gi2 has been identified as the inhibitor of adenylyl 
cyclase in a number of systems (Simonds et al. 1989a; McKenzie and 
Milligan, 1990; McClue and Milligan,1990), and in the case of 
neutrophilic cell lines, Gi2 and Gi3 have been implicated in coupling of 
chemoattractant receptors to phospholipase C (Gierschik et al. 1989).
Go is the major pertussis toxin substrate in brain, accounting for a 
remarkable 1% of total brain protein. It was first discovered in 1984 
(Stemweis and Robishaw, 1984; Neer et al. 1984) and has a Mr of 39kDa. 
Goa has 82% homology with Gil/Gi3a, and only 50% homology with Gsa 
(Van Meurs et al. 1987). It now seems likely that there are different forms 
of Go, variously called Goi, G0 2 , and Go*. Studies on brain initially 
demonstrated the occurrence of two forms of Go, called Go and Go* 
(Goldsmith et al. 1988). More recently, it has been shown that at least two 
more forms exist in bovine brain (Kobayashi et al. 1989; Padrell et al. 
1991). Go is poorly expressed in peripheral tissues (Homburger et al.
17
Chapter 1
TABLE 1,1: G-PROTEIN HETEROGENEITY
G-protein Size
0
Function Reference
Gs 45, 52kDa Adenylyl cyclase stimulation Bray et al. 1986
Golf 45, 52kDa Adenylyl cyclase stimulation Jones and Reed 1987
Gil 41kDa K+ channel Itoh et al. 1988
Gi2 40kDa inhibition of adenylyl cyclase Itoh et al. 1988
Gi3 41kDa K+ channel Itoh et al. 1988
Go 39kDa Ca2+ channel Stemweis et al. 1984
Gz 41kDa Phospholipase C stimulation? Fong et al. 1988
Gp(Gq) 42kDa Phospholipase C stimulation Pang et al. 1989
G 12- I 6 ? unknown Simon et al. 1991
Tdi 40kDa cGMP phosphodiesterase Lerea et al. 1986
Td2 40kDa cGMP phosphodiesterase Lerea et al. 1986
P l - 3 35-37kDa unclear Levine et al. 1990
y  1-4 8-9kDa unclear Gautam et al. 1990
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1987). This makes it likely that the function of Go is one exclusive to 
nervous tissues, and indeed there is now considerable evidence that Go is 
responsible for coupling neurotransmitter receptors to voltage operated 
Ca2+ channels (VOCCs). Hescheler et al. demonstrated that Go was 
responsible for coupling opioid receptors to Ca2+ channels in NG108-15 
neuroblastoma x glioma cells (Hescheler et al. 1987), and Harris-Warrick 
et al. have shown that antibodies raised against Goa blocked dopamine- 
induced reductions in VOCCs in snail neurons (Harris-Warrick et al.
1988).
While it is clear that a G-protein is involved in coupling receptors to 
phospholipase C (PLC), the identity of the G-protein(s) involved is 
unknown, and is the subject of much study (for review, see Boyer et al.
1989). One of the problems facing researchers into the G-protein involved, 
known as Gp, is that in many cases, receptors coupled to PLC are 
unaffected by either pertussis or cholera toxin. In addition, it seems almost 
certain that there will be different forms of Gp, if only for the reason that 
there are a number«f isozymes of PLC (see also Boyer et al. 1989).
Strathmann and Simon in 1989 used the polymerase chain reaction 
on mouse brain and sperm and, in addition to the well known G-protein a- 
subunits, they also detected five unknown a-subunits (Strathmann et al.
1989). Analysis of the sequences of some of these a-subunits led Simon and 
Strathmann to suggest that a separate class of toxin-insensitive a-subunits 
existed, and that they might be involved in coupling receptors to PLC 
(Strathmann and Simon, 1990). One member of this class is Gq, isolated by 
Pang and Stemweis by using an affinity chromatography column of 
immobilised py-subunits (Pang and Stemweis, 1989) and which appeared 
to be a 42kDa protein, insensitive to pertussis toxin, and not recognised by 
antibodies against any known G-protein (Pang and Stemweis, 1990). Gq©r 
has only 50% homology with members of the “G £ group, or with Gs^and
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lacks the cysteine residue at the C-terminus which is the site for pertussis- 
toxin ADP-ribosylation. It also lacks the sequence for N-terminal 
myristoylation (Strathmann and Simon, 1990). Gq has now been shown to 
be capable of regulating the p i isozyme of PLC (Smrcka et al. 1991;
Taylor et al. 1991).
Another potential member of the “Gp” family is Gz, which was 
cloned from a human retinal cDNA library, and, again, lacks the site for 
pertussis toxin catalysed ADP-ribosylation (Fong et al. 1988). The mRNA 
for Gz appears to be localised to nervous tissue but the function of Gz 
remains speculative. At the same time as Fong et al. isolated Gz, Matsuoka 
et al. isolated the cDNA for another pertussis toxin -insensitive G-protein 
a-subunit, which they called Gx, from rat brain (Matsuoka et al. 1988), but 
it seems likely that Gx and Gz are identical. Gz/x^ cDNA encodes a protein 
of 355 amino acids with a Mr of ~ 41kDa, the mRNA for which appears 
mostly in brain tissues (Matsuoka et al. 1990).
The G-proteins involved in visual transduction, the transducins, 
occur in two forms. Tdi is localised to rod cell outer segments, while Td2  
occurs only in cone cells (Lerea et al. 1986). They have been extensively 
studied, due to their abundance in visual tissues and due to the fact that they 
can be easily extracted without the use of detergents (for review see Stryer, 
1986). The sequences of the two transducins differ in -20% of the amino 
acids, but both encode proteins of ~40kDa. Their function is clear. They 
couple their light-activated receptors to cGMP phosphodiesterase, resulting 
in a rapid drop in cGMP levels which ultimately causes hyperpolarisation 
of the rod or cone cell, leading to transmission of a nerve impulse (Stryer,
1986).
Just as there are multiple forms of the G-protein a-subunits, it is 
now becoming clear that there are also many forms of the p- and y- 
subunits. There are, to date, three forms of the P-subunit. p i and p2  have
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molecular masses of 36 and 35kDa respectively, which are the products of 
different genes, and which differ in 1 0 % of their amino-acid sequence 
(Gao et al. 1987; Amatruda et al. 1988). Recently, (33 has been cloned from 
human and bovine retinal cDNA libraries (Levine et al. 1990). Apparently 
ubiquitously expressed, (33 has an Mr of~37kDa, and shares 83 and 81% 
homology with (31 and (32, respectively (Levine et al. 1990).
There are at least 4 forms of the y-subunit. The first y-subunit cloned 
(yi) was that from bovine retinal transducin (Hurley et al. 1984). This 
cDNA encodes a protein of Mr 8400, which was shown to be both 
hydrophilic and acidic. Furthermore, the C-terminus contained a CAAX 
box (see discussion of (3y structure, above), the putative signal for carboxy- 
terminal isoprenylation in ras oncogene products (Hurley et al. 1984).
Since then, three other y-subunits have been cloned: J2 from brain and 
liver (Gautam et al. 1989), and recently y3 and y4  from mouse and bovine 
brain (Gautam et al. 1990). Immunoblot analysis of the tissue distribution 
of these y-subunits suggested that yi was expressed solely in retina, y3 only 
in brain, and that y2  was ubiquitously expressed (Gautam et al. 1990). This 
suggests that, as with the a-subunits, some forms of y-subunits are tissue 
specific.
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F igure 1.2
The cvcle of G-protein activation and inactivation.
Reproduced from Milligan, 1988.
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G-PROTEIN FUNCTION
A. a-subunit function
The model of G-protein function proposed by Cassel and Selinger 
(1977) has, with some modification, been found to be generally applicable 
to the mechanism of action of G-proteins. Figure 1.2 illustrates the general 
principle. Binding of a ligand to its receptor causes a conformational 
change in the receptor (see adrenergic receptors, below). This 
conformational change promotes the dissociation of GDP from the G- 
protein a-subunit, and the rate of GTP association with the a-subunit 
increases. In the GTP-bound state, the a-subunit dissociates both from its 
receptor, and also from its Py subunits. It is now said to be in an 
“activated” state, in that it can now interact with its intracellular effector. 
This activation of the G-protein a-subunit, and subsequent dissociation 
from its receptor also affects the receptor, which now shows a lowered 
affinity for its ligand (thereby increasing the “off-rate” of the ligand from 
the receptor, ie. promoting the release of the ligand from the receptor). 
The activated G-protein a-subunit now interacts with its effector until the 
intrinsic GTPase activity cleaves the terminal phosphate from GTP, 
returning the a-subunit to its inactive state, in which it can now re­
associate with both its Py-subunits, and its receptor. The various sequences 
of this model will now be discussed. A review of the kinetics of guanine 
nucleotide binding and hydrolysis is provided by Casey and Gilman (Casey 
and Gilman, 1988).
1. Guanine-nucleotide exchange
Hormone-receptor induced dissociation of GDP from the a-subunit 
is a Mg2+ dependant event (Brandt and Ross, 1986). The presence of
23
Chapter 1
hormone lowers the concentration of magnesium required for GTP binding 
- eg. glucagon lowers the Mg2+ concentration required for GTPy5 
activation of Gs from 25mM to lOjiM (Iyengar and Bimbaumer, 1982). As 
the intracellular concentration of Mg2+ is around 2mM, this ensures rapid 
activation of Gs on hormone stimulation. The Mg2+ ion is also vital for 
GTP-induced activation of the a-subunit, and for its GTPase activity. The 
importance of Mg2+ in the conformational change has been assessed by 
measuring the intrinsic tryptophan fluorescence of Gi and Go o(-5«J>un’rt5; 
(Higashijima et al. 1987a). In the absence of Mg2+, binding of GTP 
produces little change in fluorescence, but fluorescence is greatly enhanced 
in the presence of Mg2+, and then decays in parallel with the hydrolysis of 
GTP->GDP (Higashijima et al. 1987b).
The rate of spontaneous GDP dissociation from the a-subunit is slow 
(<0.1/min) (Ferguson et al. 1986). This helps to stabilise the apy  
heterotrimer until receptor occupation, which increases the rate of GDP 
dissociation (Brandt and Ross,1986). The high concentration of GTP in the 
cell then ensures that the nucleotide binding site is rapidly occupied by 
GTP. Recent studies on the guanine nucleotide binding properties of 
purified G il, Gi2, and Gi3 have suggested that the rate of GDP release and 
GTP binding may be different for each a-subunit, eg. Gi^binds GTPyS 
and releases GDP more rapidly than Gi^and Gi^(Carty et al. 1990). The 
importance of these differences in activation kinetics remains to be 
assessed.
2. Dissociation of a -su b u n its
Little is known about the mechanism of GTP-induced dissociation of 
a-subunit from receptor and Py subunits. The first observation of subunit 
dissociation was provided by Howlett and Gilman (Howlett and Gilman, 
1980) who noticed that persistent activation of Gs withGpp(NH)p caused a
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Wreggett and De Lean (1984) model some systems (eg. receptors 
which inhibit adenylyl cyclase) where antagonist binding is affected by the 
presence of guanine nucleotides. Their analysis suggested that in the 
presence of guanine nucleotides, antagonist binding may be increased, 
although they note that this property may be related to the potency of the 
ligand rather than to intrinsic activity (see De Lean et al. 1980).
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decrease in the size of Gs. In 1981, Stryer et al. showed that this was due to 
dissociation of the heterotrimer into a - and py-subunits, one of which (the 
a-subunit) still had (ppp(NH)p associated with it (Fung et al. 1981). It has 
been shown that persistent guanine nucleotide activation results in release 
of the a-subunit from the membrane, implying that physical dissociation 
can occur, (Milligan et al. 1988) and Rodbell has suggested that this 
released a-subunit could form another intracellular second messenger 
(Rodbell, 1985), however receptor-generated release of a-subunits has yet 
to be demonstrated.
3. G-protein modulation of receptor-Iigand affinity
One of the first observations of the effects of G-proteins was the 
demonstration of the ability of guanine nucleotides to modulate receptor 
affinities for ligands. In particular, it was repeatedly observed that GTP 
and its analogues caused a reduction in radiolabelled agonist binding (eg. 
Rodbell et al. 1971; Maguire et al. 1976; Berrie et al. 1979). It became 
clear that this effect was confined to agonist binding, and not to antagonist 
binding, as the result of studies on the displacement by agonists of P- 
adrenoceptor antagonist binding (Maguire et al. 1976). De Lean suggested 
the “ternary complex” model, in which there are two affinity states for the 
P-adrenoceptor, high and low, which are recognised by agonists, and which 
can be interconverted by GTP and its analogues (De Lean et al. 1980). The 
presence of GTP or 6 pp(NH)p causes the receptor to adopt a configuration 
of low affinity for its agonist, while the absence of GTP results in a high 
affinity state, antagonist binding being unaffected by the presence of 
guanine nucleotides (Wregget and De Lean, 1984). It is now clear that 
agents such as GTP, #pp(NH)p, and (in the case of “Gi”) pertussis toxin, 
which cause uncoupling of G-proteins from their receptors (ie. the 
dissociation of the activated a-subunit) all produce an apparent lowering of
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the affinity of the receptor for its agonist, presumably as the result of a 
conformational change in the receptor caused by a-subunit uncoupling. 
This lowering of receptor affinity for its agonist would promote 
dissociation of that agonist, and coupling to a fresh molecule of GDP- 
liganded G-protein.
Receptor affinity changes occur rapidly enough to allow one 
receptor to interact with a number of molecules of G-protein, this being 
one of the main methods of amplification of hormone-generated signals. It 
has been estimated that one P-adrenergic receptor can activate over six 
molecules of Gs (Brandt and Ross, 1986) within the timespan from the 
activation of the first Gs until its de-activation by GTP hydrolysis.
This change in receptor affinity has been used by a number of 
groups to infer the action of G-proteins on their receptor systems (eg. 
Rodbell 1980; Kurose et al. 1983). One group has observed that G-protein- 
specific antisera can also cause changes in receptor affinity by uncoupling 
a-subunits from receptors, and used this as a method of identifying Gi2 as 
the G-protein coupling the 6 -opioid receptor to adenylyl cyclase inhibition 
( McKenzie and Milligan, 1990).
4. Interaction with effector
This is one of the areas of ignorance in G-protein ^ research. The 
domain for G-protein-effector interaction is unclear, although the work of 
Osawa suggests that this may lie in the a-subunit C-terminal region (Osawa 
et al. 1990). Exactly how the a-subunit interacts with its effector is not 
known. Levitzki has argued that Gs and its effector, adenylyl cyclase are 
coupled in vivo (Arad et al. 1984), but this idea has not been widely 
accepted (see Gilman, 1987).
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5. GTP hvdrolvsis
Bourne and colleagues have frequently suggested that the GTPase 
activity of G-proteins (and not only the heterotrimeric G-proteins) is a 
kind of molecular switch, with the “on” position being generated upon 
binding of GTP, and the “o ff’ position by its hydrolysis (see Bourne et al. 
1990, for example). GTP hydrolysis, depending on its rate, acts as a 
“timer”, allowing one activated G-protein a-subunit to interact with a 
number of effector molecules until the timer is switched off by the GTPase 
activity.
The rate of GTP hydrolysis is comparatively slow. The Km for GTP 
in the GTPase reaction is 0.3jiM (Brandt and Ross, 1985), and the catalytic 
rate, kCat for GTP is around 2-4/min, (Graziano and Gilman, 1989; Brandt 
and Ross, 1986) so the lifetime of Ga-GTP is many seconds. This allows 
the activated a-subunit to interact with a number of effector molecules, 
providing amplification of receptor-generated signals. It has been estimated 
that activated Gs can interact with adenylyl cyclase to generate over 500 
molecules of cAMP, and as a single receptor can activate a number of 
molecules of Gs, the true amplification is likely to be greater than this 
(Higashijima et al. 1987b).
As has already been noted, the rate of GDP dissociation from the a- 
subunit is slow, and the catalytic rate for GTP hydrolysis exceeds this by an 
order of magnitude, hence the rate limiting step in GTP hydrolysis is GDP 
release (Ferguson et al. 1986). Agonist presence does not affect steady state 
GTP hydrolysis, and by contrast with the comparatively high concentration 
of Mg2+ (IOjiM) required for GTP binding, hydrolysis of GTP requires 
only 20nM Mg2+ (Brandt and Ross, 1986). The turnover time for Gs to 
traverse a complete catalytic cycle is of the order of 0.8 min-1 (Brandt and 
Ross 1986).
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There are two general models of how Py subunits might inhibit 
adenylyl cyclase. Firstly, as discussed in the text, they could inhibit 
adenylyl cyclase directly. Secondly, dissociation of “Gi” after receptor 
activation could lead to generation of free py subunits which then might 
associate with the a-subunit of Gs, causing it to return to a resting state in
which it is not activating adenylyl cyclase. In this model, “Gi” acts as a 
reservoir of Py, which, on receptor stimulation, can buffer the release of 
Gsa. For a review of this “mass action” theory of adenylyl cyclase 
inhibition , see Gilman, 1987.
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B. py-subunit function
The idea that the Py subunit has a function other than the simple 
physical one of a membrane anchor for the a-subunit is somewhat 
contentious. There is evidence that purified Py-subunits can activate 
muscarinic-gated K+ channels in chick embryo heart (Logothetis et al. 
1988). Py subunits have also been suggested to stimulate phospholipase A2 
(PLA2 ) in rod-outer segments, (Jelsema and Axelrod, 1987) and indeed the 
effect on K+ channels may be mediated by PLA2  (Kim et al. 1989). It is the 
proposed effect of Py on adenylyl cyclase inhibition that generates the 
greatest controversy, however.
Py subunits and inhibition of adenvlvl cvclase
The question of the identity of the moiety which is responsible for 
the inhibition of adenylyl cyclase has become confusing and somewhat 
vexatious. The group led by Neer and Clapham have consistently 
challenged the orthodox view that it must be the a-subunit of “Gi” which 
inhibits adenylyl cyclase. In a recent review (Neer and Clapham, 1990) 
they muster their evidence. They point out that it has been difficult directly 
to demonstrate inhibition of adenylyl cyclase by G-protein a-subunits.
They also note the results of Katada (Katada et al. 1987) who inhibited the 
catalytic subunit of adenylyl cyclase from bovine brain by addition of 
purified Py subunits. This result was attributed to the association of py 
subunits with calmodulin, the Ca2+ chelator which can activate bovine 
brain adenylyl cyclase (Salter et al. 1980) and the subsequent removal of 
this calmodulin activation of cyclase. More recently the cDNAs for the a- 
subunits of G il, 2 ,3 and Go were expressed in E. coli, purified, and used
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in reconstitution experiments, (Linder et al. 1990) where it was shown that, 
despite activation of Gsa with GTP7S or forskolin, and even at high 
concentrations of a-subunits, none of the expressed “Gias” were capable of 
inhibiting adenylyl cyclase purified from bovine brain, even though they 
were found to be active in other signalling systems.Linder et al. do, 
however, address the possibility that post-translational modification of “Gi” 
may be required for its action in vivo.
Levitzki has recently proposed an alternative hypothesis to account 
for the role of Py subunits in adenylyl cyclase inhibition (Marbach et al.
1990). Much of the work on inhibition of adenylyl cyclase by Py subunits 
has required the purification of py and a  subunits. He points out that in the 
absence of high salt concentrations the P subunit copurifies with the 
catalytic subunit of6 pp(NH)p activated adenylyl cyclase, implying that the 
a  and Py subunits of Gs do not dissociate in vivo on activation of the 
enzyme. He suggests that different G-proteins have different tendencies to 
dissociate in the presence of GTP or its analogues, and that, in the case of 
adenylyl cyclase, Gsa and Py subunits do not dissociate, and the active 
moiety for stimulation of cyclase is GTP-bound GsaPy, while the active 
agent for inhibition of cyclase is GTP-bound GiaPy.
The identity of the G-protein moiety responsible for mediating 
inhibition of adenylyl cyclase is, therefore, not as clear as had first been 
thought. Nevertheless, it is documented that antibodies directed against the 
a-subunits of Gi2 are capable of alleviating the receptor-driven inhibition 
of adenylyl cyclase. Simonds et al. (1989a) have achieved this in the human 
platelet with the adrenergic inhibition of cyclase, and McKenzie and 
Milligan (1990) have also shown this using the NG108-15 cell line, where 
cyclase is inhibited by the 8 -opioid receptor. It might be argued that in 
these cases, the lack of inhibition is due to the prevention of py subunit 
release from the uncoupled a-subunit, however recently further evidence
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has supported the role of the a-subunit as the mediator of adenylyl cyclase 
inhibition. Wong et al. reported the expression of a mutant form of Gi2a 
in human embryo kidney cell line 293. This mutant Gi2a was shown to 
constitutively inhibit adenylyl cyclase (Wong et al. 1991), even when 
expressed at levels where the a-subunit clearly exceeded py levels.
It may be that different approaches used to address this question of 
the identity of the true inhibitor of adenylyl cyclase, and the possible 
involvement of py subunits, are producing results which may not be 
applicable in vivo. It is possible that addition of sufficient py will indeed 
cause inhibition of cyclase, however the relevant question would then be, 
does the enzyme in vivo ever see such levels of Py ? It has been shown in 
the S49 murine lymphoma cell, where cyclase is inhibited by somatostatin, 
that added py subunits were much less effective than somatostatin in 
inhibiting isoproterenol stimulation of the P-adrenergic receptor, although 
they found that Py was a more potent inhibitor of basal cyclase activity than 
somatostatin (Hildebrandt and Kohnken, 1990). It was proposed that 
hormonal and py inhibition of cyclase occur by different mechanisms, and 
that a i is the primary mediator of hormone inhibition of the enzyme.
It is worth noting that there is a strong theoretical argument against 
the Py subunit being solely responsible for cyclase inhibition. If one 
believes that it is the diversity of the a-subunits that accounts for the 
fidelity of coupling of G-proteins to their receptors, then it seems unlikely 
that the Py subunits, which are even more homologous in sequence than the 
a-subunits, could confer the specificity of coupling which is apparent in , 
vivo. Stimulation of any receptor would then result in release of Py 
subunits which could inhibit cyclase.
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Use of Anti-Peptide Antisera to detect and modify G-protein 
function
For many years, the only methods of G-protein detection were 
indirect. Hormonal simulation or inhibition of adenylyl cyclase activity 
could be shown to be dependant on the presence of GTP or its analogues. 
Alteration in receptor affinity by guanine nucleotides could be detected by 
radioligand binding studies. But these methods could not identify the G- 
proteins responsible. The use of the bacterial toxins cholera and pertussis 
toxin could only divide G-proteins into two broad classes, both of which 
expand with the discovery of ever more cDNAs encoding G-protein a- 
subunits. To date, the most effective and specific method for detection of 
G-proteins is the use of immunological probes. These antibodies, raised 
against various parts of various G-protein components have allowed 
assesment of G-protein distribution, detection of similarities and 
differences between members of the G-protein family and, finally, they 
have been used recently to probe specificity of G-protein function. For a 
recent review, see Spiegel (Spiegel, 1990).
In 1984 Hamm and Bownds raised an antibody against frog rod outer 
segments, which bound to transducin. This antibody blocked light- 
activation of GDP/GTP exchange and cGMP phosphodiesterase activity 
(Hamm and Bownds, 1984). They were later able to show, by use of tryptic 
cleavage, that the antibody recognised an epitope near the C-terminus of 
Tdoc, (Deretic and Hamm, 1987) and thus provided evidence that it was the 
C-terminus of the a-subunit which interacted with receptor.
The antibody raised by Hamm and Bownds was fortuitous in its 
functional effect. Nowadays “designer antibodies” can be generated, 
allowing the targeting of specific G-proteins. Determination of the peptide 
sequences of Gs and Gi allowed the generation of synthetic peptides
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corresponding to parts of G-protein a,p, or y-subunits, and this provided 
the means for the immunochemical distinction of new forms of the various 
subunits. For example, the two distinct forms of transducin were shown to 
be tissue specific by the use of such antibodies (Lerea et al. 1986). In a 
similar fashion, Mumby et al. were able to identify different forms of the 
P-subunit (Mumby et al. 1986). Antipeptide antisera raised against the C- 
terminus of Tda detected various forms of Gi (Gil and Gi2) in neutrophils 
and brain (Falloon et al. 1986; Goldsmith et al. 1987).
The use of specific antipeptide antisera unambiguously to identify the 
G-protein coupling to specific receptors has already been mentioned. 
McKenzie and Milligan used antiserum AS7, raised against Tda, but which 
also recognises G il and Gi2a, to identify Gi2 as the G-protein coupling the 
8 -opioid receptor in the neuroblastoma x glioma cell line, NG108-15, to 
inhibition of adenylyl cyclase. They were aided in this task by the fact that 
the NG108-15 cell was shown to express only Gi2, and not G il, making 
their antibody specific for this G-protein alone in this cell line (McKenzie 
and Milligan, 1990). Similarly, Simonds et al. used AS7 to show that the 
adrenergic receptor in the human platelet was coupled to inhibition of 
adenylyl cyclase via Gi2 (Simonds et al. 1989a).
The functions of Go and Gs have also been probed using C-terminal 
specific antisera. Antibodies raised against the Gsa carboxy terminus were 
shown to block receptor-mediated activation of Gs and adenylyl cyclase in 
membranes from S49 cells (Simonds et al. 1989b). A number of groups 
have used antisera against Go to show its interaction with calcium channels. 
As has been mentioned above, (see G-Protein Heterogeneity) Harris- 
Warrick et al. raised an antibody against Go and injected it into snail 
neurons, where they found that it prevented dopamine-induced reductions 
in voltage-dependant Ca2+ currents (Harris-Warrick et al. 1988). 
McFadzean et al. showed that injection of NG108-15 cells with the antibody
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0C1, raised against the C-terminus of Go, prevented noradrenaline- 
induced reductions in calcium currents (McFadzean et al. 1989).
It is clear, therefore, that G-protein-specific antisera provide a 
powerful tool for investigation of identity, prevalence, and function of G- 
proteins.
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ADRENERGIC RECEPTORS
Adrenergic receptors mediate the effects of the catecholamines adrenaline 
and noradrenaline in the body. As a group they are well characterised, with 
many of the receptor subtypes purified to homogeneity, and the genes or 
cDNAs isolated and sequenced. They will be discussed here as archetypes 
of receptors which interact with heterotrimeric G-proteins.
The structure of the adrenergic receptors seems to fall into a pattern 
common to a family of receptors which all couple to heterotrimeric G- 
proteins (for review see O’Dowd et al. 1989). The adrenoceptors have 
molecular weights between 64 and 80 kDa. Each appears to be an integral 
membrane glycoprotein consisting of a single polypeptide chain, ranging 
in size from 477 amino acids (for the human fii receptor) to 413 amino 
acids (human 8 2 ). Elucidation of the primary sequences has shown 
similarities between the adrenergic receptors and bacteriorhodopsin, (the 
principal membrane protein of the purple bacterium Halobacterium 
halobium ) for which structural information has been obtained by
. and hydropathicity analysis. The striking common feature 
of the adrenergic receptors, and indeed of all the members of the family of 
G-protein linked receptors, is the appearance in the primary sequence of 
seven stretches of -20-28 hydrophobic amino acids which seem to 
represent membrane spanning a-helical regions. The amino acid sequences 
around these domains presumably represent intra- and extra-cellular loops. 
Figure 1.3 shows the organisation of G-protein coupled receptors within 
the plasma membrane.
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Figure 1.3
The organisation of G-protein coupled receptors within the 
plasma membrane
Adapted from Harrison et al. 1991.
NH.
extracellular
intracellular
Conceptual amino acid sequence of a rat <x2B-adreno-
ceotoi .
COOH-
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The putative membrane spanning sequences are highly conserved: the
0C2 -adrenergic receptors so far cloned share -75% amino-acid 
homology in this region, with the least homology being found in those 
regions thought to lie close to the extracellular surface. This may indicate 
that the amino acids in this region of the receptors account for their unique 
pharmacological properties, ie. this region encompasses the ligand-binding 
pocket. Some evidence for this comes from site-directed mutagenesis of the 
hamster p2 -adrenergic receptor, converting Asp113—»Asn on the third 
transmembrane helix, which resulted in a receptor with markedly 
attenuated affinities for both adrenergic agonists and antagonists, and which 
was unable to mediate isoproterenol stimulation of adenylyl cyclase activity 
(Strader et al. 1988). It has also been shown that ligand binding in the rat 
OC2 B receptor depends upon a cysteine residue (Cys*69) in the second 
extracellular loop. This cysteine is conserved among all members of the 
seven-transmembrane-region family and mutation of this cysteine to 
phenylalanine resulted in a receptor which failed to bind the adrenergic 
antagonist rauwolscine (Zeng et al. 1990). Furthermore, it has been 
reported that the alkylating agent [l25I]pBABC, a probe which covalently 
binds to the hamster P2 -adrenoceptor, binds to either the His93  or Ser92  on 
the extracellular face of the second transmembrane helix (Dohlman et al.
1988).
The N-terminus lies outside the cell, and has consensus sequences 
for glycosylation. The pi ,p2 , and OC2A adrenergic receptors have been 
shown to contain oligosaccharides, although the OC2B receptor is distinctive 
amongst adrenergic receptors in that it lacks the N-terminal glycosylation 
sequence (Zeng et al. 1990). The role of N-terminal glycosylation is 
unclear. It has been shown recently that removal of the glycosylation sites 
of the hamster P2 -adrenergic receptor had no effects on ligand binding or 
coupling to G-proteins, however only half of the total number of non­
36
Chapter 1
glycosylated receptors appeared at the cell surface, which suggests that 
glycosylation may be important in localising the receptor to the membrane 
surface (Rands et al. 1990).
The C-terminus lies within the cytosol, and it has been shown that 
certain serine and threonine residues in the carboxy tail are substrates for 
phosphorylation. The P-adrenergic receptor is phosphorylated by a specific 
kinase (PARK) when occupied by agonist (Benovic et al. 1986b). This 
phosphorylation, which is independant of cAMP levels, results in 
uncoupling of the p-adrenergic receptor from Gs (Benovic et al. 1986a). It 
has been shown that mutant P-adrenergic receptors truncated at the C- 
teiminus which are exposed to the agonist isoproterenol do not show the 
rapid (2  minutes) decrease in adenylyl cyclase activity observed in the wild 
type receptor (Bouvier et al. 1988). Thus, the C-terminal region of the 
adrenergic receptors may be important as part of the mechanism for 
desensitization or down-regulation of the receptors, the first step of which 
involves phosphorylation of the agonist-occupied receptor, and subsequent 
uncoupling of the G-protein linked to that receptor.
The intracellular (cytoplasmic) loops of the receptors have been 
shown to be vital in coupling of the receptor to its G-protein. Various 
groups have used mutant receptors to demonstrate that the third 
cytoplasmic loop, in particular, is critical for receptor-G-protein coupling. 
Strader et al. have constmcted deletion mutants of the hamster (32- 
adrenergic receptor, removing most of the loop (residues 239-272), or 
alternatively only the residues at the amino- (222-229) and carboxy- (258- 
270) terminal portions of the loop. In each case, the mutant receptor 
showed impaired ability to mediate stimulation of adenylyl cyclase (Strader 
et al. 1987). It is noteworthy that the amino acid sequences in these regions 
are highly conserved among different members of the adrenergic receptor 
subfamily. Further evidence that the third cytoplasmic loop couples the
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receptor to its G-protein comes from the constmction of chimeric 
receptors where the third loop from the human platelet (a 2 -C1 0 ) receptor 
was replaced with the corresponding loop from the p2 -adrenergic receptor, 
and expressed in Xenopus oocytes. In this way, a receptor was created 
which stimulated adenylyl cyclase in response to 0C2 -adrenergic agonists, 
which would normally inhibit cyclase (Kobilka et al. 1988).
Taken together, a model of receptor function and activation can be 
suggested from these data. The glycosylation of sites on the N-tenninus 
ensures correct placement of the receptor at the cell surface. A ligand 
binding pocket is formed from the extracellular amino acid residues of the 
transmembrane helices in the receptor. The negatively charged residues in 
helices II and E l may form a charge network which comprises both high- 
and low- affinity states of the receptor and which, in the absence of bound 
ligand, may be complexed with water, or mono- or di-valent cations. 
Displacement of these residues upon binding of ligand may result in the 
movement of one transmembrane helix relative to the others, and this 
movement is then transmitted to the third cytoplasmic loop, allowing 
activation of the G-protein coupled to the receptor. Persistent activation of 
the receptor causes phosphorylation of the C-terminal serine and threonine 
residues, resulting in receptor uncoupling from G-protein, and ultimately, 
receptor downregulation.
a  ADRENERGIC RECEPTOR PHARMACOLOGY
Subdivision of adrenergic receptors into a  and (5 was first suggested by 
Ahlquist (for review, see Ahlquist, 1967) in order to account for the 
differential effects of some sympathomimetic amines, and this was
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validated in 1958 when selective blockade of (3-adrenoceptors was 
demonstrated (Moran and Perkins, 1958). The further subdivision of (3 
receptors into pi and P2  types was originally proposed by Furchgott
(Furchgott, 1967). Subdivision of the a-adrenergic receptor came about 
when it was found that the a  receptor, which had previously been thought 
of as a “post-synaptic” receptor, stimulation of which caused a 
pharmacological effect, could also occur pre-synaptically, this time in the 
form of an inhibitory receptor, stimulation of which resulted in negative 
feedback on adrenaline release from the synapse. Thus the postsynaptic 
receptor became the 0C2  receptor, while the presynaptic receptor was called 
the a i  receptor. Nowadays the concept of “pre-” or “post-” synaptic forms 
of the a  adrenergic receptor has broken down, and the terms a i  and 0C2  
simply denote receptors with different pharmacological characteristics. In 
terms of function, however, the distinction holds good. The oci receptors 
couple to stimulation of the membrane associated enzyme
p h o s p h o C ,  which cleaves the membrane phospholipid 
phosphatidylinositol 4,5-bisphosphate into the two second messenger 
molecules inositol(l,4,5,) trisphosphate and diacylglycerol. The (X2  
receptors in contrast, couple to inhibition of adenylyl cyclase.
The pharmacology of the different 0C2  subtypes has been reviewed by 
Bylund (Bylund, 1988) and the relationship between pharmacological and 
genetic subtypes by Harrison et al. (1991). All the 002 receptors have a high 
affinity (i.e.Ko <2 0 nM) for the antagonists rauwolscine and its 
diastereoisomer, yohimbine. It is now accepted that the two well 
characterised subtypes of the (X2  receptor, 0C2A and OC2B, can be 
distinguished by their differential affinities for the adrenergic agonist 
oxymetazoline, and for the antagonist prazosin. The (X2A subtype has a high 
affinity for oxymetazoline and a low affinity for prazosin, while the 0C2 B 
subtype has a high affinity for both oxymetazoline and prazosin (Bylund et
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al. 1988). A third subtype was also reported by Bylund, this time on OK 
cells, derived from opossum kidney. This <X2C subtype is similar to the CC2B 
in that it has a high affinity for prazosin, however the Kd for yohimbine is 
similar to that expected for the OC2A receptor (Murphy and Bylund, 1988).
To date, several different a  adrenoceptors have been cloned (see 
Table 1.2). The first clone was from the human genome chromosome 10 
(OC2-C10) and was isolated using a partial amino-acid sequence from the 
purified human platelet CC2 adrenoceptor (Kobilka et al. 1987). The gene 
for this receptor was subsequently expressed permanently in CHO cells and 
bound adrenergic ligands with the expected profile of an (X2A receptor 
(Fraser et al. 1989). Identification of the CC2B receptor has been less 
straightforward. Southern blots of human genomic DNA probed with a 
radiolabelled fragment of the OC2-C10 clone resulted in the appearance of 
three bands, which suggested that there were at least two other (X2 
adrenoceptors in the human genome , probably located on chromosomes 2 
and 4 (Kobilka et al. 1987). Two more clones, OC2-C4 and RNG0C2 , a Rat 
Non Glycosylated clone, were subsequently isolated by screening human 
and rat kidney cDNA libraries with cloned DNA or oligonucleotides under 
conditions of reduced stringency (Regan et al. 1988, Zeng et al. 1990). The 
human genomic form of the RNG(X2 receptor was localised to chromosome 
2 ((X2-C2) by two groups (Lomasney et al. 1990; Weinshank et al. 1990). 
The OC2-C4 and (X2-C2 clones both encoded receptors with the expected 
pharmacological characteristics of the OC2B receptor, however it has been 
shown that the 0C2-C2/RNGa2 clones do not have the concensus sequence 
for N-terminal glycosylation, and that mRNA for the RNG0C2 receptor is 
present in extracts of neonatal rat lung, as well as in rat kidney (Zeng et al. 
1990). This makes it likely that the CC2-C2/RNG(X2 receptor is the true (X2B 
receptor. It is possible that the (X2-C4 receptor is the OC2C subtype suggested 
by Bylund’s studies on the opossum kidney OK cell line.
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TABLE 1.2: oc-ADRENERGIC RECEPTORS
Subtvpe Clone R eference
aiA  - Harrison et al. 1991
aiB  - Cotecchia et al. 1988
a i c  - Schwinn et al. 1990
0C2A CIO Kobilka et al. 1987
OC2B C2 Weinshank et al. 1990
a 2B RNG Zeng et al. 1990
0C2C (?) C4 Regan et al. 1988
OC2B (?) - Flordellis et al. 1991
a 2D RG20 Lanier et al. 1991
Within the last few months a glycosylated receptor with the 
pharmacological characteristics of an OC2B type has been cloned from rat 
brain. This shows 87% sequence homology with the oc2-C4 receptor, but 
has two potential N-glycosylation sites (Flordellis et al. 1991). Finally, the 
existence of a fourth a 2  subtype has been suggested by the isolation of a 
clone (RG20) from a rat genomic library which has a lower affinity for 
rauwolscine than the other 0C2 -receptors, and which has 89% sequence 
homology to the a2-C10 receptor (Lanier et al. 1991). This has been 
suggested as the presynaptic 0C2D receptor.
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RESEARCH ATMS
Although the adrenergic receptors are very well characterised in 
terms of their structure and pharmacology, very little is known about their 
interactions with G-proteins. The aim of the work presented in this thesis 
was to examine the coupling of adrenergic receptors to G-proteins and, in 
particular, to address the question of specificity of interaction of the 
receptor and G-protein.
Two model systems were used. Firstly, the neuroblastoma x glioma 
cell line, NG108-15, which is a popular model system for the study of 
signal transduction processes. This cell line, which is discussed in detail in 
Chapter 3, expresses an adrenergic receptor which is known to mediate 
inhibition of adenylyl cyclase (Sabol and Nirenberg, 1979). The identity of 
the G-protein mediating this effect was unknown, and it was decided to 
attempt this identification.
The second model system utilised in these studies was the Rat 1 
fibroblast cell line. These cells do not normally express an adrenergic 
receptor, but the DNA for the human platelet adrenergic receptor (a2- 
C1 0 ) was transfected into this cell, in order to examine the specificity of 
coupling of this receptor, in an “unnatural” surrounding, to G-proteins. 
This work is discussed in Chapter 4.
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MATERIALS AND METHODS
MATERIALS
All reagents employed were of the highest quality available and were 
obtained from the following suppliers;
B.R.L., Paisley, Scotland.
Prestained molecular weight markers.
Boehringer (U.K.) Ltd, Lewes, East Sussex
GTPyS, Gpp(NH)P, GDP, GDPpS, App(NH)p, Dithiothreitol, 
Creatine phosphate, Creatine phosphokinase, Triethanolamine 
hydrochloride, Tris, Thymidine
F.S.A. Lab. Supplies, Loughborough.
Acrylamide, N,N’-methylenebisacrylamide, Hydrogen peroxide
Koch-Light Lab.Ltd, Haverhill, Suffolk.
DMSO, sodium potassium tartrate
M & B, Dagenham.
Ammonium persulphate
National Diagnostics, Aylesbury, Buckinghamshire 
’Ecoscint" scintillation fluid
GENERAL REAGENTS
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Pfizer Central Research, Sandwich, Kent.
UK14,304 tartrate (bromoxidine).
Porton Products, Porton Down, Salisbury, Wiltshire.
Pertussis toxin
Reckitt and Coleman, Dansom Lane, Kingston-upon-Hull.
Idazoxan
Sigma Chemical Co., Poole, Dorset.
Cholera toxin, Bovine Serum Albumin, NAD, TEMED, Trypsin, 
Norit-A charcoal, Ouabain, Theophylline, Arginine hydrochloride, N- 
ethylmaleimide, o-dianisidine hydrochloride, ATP disodium salt, cAMP 
sodium salt, Keyhole limpet Haemocyanin, Freund’s complete adjuvant, 
Freund's incomplete adjuvant, Coomassie blue R-250, Bromophenol Blue, 
Thimerosal, Protein-A Sepharose 4B, Tween 20, Dowex AG50W-X4 (200- 
400 mesh), Alumina (neutral), Imidazole, (-) Adrenaline bitartrate, (-) 
Noradrenaline bitartrate, Yohimbine hydrochloride, Oxymetazoline 
hydrochloride, Prazosin hydrochloride, Forskolin.
Whatman International Ltd. Maidstone.
GF/C Glassfibre filters, 3mm Chromatography paper, No. 1 Filter
paper.
All other reagents used were obtained from BDH (Dorset, Poole, England).
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TISSUE CULTURE PL AS TIC WARE
Bibby Science Products Ltd, Stone, Staffordshire.
75cm2  tissue culture flasks.
Costar, 205 Broadway, Cambridge M.A., U.S.A.
Biofreez vials
Elkay Products, Shrewsbury, M.A., U.S.A.
50ml centrifuge tubes
CELL CULTURE MEDIA
Gibco Life Technologies, Paisley, U.K.
Dulbecco's modification of Eagle's medium (lOx), Donor Calf 
Semm, Glutamine (200mM), Sodium Bicarbonate, HAT(50x): 
Hypoxanthine (O.lmM), Aminopterin (ImM),Thymidine (16mM), 
Penicillin (100 I.U./ml) and Streptomycin (lOOmg/ml) (lOOx).
Imperial Labs, West Portway, Andover, Hants.
Foetal Calf Serum, Normal Calf Serum
RADIOCHEMICALS
Amersham pic, Amersham, Buckinghamshire
Guanosine 5'-[y-32P] triphosphate, triethylammonium salt
(product no. PB144) lOCi/mmol
[8 -3H] Adenosine 3',5'-cyclic phosphate, ammonium salt
(product no. TRK304) 24Ci/mmol
Adenosine 5'-[a-32P] triphosphate, triethylammonium salt
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(product no. PB10160) lOmCi/ml
New England Nuclear, Boston, Mass., U.S.A
[Adenylate-32P]-Nicotinamide adenine dinucleotide, 
di(triethylammonium) salt.
(product no. NEG-023X) 800Ci/mmol 
[methyl-3H] Yohimbine 
(product no. NET-659) 79.1Ci/mmol
St a n d a r d  b u f f e r s
Phosphate Buffered Saline (PBS)
2 g potassium chloride 
80g sodium chloride
2 g potassium dihydrogen orthophosphate 
2 1 .6 g disodium hydrogen 
orthophosphate, heptahydrate 
to a final volume of 1 litre, pH7.4.
Tris Buffered Saline (TBS)
500mM sodium chloride,
20mM Tris-HCI, pH 7.5.
Tris Buffered Saline with Tween 20 (TTBS)
500mM sodium chloride 
20mM Tris-HCI, pH 7.5
0.05% (v/v) Tween 20.
47
Chapter 2
METHODS
1. CELL CULTURE 
Cell growth.
NG108-15 neuroblastoma x glioma hybrid cells were a kind gift from 
Dr. W. Klee (N.I.H., Bethesda, M.D. USA) and were grown in 75cm2  
tissue culture flasks in 0.0375% (w/v) sodium bicarbonate buffered 
Dulbecco’s modification of Eagle’s Medium (DMEM), containing 10% (v/v) 
foetal calf serum (FCS) which had been heat inactivated at 56^C for 90 
minutes. The medium was supplemented with glutamine (2mM), 
hypoxanthine (O.lmM), aminopterin (lmM) and thymidine (16mM). Both 
penicillin (100 units/ml) and streptomycin (lOOmg/ml) were routinely 
included. This growth medium will henceforth be termed DMEM/10%
(v/v) FCS.
Rat 1 fibroblasts were obtained from Dr P. White (Beatson Institute 
for Cancer Research, Glasgow). Rat 1 fibroblasts and clone 1C cells were 
grown in 75cm2  tissue culture flasks in 0.0375% (w/v) sodium bicarbonate 
buffered Dulbecco’s modification of Eagle’s medium (DMEM), containing 
10%(v/v) newborn calf serum (NCS) which had been heat inactivated at 
56^C for 90 minutes. This medium was supplemented with glutamine 
(2mM), and penicillin (100 units/ml) and streptomycin (lOOmg/ml) were 
routinely included. Selection of transfected clones was maintained by 
addition of geneticin (800jig/ml) to the growth medium.
All cells were grown in a humidified atmosphere of 5% CO2/  95%
air.
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Cell subculture.
Confluent cells (typically 107 cells per 75cm2  flask) were passaged 
using a trypsin solution containing 0.1% (w/v) trypsin, 0.67mM EDTA and 
lOmM glucose in PBS. Growth mediifowas removed from the cells and 2mls 
of trypsin solution added. When the cells had been removed from the 
surface of the flask, trypsinisation was stopped by the addition of two 
volumes of growth medium. This cell suspension was centrifuged at 800 x g 
in an MSECentaur centrifuge for two minutes to pellet the cells. The cell 
pellet was resuspended in growth medium and plated out as required.
Cell maintenance.
Confluent cells were removed from the surface of the flask by 
trypsinisation as described above and the cells resuspended in freezing 
medium, which consisted of 8 % (v/v) DMSO in FCS (for NG108-15 cells) 
or 8 % (v/v) DMSO in NCS (for Rat 1 fibroblasts). The suspension was 
aliquoted into 0.5 ml volumes into Biofreez vials, frozen overnight packed 
in cotton wool at -80 °C, and then transferred to liquid nitrogen for storage.
Cells to be brought up from liquid nitrogen storage were thawed 
immediately at 37°C, resuspended in 10 mis of appropriate growth medium, 
and centrifuged at 800 x g in an MSE Centaur centrifuge for two minutes to 
pellet the cells. The cell pellet was resuspended in growth medium and 
plated out in a final volume of lOmls in a 75 cm2  flask.
Toxin treatment of cells.
Confluent cells to be treated with toxin were given a change of medic/** 
into medium supplemented with either pertussis toxin (to a final 
concentration of 25ng/ml) or cholera toxin (to a final concentration of 
lOOng/ml). A parallel set of control flasks were treated with an equal
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volume of ... vehicle. After 16 hours treatment, cells were harvested as 
described below.
Cell Harvesting.
When confluent, growth medium was removed from the cell culture 
flask and lOmls of ice -cold PBS added. Cells were gently washed from the 
surface of the flask, collected in a 50ml conical tube and centrifuged at 800 
x g in a Beckman TJ6  centrifuge for 10 minutes. The resulting cell pellet 
was washed with ice-cold PBS and re-centrifuged. The final pellet was 
stored at -80°C until use. Pellets which had been stored for up to one year 
were found to retain full activity.
2. PRODUCTION OF PLASMA MEMBRANES
Membranes were produced according to Koski and Klee (1981). 
Frozen cell pellets were thawed and suspended in 5 volumes of ice-cold 
lOmM Tris-HCI., O.lmM EDTA pH 7.5 and homogenised with 15 strokes 
of a Potter homogeniser.
The homogenate was centrifuged at 500 x g for 10 minutes in a 
Beckman L5-50B centrifuge with a Ti50 rotor, to remove unbroken cells 
and nuclei. Plasma membranes were collected by centrifugation of the 
supernatant at 48,000 x g for 10 minutes, washed in 10 volumes of the same 
buffer and after a second centrifugation, were resuspended in the same 
buffer to a final protein concentration of between 1-4 mg/ml, aliquoted, and 
stored at -80°C until required.
Protein Determination.
The method used is based on that of Lowry (Lowry et al, 1951).
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Stock Solutions;
A) 2% (w/v) sodium carbonate in 0.1 M sodium hydroxide.
B) 1% (w/v) copper sulphate.
C) 2% (w/v) sodium potassium tartrate.
Just prior to use, the stock solutions were mixed in the following
ratio, A:B :C, 100:1:1, to produce solution D.
Protein standards were prepared using a lmg/ml bovine semm 
albumin fraction 5, and a standard curve constructed for a maximum of 
30 jj g of protein per sample. Unknowns were assayed in 2, 4 and 8 jil 
volumes in duplicate. 1ml of solution D was added to each sample, mixed 
and left to stand for 10 minutes. 100ml of Folin Ciocalteau reagent diluted 
1:1 with H2O was added to each sample, mixed and allowed to stand for a 
further 20 minutes. The absorbance of light by each sample was assessed 
spectrophotometrically at 750nm in an LKB Ultrospec 2 spectrophotometer.
3. ANTIBODY PRODUCTION.
All antisera used were generated against synthetic peptides, essentially 
as described by Goldsmith and colleagues, (Goldsmith et al. 1987).
Synthetic peptides were obtained from Dr. C.G. Unson, the Rockerfeller 
University, New York, U.S.A. with the exception of the peptide 
NLKLEDGISAAKDVK, which was synthesised by Dr. A. I. Magee, 
N.I.M.R., Mih Hill, London, and the peptide KNNLKECGLY which was 
obtained from Biomac Ltd., Glasgow, U.K.
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3mg of the appropriate peptide and lOmg of keyhole limpet 
haemocyanin were dissolved slowly in 1ml of 0.1 M phosphate buffer pH 
7*0. 0*5ml of 21mM glutaraldehyde (also in 0-1M phosphate buffer, pH 
7*0) was then added drop wise with stirring and the combined l-5 ml 
incubated overnight at room temperature.
The l-5ml solution was mixed with an equal volume of complete 
Freund's adjuvant and briefly sonicated with a Branson 'soniprobe' (Type 
7532B). 1ml aliquots of the resulting emulsion were injected in multiple 
subcutaneous sites in New Zealand white rabbits. Four weeks later each 
animal received a booster immunization with material identically prepared, 
except one half as much keyhole limpet haemocyanin and peptide were 
injected in incomplete Freund's adjuvant.
Bleeds were performed monthly with approximately 15ml taken from 
the ear vfe/A and collected into a glass Blood was left to clot
overnight at 4°C and the plasma removed and centrifuged at 1000 x g in a 
Beckman TJ 6  centrifuge for 10 minutes to pellet any remnants of the clot. 
The supernatants thus produced were aliquoted into 250ml volumes and 
stored at -80 until use.
A range of different antisera were produced in the manner described, 
as summarised in Table 2.1;
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Table 2.1: Anti G-protein antisera
Antiseram Peptide Used G-protein sequence Antiserum
Identifies
AS7 KENLKDCGLF Tda 341-350 Td, G il, Gi2
OC1 ANNLRYCGLY Goa 345-354 Go
IM1 NLKEDGISAAKDVK Goa 22-35 Go
I3B KNNLKECGLY Gi3a 345-354 Gi3
CS1 RMHLRQYELL Gsa 385-394 Gs
I1C LDRIAQPNYI G ila  159-168 Gil
BN1 MSELDQLRQE GP 1-10 PI, p2
ANTIBODY PURIFICATION
Crude antisera were chromatographed on a l-5cm x 2cm column of 
protein-A-sepharose 4B. A 5ml volume of antiserum in glycine buffer 
(1.5M Glycine, 3M NaCl, pH 8.9) was added to the column and allowed to 
equilibrate. The column was washed with glycine buffer until the eluate had 
an A28O of zero and was then eluted with lOOmM citric acid, pH 4.0 into 
2M Tris/HCI, pH 7.5. The eluted IgG fractions were dialysed overnight 
against 1000 volumes of lOmM Tris-HCI and O.lmM EDTA pH 7.5, and 
lyophilised. Just prior to use, samples were reconstituted to the required 
dilution with the same buffer.
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4. GEL ELECTROPHORESIS
Gel electrophoresis was carried out according to the discontinuous 
system described by Laemmli (1970).
a . Re s o l v in g  G e l  Pr e p a r a t io n
Stock Solutions; (stored at 4°C and filtered through Whatmans No.l 
filter paper prior to use)
Solution A 1.5M Tris,0.4% (w/v) SDS, pH 8 .8  with H C I.
Solution B 0.5M Tris,0.4% (w/v) SDS, pH 6 .8  with H C I.
Solution C 30% (w/v) Acrylamide,0.8% (w/v) N,N’-methylene 
bisacrylamide.
Solution D 30% (w/v) Acrylamide,0.15% (w/v) N,N'-methylene 
bisacrylamide.
Solution E 50% Glycerol.
Solution F 10% (w/v) Ammonium persulphate (made daily) 
Solution G TEMED.
Reservoir buffer; 0.025M Tris, 0.192M Glycine, 0.1% (w/v) SDS, pH 7.5.
10% (w/v) Acrylamide/0.25% (w/v) N,N'-methylene -bisacrylamide 
gels were prepared from stock solutions as follows;-
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Solution Volume (ml)
A 6
C 8
E 1.6
F 0.09
G 0.008
To a final volume of 24ml with H2O.
The solution was immediately mixed and poured into a LKB gel 
casting apparatus, which consisted of 180 x 160 mm glass plates with 
1.5mm spacers. The gel was layered with 0.1% (w/v) SDS to exclude air, 
and left to set at room temperature for approximately 2  hours.
12.5% (w/v) Acrylamide/0.0625 % (w/v) N,N'-methylene 
bisacrylamide gels were prepared from the stock solution as follows;
Solution Volume (ml)
A 12
D 20
E 4
F 0.160
G 0.015
To a final volume of 36ml with H2O
The solution was immediately mixed and poured into a Bio-Rad 
Protean II gel casting apparatus, which consisted of 200 x 200 mm glass 
plates with 1.5mm spacers. The gel was layered with 0.1% (w/v) SDS to 
exclude air, and left to set at room temperature for approximately 2  hours.
55
Chapter 2
b . St a c k in g  get, p r e p a r a t io n
Stacking gels were prepared from the stock solutions as folio ws;-
Solution
B
F
G
C
Volume (ml) 
3.75 
1.5 
0.150 
0.008
To a final volume of 15 ml with H2 O.
The solution was mixed, layered on top of the resolving gel and 
allowed to polymerize around a 15 well teflon plate.
Electrophoresis was performed overnight at either 50V (Bio-Rad 
system) or 100V (Protean II system).
c . Sam ple  pr e pa r a tio n  
Pr o t ein  pr ec ipita tio n
Samples were prepared for gel electrophoresis by sodium 
deoxycholate/trichloroacetic acid precipitation; 6.25pl of 2% (w/v) sodium 
deoxycholate was added to each sample, followed by 750|il of H2O, and 
then 250jil of 24% (w/v) trichloroacetic acid. Samples were centrifuged in a 
Hettich Mikro Rapid/K centrifuge at 12000 x g for 20 minutes, after which 
time the supernatants were removed and the pellets dissolved in 20pl of 1M 
Tris base followed by 20jil of Laemmli buffer, which consisted of 5M 
Urea, 0.17M SDS, 0.4M DTT, 50mM Tris-HCI pH 8.0, 0.01% ''
Bromophenol Blue
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Pr o tein  a l k y l a t io n
As a means of obtaining better resolution of the pertussis toxin 
sensitive G-proteins, samples to be mn on 12.5% (w/v) Acrylamide 
0.0625% (w/v) N,N!-methylenebisacrylamide gels were firstly alkylated by 
treatment with N-ethylmaleimide (NEM) (Stemweis and Robishaw, 1984).
Samples were centrifuged in a Hettich Mikro Rapid/K at 12000 x g, 
the supernatants discarded and the pellets resuspended in 20|il of lOmM 
Tris-HCI, ImM EDTA pH 7.5. lOpl of 5% (w/v) SDS, 50mM DTT was 
added to each sample, mixed, and placed in a boiling water bath for 15 
minutes. Samples were then cooled to hand temperature and lOjil of lOOmM 
NEM added. After 15 minutes at room temperature 20pl of Laemmli buffer 
was added to each sample, leaving the samples ready for gel electrophoresis.
p. g e t , p r o t e in  s t a in in g
After electrophoresis, the gel was placed in a tray on a stirring table 
and covered in stain solution which consisted of 0.1% (w/v) Coomassie blue 
in 50% (v/v) H2 O, 40 % (v/v) Methanol, 10% (v/v) Glacial Acetic acid for 
1 hour. The stain solution was discarded and the gel soaked in destain 
solution (identical to stain solution, but lacking coomassie blue) until excess 
stain had been removed to leave a clear background, and proteins were 
apparent on the gel as discrete bands.
e . Au t o r a d io g r a p h y
Gels to be autoradiographed were firstly stained for protein with 
coomassie blue as described above, and dried down onto Whatman 3mm 
chromatography paper at 80^C for 1 hour under vacuum. The dried gel was
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placed next to KODAK X-OMAT X-ray film in a cassette with 
intensification screens for up to 1 week at -80 °C. Films were developed by 
hand using Kodak LX 24 developer and FX 40 fixer.
5. WESTERN BLOTTING
Proteins were separated under appropriate resolving conditions on 
SDS/polyacrylamide gels overnight at 50V. The proteins were transferred 
to a nitrocellulose sheet (Schleicher and Schuell) for 2 hours at 1.5mA in an 
LKB transblot apparatus (Towbin et al. 1979) with blotting buffer which 
consisted of 0.192M Glycine, 25mM Tris, 20% (v/v) methanol. The sheet 
was then “blocked” for 2 hours in 5% (w/v) gelatin in TBS, after which 
time gelatin was washed off with distilled H2O, and the nitrocellulose sheet 
incubated overnight at 30 ^ C with the appropriate dilution of antiserum in 
1% (w/v) gelatin in TBS. Next day, the antiserum was removed and the 
sheet subjected to a series of washes in distilled H2O, TTBS, and TBS for 10 
minutes each, after which the blot was incubated with a second antibody 
(peroxidase conjugated goat anti-rabbit IgG) for 2 hours at room 
temperature. The second antibody was then removed and the sheet subjected 
to the series of washes in distilled H2O, TTBS and TBS as before. The blot 
was then developed in 40ml of lOmM Tris pH 7.5 with 0.025% (w/v) 0- 
dianisidine as substrate. Development of the blot was begun by addition of 
lOjxl of hydrogen peroxide, and stopped by immersion of the blot in sodium 
azide (1 % w/v).
Both first and second antibodies could be reused up to four times, and 
were stored at 4 °C using 0.004% (w/v) thimerosal as an anti-bacterial 
agent.
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6. APP-RIBOSYLATION
Membranes to be ADP-ribosylated were diluted in lOmM Tris-HCI , 
O.lmM EDTA pH 7.5, to a protein concentration of between 1 to 3 mg/ml. 
20pl aliquots were assayed in a final volume of 50]xL containing the 
following;-
250mM potassium phosphate buffer, pH 7.0 
3mM [32p] NAD (~4xl 0  ^c.p.m.)
20mM Thymidine 
ImM ATP pH 7.5 
lOOmM GTP pH 7.5 
20mM Arginine/HCI
The appropriate toxin was added at a final concentration of lOmg/ml 
(pertussis toxin) or 50mg/ml(cholera toxin). Both toxins were activated 
prior to use by preincubating with an equal volume of lOOmM DTT for 1 
hour at room temperature.
The ribosylation assay was initiated by addition of membranes and 
transferral of tubes to a 37°C water bath. Assays proceeded for 1- 2 hours 
and were terminated by removal to ice followed by sodium deoxycholate/ 
trichloroacetic acid precipitation as detailed above. Samples were then 
resolved under appropriate SDS/polyacrylamide gel electrophoresis.
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7. GTPASE ASSAY
The assay monitors the release of 32Pi from y[32P]GTP and is 
essentially performed as by Koski and Klee (Koski and Klee, 1981), which 
is a modification of the method described by Cassel and Selinger except that 
the concentration of 5f^krtJ^dmidodiphosphate (App(NH)p) was lowered 
to O.lmM (Cassel and Selinger, 1976).
The assay system contained 0.5mM yp2P]GTP (approx. 50,000 
c.p.m.),'lmM App(NH)p, ImM ATP, ImM ouabain, lOmM creatine 
phosphate, 5 units creatine phosphokinase, lOOmM sodium chloride, 5mM 
magnesium chloride, 2mM dithiothreitol, 0.1 mM EDTA, 12.5 mM 
Tris.HCl and 3 to 10jig membrane protein in a final volume of lOOjil at pH 
7.5.
Aliquots of the reaction mixture (50jil) were added to tubes on ice 
containing membrane protein and the appropriate dmg. Low affinity 
hydrolysis of y[32P]GTP was assessed in the presence of lOOmM GTP, 
blank values were determined by the replacement of membrane protein with 
buffer. Hydrolysis of y[32P]GTP at 0°C was negligible.
The reaction was initiated by transferring the tubes to a 37 ^ C water 
bath. After 20 minutes, the tubes were immersed in an ice bath and 900jil 
aliquots of 20mM phosphoric acid (pH 2.3) containing 5% (w/v) activated 
charcoal were then added. After centrifugation for 20 minutes at 12000 x g 
in an MSE microcentaur centrifuge, radioactivity was measured in 500jil 
aliquots of the supernatant fluids by Cerenkov counting in a Rackbeta 
scintillation counter set to the tritium counting channel.
In some experiments membrane protein was preincubated with 
antibodies which had been purified on a column of protein-A sepharose and 
reconstituted to the required concentration. Preincubation was at 37 °C for 1 
hour in the presence of the GTPase assay components excluding y[32P]GTP
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and receptor ligands. After preincubation, y[32P]GTP and ligands were 
added and the assay proceeded as normal.
8. RADIOLIGAND BINDING ASSAY
Binding assays were performed by the rapid filtration method as 
described by Pert and Snyder, (Pert and Snyder, 1973) in lOmM Tris-HCI, 
50mM sucrose, 20mM magnesium chloride pH 7.5, containing 20-150pg of 
membrane protein and radiolabelled ligand in a final volume of 250jil. 
Non-specific binding was assessed in parallel tubes containing an 
appropriate drug. Blank values were determined by replacement of 
membrane protein with buffer.
The assay was initiated by transferral of tubes to a 30 water bath 
for 30 minutes, after which time the tubes were removed to ice and a 200jil 
volume rapidly filtered through Whatman GF/C glassfibre filters which had 
been presoaked in assay buffer, followed with three 5ml washes of the filter 
with ice-cold buffer. Filters were soaked overnight in Ecoscint scintillation 
fluid prior to counting in a Rackbeta scintillation counter. In some assays, 
membranes were pre-incubated with an IgG fraction purified from either 
normal rabbit serum or an anti-G-protein antiserum (as detailed above) for 
60 minutes at 30 *C prior to addition of radiolabelled ligand. After the pre­
incubation period the assay continued as normal. In binding assays designed 
to determine the rate at which equilibrium binding was achieved, the assay 
volume was increased to lOOOjil, with protein and ligand concentrations 
altered accordingly. After transferrral to a 30 *C water bath, aliquots 
(lOOjil) were removed and filtered at varying time intervals, filters being 
then treated as described.
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In some instances, data was manipulated according to the method of 
Scatchard (Scatchard, 1949).
9. ADENYLYL CYCLASE ASSAY
This was essentially the method of Salomon, (Salomon 1979) except 
that the amount of oc[32P] ATP was reduced to Ijj Ci per sample. This assay 
monitors the production of [32P] cAMP from the substrate a[32P]ATP. The 
cAMP thus produced is separated from unreacted oc[32P] ATP by a two-step 
column method.
Sa m p l e  p r e p a r a t io n
Briefly, reaction mixtures of 50jil containing; 5mM creatine 
phosphate, lOOmM NaCl, lOOU/ml creatine phosphokinase, 25mM Tris 
acetate pH7.0, 5mM Mg acetate, 0.5mM ATP pH 7 .0 ,0.05mM cAMP, ImM 
DTT, O.lmg/ml BSA, lOmM GTP pH 7.0, oc[32p]ATP (1x1 0 6  c.p.m.), 
between 5 to 20jig of membrane protein., together with the ligand(s) of 
interest. Reaction tubes were kept on ice at all times and the reaction started 
by removal to a 30°C water bath. After 15 mins, the reaction was 
terminated by removal to ice and the addition of lOOjil of stopper solution 
which was 2% (w/v) SDS, 45mM ATP, 1.3mM 3’5’cAMP. 50pl of [8 - 
3H]3t-5'cAMP (approx. 10,000 c.p.m) was added to each tube prior to 
boiling for 15 mins. 750jil of water was then added to each sample, and the 
32p cAMP content of each tube determined.
Pr e p a r a t io n  o f  p o w e x  a n d  a l u m in a  c o l u m n s
The method used to quantitate the amount of cAMP produced by each 
sample was identical to that of Salomon (Salomon, 1979) and involves the
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separation of cyclic AMP from other nucleotides by Dowex and then 
alumina chromatography. Dowex H+ 50x4(200-400) was washed in twice its 
packed volume with 1M Hydrochloric acid and then with the same volume 
of water four times. The Dowex was mixed with water to a slurry (1:1 v/v 
ratio) and then 3mls removed and added to glass wool stoppered columns. 
The water was allowed to drain out and the columns washed with 2mls of 
1M hydrochloric acid and stored at room temperature. Prior to use, the 
columns were washed with 1ml of 1M hydrochloric acid followed by 20mls 
of water.
The alumina columns were prepared by the addition of 0.6g of dry 
neutral alumina to glass wool stoppered columns and the columns washed 
with 12mls of 1M Imidazole buffer pH 7.3 followed by 15mls of 0.1M 
Imidazole buffer pH 7.3 and then stored at room temperature. On the day 
of use, each column was washed with 8mls of 0.1M Imidazole pH 7.3.
Se p a r a t io n  o f  c a m p  o n  d o w e x  c o l u m n s
Prior to sample chromatography, the nucleotide elution profiles for 
each column were determined. This was performed by applying a mixture 
of pH] cAMP and P 2P]ATP to the column and determining the elution 
volume.
Stock pH]cAMP was diluted with water to give approximately 10,000 
c.p.m. in 50pl. [32P]ATP was diluted from stock of lmCi/ml to give 
approximately 2000 c.p.m. in 50|il. 50jil of each of the cAMP and ATP 
solutions were added to 900pl of water and the mixture applied to a dowex 
column. The ATP and cAMP were eluted from the column by successive 
washes of the column with 0.5mls of water. Fractions were collected in a 
vial with 5mls of Ecoscint and radioactivity determined by scintillation 
counting using a dual label programme. The elution volumes required to 
elute the cAMP from the Dowex columns were then determined
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graphically. Typical recovery from the Dowex columns was always greater 
than 80%.
The elution volume required to elute the cAMP from the alumina 
columns was determined as for the Dowex columns except that only 
pH]cAMP was used, and the eluting buffer was 0.1M Imidazole. Recoveries 
were similar to that obtained for the Dowex columns.
DETERMINATION OF CAMP PRODUCED BY MEMBRANE FRACTIONS
Samples (total volume 950jal) were added to prepared Dowex 
columns and the ATP eluted with 1.8mls of water. 3.5mls of water was then 
added to the Dowex columns and this eluate allowed to run directly onto the 
alumina columns. The cAMP fraction was eluted into vials containing 12mls 
of Ecoscint, with 6 mls of 0.1M Imidazole pH7.3. The recovery of cAMP 
from the columns was routinely greater than 75%, when recovery fell 
below 60% the columns were discarded and fresh columns prepared. This 
gave a column life of approximately 6  months.
The cAMP fractions obtained were counted on a dual label 
scintillation counting programme which automatically corrected for 
’spillover’ from each channel. The amount of cAMP produced by each 
sample was calculated by taking into account the recovery from each 
column, based on the recovery of the pH]cAMP internal standard. Data was 
thus calculable in pmoles of cAMP produced per minute per milligram of 
membrane protein, and the assay was sensitive to approximately 5 
pmoles/min/mg.
10. STATISTICAL ANALYSIS
Where appropriate, data were analysed for statistical significance 
using Student's two-tailed t-test (paired).
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CHAPTER 3
COUPLING OF THE ADRENERGIC 
RECEPTOR IN NG108-15 CELLS 
TO G-PROTEINS
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INTRODUCTION
The neuroblastoma x glioma cell line NG108-15 (also called 
108CC15) is a popular model system for the study of signal transduction 
in neuronal type cells. This cell line was generated by fusion of the 6- 
thioguanine-resistant mouse neuroblastoma cell line N18TG2 and the 
bromodeoxyuridine-resistant rat glioma cell line C6BU1 followed by 
selection with hypoxanthine, aminopterin, thymidine (HAT) medium and 
cloning (Hamprecht, 1977). These cells exhibit many of the properties 
usually ascribed to neurons, including excitable membranes, formation of 
functional synapses, and neurotransmitter synthesis and release (see 
Hamprecht et al. 1985, for review).
In addition, NG108-15 cells express a wide range of receptors, 
including adrenergic, muscarinic and opioid types, and a number of 
different second messenger generating systems, including stimulation and 
inhibition of adenylyl cyclase, and stimulation of phospholipase C. These 
intracellular effectors are coupled to their receptors by various 
heterotrimeric G-proteins (Milligan et al. 1990), but the designation of 
which G-protein couples to which receptor is not clear. Neither is the 
specificity of this coupling well defined; it is not known whether one class 
of receptor couples to only one G-protein type, or whether there is 
“promiscuity” of coupling, wherein a receptor couples to whichever G- 
protein is available.
This chapter describes the results obtained from a study of the 
coupling of the adrenergic receptor expressed in NG108-15 cells to its G- 
protein. It has been known since 1975 that noradrenaline caused inhibition 
of PGEi stimulated adenylyl cyclase activity in NG108-15 cells (Traber et 
al. 1975). Sabol and Nirenberg showed that this inhibition could be 
blocked by the a-adrenergic antagonists phentolamine and
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dihydroergotamine, but not by (3-adrenergic antagonists such as 
propranolol, (Sabol and Nirenberg, 1979) suggesting that the receptor 
involved was of the a-subtype. In addition, they found that inhibition of 
adenylyl cyclase was GTP dependant. Radioligand binding studies showed 
that the radiolabelled 0C2 -adrenergic antagonist pH]-yohimbine bound with 
high affinity to a site on membranes from NG108-15 cells, while the a i  
antagonist radioligand, pH]-prazosin did not (Kahn et al. 1982). It was 
further shown that pH]-adrenaline binding to NG108-15 membranes was 
reduced by high concentrations of GTP and &pp(NH)p, while these agents 
had no effect on pH]-yohimbine binding. Kahn et al. suggested that 
NG108-15 cells possessed a receptor of the 0C2 -adrenergic subtype which 
was coupled to adenylyl cyclase in a GTP-dependant, inhibitory manner. 
Their data supported the idea that the receptor occured in two affinity 
states, high and low, both labelled with the same affinity by pH]- 
yohimbine, while pH]-adrenaline labelled only the high affinity state.
It is clear, therefore, that NG108-15 cells possess an adrenergic 
receptor of the 0C2 -subtype which is coupled to inhibition of adenylyl 
cyclase. The regulation of receptor affinity by GTP and 6pp(NH)p 
suggests the involvement of a G-protein in this coupling (see 
Introduction). Klee et al. showed that pretreatment of NG108-15 cells with 
pertussis toxin abolished the inhibition of adenylyl cyclase by adrenaline, 
hence the G-protein involved is a pertussis toxin substrate (Klee et al. 
1985). However, it has been demonstrated that there are at least three 
pertussis toxin substrates expressed in NG108-15 cells (McKenzie and 
Milligan, 1990), hence the identity of the G-protein responsible for 
coupling the adrenergic receptor in NG108-15 cells to inhibition of 
adenylyl cyclase is unclear. It was decided to make use of specific anti-G- 
protein antibodies to attempt to identify the G-protein which functions as 
“Gi”, the inhibitory G-protein of adenylyl cyclase in NG108-15 cells.
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This chapter shows how this identification was achieved. Firstly, a 
study of the G-protein complement of NG108-15 cells was made, using 
antibodies against various G-protein a-subunits, and pertussis and cholera 
toxin catalysed ADP-ribosylation of these subunits to define the G-proteins 
present. These results confirmed the presence of Gs, Gi2, Gi3, and Go in 
NG108-15 cells. Secondly, the adrenergic receptor in NG108-15 cells was 
characterised by radioligand binding, suggesting that the receptor was of 
the 0C2B-subtype. It was further shown that agonist displacement of 
antagonist binding to the receptor was reduced by &pp(NH)p, a GTP 
analogue known to uncouple G-proteins from their receptors. Finally, it 
was shown that pre-incubation of membranes from NG108-15 cells with 
antibodies raised against the C-terminal sequence of Gi2 had a similar 
effect to#pp(NH)p on ligand binding, and that this effect was specific to 
the antiserum against Gi2, antisera against equivalent regions of Gi3, Go, 
and Gs being ineffective. These results suggest that the adrenergic receptor 
in NG108-15 cells interacts directly, and specifically, with Gi2.
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RESULTS
1. CHARACTERISATION OF THE G-PROTEIN 
COMPLEMENT OF NG108-15 CELLS
Immunoblots of membranes from NG108-15 cells using the antisera 
described in Table 2.1 (Chapter 2) demonstrated the presence of a range 
of G-protein oc-subunits (Figure 3.1). Antiserum OC1, raised against a 
decapeptide of the C-terminal sequence of Goa, recognised a 39kDa 
protein in NG108-15 membranes which comigrated with Go from rat 
brain. Antiserum AS7 recognised a 40 kDa protein in membranes from 
NG108-15 which comigrated with Gi2 from rat brain and C6BU1 cells. 
AS7 also identified a 41kDa protein in rat brain which is G il, however 
this peptide was not recognised in NG108-15 membranes or from 
membranes of C6BU1 cells. Antiserum AS7 was raised against the C- 
terminal 10 amino-acids of the a-subunit of transducin, and as this 
sequence is (with a single amino acid difference) common to transducin, 
G il, and Gi2, AS7 recognises all of these a-subunits (Spiegel, 1990). 
Antiserum I3B, which was raised against the Gi3a C-terminus recognised 
a single protein in membranes from NG108-15, which had an apparent 
molecular weight of 41kDa, and which comigrated with Gi3oc from 
C6BU1 cells and rat adipocytes. Antiserum CS1 recognised two proteins in 
membranes from NG108-15, which comigrated with the two forms of Gs 
from rat adipocyte membranes. The identities of the G-protein a-subunits 
from the membranes used as standards in these immunoblots had 
previously been established in a study by Mitchell et al. (Mitchell et al. 
1989). These immunoblots, therefore, showed that membranes from 
NG108-15 cells contained the a-subunits of Gs, Go, Gi2, and Gi3. Figure
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3.2 demonstrates the expression of the G-protein (3-subunit in membranes 
from NG108-15 cells.
Thiol-activated pertussis toxin-catalysed ADP-ribosylation of 
membranes from NG108-15 cells in the presence of [32P] NAD+ followed 
by SDS-PAGE under conditions which allowed resolution of proteins in 
the 35-45 kDa range, and subsequent autoradiography, showed that 
pertussis toxin incorporated radiolabel into 3 proteins (Figure 3.3). These 
proteins had apparent molecular weights of 39, 40 and 41kDa, and were 
found to comigrate with proteins identified on immunoblots as Goa,
Gi2a, and Gi3a, respectively (Figure 3.3). Hence the pertussis toxin 
substrates from membranes of NG108-15 cells are the a-subunits of Go, 
Gi2, and Gi3. Treatment of NG108-15 cells with pertussis toxin (50ng/ml 
for 16 hours) resulted in complete ADP-ribosylation of pertussis toxin 
substrates, as was confirmed by challenging membranes from pertussis 
toxin-treated NG108-15 cells with fresh thiol-activated pertussis toxin in 
the presence of [32P]NAD+ as substrate (Figure 3.4). Membranes from 
control cells were shown to be [32P] ADP-ribosylated, but membranes 
from pertussis toxin pretreated cells were not (Figure 3.4).
Thiol-activated cholera toxin-catalysed ADP-ribosylation of 
membranes from NG108-15 cells in the presence of [32P] NAD+ followed 
by SDS-PAGE under resolving conditions, and subsequent 
autoradiography showed that cholera toxin incorporated radioactivity into 
two proteins of apparent molecular weight 42 and 44 kDa (Figure 3.5). 
These proteins comigrated with those recognised on immunoblots by the 
antiserum CS1. Hence the cholera toxin substrates of membranes from 
NG108-15 cells are two forms of Gsa.
The experimental design of “uncoupling experiments” to investigate 
which G-protein was coupled to a particular receptor required that 
membranes from NG108-15 cells be incubated with protein-A Sepharose-
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purified anti-G-protein antisera. Protein-A purification of the plasma 
fraction of rabbit blood results in an antibody fraction free from other 
plasma proteins which may interfere with antibody binding. It was 
therefore necessary to establish that protein-A purified antisera recognised 
the same G-protein a-subunits as crude antiserum. Figures 3.6 and 3.7 
show that the antisera OC1, CS1,13B, and AS7, when purified on Protein- 
A Sepharose (as detailed in Chapter 2) show the same specificity as the 
crude antisera, indeed there is some improvement in the signal, as 
background bands recognised by the crude antisera are not detected by the 
protein-purified antisera (Figure 3.6).
2. CHARACTERISATION OF THE ADRENERGIC RECEPTOR 
IN NG108-15 CELLS.
The adrenergic receptor in NG108-15 cells was characterised by use 
of the specific a 2 -adrenergic antagonist radioligand, pH]-yohimbine 
(Daiguji et al. 1980). Radioligand binding experiments established that 
membranes from NG108-15 cells bound pH]-yohimbine rapidly at 30°C, 
with equilibrium being attained after 5-10 minutes (Figure 3.8). Non­
specific binding, as assessed by co-incubation of pH]-yohimbine with 
IOOjiM(-) noradrenaline, reached equilibrium within 1 minute (results not 
shown). This binding was linear over a range of NG108-15 membrane 
concentrations from 25-200jig protein (Figure 3.9). All subsequent assays, 
unless otherwise stated, were performed at 30°C, for 30 minutes, using 
lOOpg of membrane protein.
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It should be noted that the slopes of the displacement curves in 
Figure 3.11 are not simple, with Hill slopes that are not equal to 1. This 
might suggest that prazosin and oxymetazoline are binding to two forms of 
a single receptor, or that they are binding to a number of receptors which 
have similar affinities for yohimbine, but which have different affinities 
for oxymetazoline and prazosin. This has some implications which are 
mentioned in the Discussion (page 103)
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Saturation binding isotherms indicated that, in the presence of 
20mM Mg2+, [3H]-yohimbine bound to a single high affinity site (Figure 
3.10a). Scatchard transformation of the results suggested a Kd of 2.3 (± 
0.5) nM (mean ± SD, n=4), and a mean Bmax of 93.6 (± 9.4) ftnoles/mg, 
(Figure 3.10b). Non-specific binding was typically 40-50% of total 
binding (results not shown).
Bylund et al. have shown that the subtypes of the oc2 -adrenoceptor 
can be discriminated pharmacologically on the basis of their affinities for 
the adrenergic agonist oxymetazoline, and the antagonist, prazosin (Bylund 
et al. 1988). pH]-yohimbine binding to membranes of NG108-15 cells was 
displaced by oxymetazoline with a Ki of 24.0 (± 6.9) nM (mean ± SEM, 
n=3), and by prazosin with a Ki of 33.1 (± 2.5) nM (n=4) (Figure 3.11). 
Ki was estimated from IC50  values corrected for receptor occupancy by 
the method of Cheng and Prussoff (Cheng and Prussoff, 1973). This high 
affinity for both prazosin and oxymetazoline is typical of an 0C2B 
adrenergic receptor (Bylund 1988).
The effect of the poorly-hydrolysed GTP analogue, £pp(NH)p, on 
the 0C2B-receptor in membranes from NG108-15 cells was examined by 
displacing pH]-yohimbine with noradrenaline (Figure 3.12). The presence 
of the GTP analogue (IOOjxM) caused a shift in the IC50 for noradrenaline 
displacement of pH]-yohimbine from 0.35 (±0.3)pM to 4.8(±3.2)pM  
(means ± SEM, n=4), suggesting that the receptor possesses multiple 
affinity states, which can be modulated by guanine nucleotides (see 
Chapter l).6pp(NH)p altered the apparent Hill slopes (nn) from 0.52 to 
1.03, indicating a decrease in cooperativity, or a shift from a multiple 
affinity state receptor to a receptor with only one affinity state. This effect 
of Spp(NH)p is common to agents which interfere with receptor-G-protein 
coupling, and was used in the following experiments to examine receptor- 
G-protein coupling.
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Displacement of [3H]-yohimbine binding with a single concentration 
of noradrenaline in the presence of agents which interfere with receptor- 
G-protein coupling results in an measured increase in specific pH]- 
yohimbine binding - this being due to the reduction in receptor affinity for 
agonist, while antagonist binding remains unaffected (see Chapter 1 for a 
discussion of G-protein modulation of receptor affinities). This apparent 
increase in pH]-yohimbine binding in the presence of noradrenaline 
therefore represents a measure of the receptor-G-protein coupling. 
Uncoupling of the adrenergic receptor from NG108-15 cells by 
preincubation of membranes from NG108-15 cells with specific anti-G- 
protein antisera should thus be detected as an increase in pH]-yohimbine 
binding.
3. UNCOUPLING OF THE ADRENERGIC RECEPTOR IN 
NG108-15 CELLS
The rationale of uncoupling experiments using specific anti-G- 
protein antisera required that membranes from NG108-15 cells be 
incubated with specific anti-G-protein antisera followed by radioligand 
binding of pH]-yohimbine in the presence of a displacing concentration of 
noradrenaline. It has previously been established that a 60 minute 
preincubation period at 30°C was sufficient to elicit binding of antisera to 
G-proteins under these assay conditions (McKenzie and Milligan, 1990, 
and FR McKenzie PhD thesis, University of Glasgow 1989). Table 3.1 
shows that pH]-yohimbine binding to membranes from NG108-15 cells
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was unaffected by preincubation of membranes for up to 60 minutes at 
30°C, and Figure 3.13 shows that preincubation of membranes from 
NG108-15 cells with a protein-A purified IgG fraction from normal 
rabbit serum or from antisemm AS7, or with lOOjiM Spp(NH)p, did not 
affect total specific pH]-yohimbine binding.
Figure 3.14 shows the effect of incubation of membranes from 
NG108-15 cells with antisera raised against specific G-protein a-subunits 
followed by assessment of specific [3H]-yohimbine binding in the presence 
of ljiM (-) noradrenaline, a concentration which displaces -70% of 
specific [3H]-yohimbine binding (see Figure 3.12). Incubation with 
protein-A purified IgG from normal rabbit serum, or from antisera OC1, 
CS1 or I3B does not affect (-) noradrenaline displacement of pH]- 
yohimbine binding. However, incubation with 6pp(NH)p (lOOjiM), or with 
protein-A purified IgG from antisemm AS7 caused a statistically 
significant increase in apparent pH]-yohimbine binding (PcO.OOl, 
Student’s t-test). This effect is likely to be due to the alteration in the 
affinity state of the receptor which results from uncoupling of the G- 
protein from the receptor. Antisemm AS7 was raised against a synthetic 
decapeptide representing the C-terminus of transducina, which sequence 
is, with a single amino acid difference, shared by G ila and Gi2a . In 
NG108-15 cells, AS7 recognises the a-subunit of Gi2 only (Figure 3.1), 
therefore this uncoupling effect of AS7 must be due to interaction of the 
antibody with Gi2.
Coincubation of membranes from NG108-15 with protein-A 
purified AS7 and lOOjiM£pp(NH)p (Figure 3.15) produced no greater 
increase in pH]-yohimbine binding in the presence of ljiM noradrenaline 
than incubation with protein-A purified AS7 or£pp(NH)p alone, 
suggesting that antisemm AS7 had completely uncoupled the a2B receptor 
in NG108-15 cells, and that no other G-protein was involved. This idea
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was supported by experiments using membranes from pertussis toxin 
pretreated NG108-15 cells, where incubation with protein-A purified AS7 
or IOOjxM £pp(NH)p caused no further increase in [3H]-yohimbine binding 
in the presence of ljiM noradrenaline (Figure 3.16).
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Figure 3.1
IMMIJNOBLOT ANALYSTS OF MEMBRANES FROM NG108-15 CELLS
Membranes from NG108-15 cells were separated on SDS-PAGE as 
described in Chapter 2, and western blotted onto nitrocellulose sheets. 
Western blots were incubated with anti-G-protein antisera as described in 
Chapter 2. Samples were incubated with 1:200 dilutions of:
A: antiserum OC1 (1; 100 jig NG108-15 membranes, 2; 10 jig
rat cerebral cortex membranes)
B: antiserum CS1 (1; 100 Jig NG108-15 membranes, 2; 50 jig
rat white adipocyte membranes)
C: antiserum I3B (1; 100 jig NG108-15 membranes, 2; 50 jig rat 
white adipocyte membranes, 3; 100 jig rat glioma C6 
BUI membranes)
D: antiserum AS7 (1; 100 jig NG108-15 membranes, 2; 50 jig
rat cerebral cortex membranes, 3; 50 jig rat glioma C6 
BUI membranes).
Primary antisera were detected by incubation with a donkey-anti- 
rabbit horseradish peroxidase-linked second antiserum, as detailed in 
Chapter 2. The substrate for the enzyme was o-dianisidine.
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Figure 3.2
IMMUNOBLOT DETECTION OF P-SIJBUNIT IN MEMBRANES FROM 
NG108-15 CELLS.
Membranes from NG108-15 cells (100jag) were separated on SDS- 
PAGE and western blotted onto nitrocellulose as described in Chapter 2. 
Western blots were then immunoblotted with antiserum BN1, which detects 
the G-protein p-subunit. Lanes are membranes from:
A. NG108-15 (lOOjig)
B. Rat brain (lOOjig)
Chapter 3
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Figure 3.3
PERTUSSIS TOXIN SUBSTRATES IN MEMBRANES FROM N G 108-15  
CELLS
Membranes from NG108-15 cells (lOOpg) were ADP-ribosylated by 
thiol-activated pertussis toxin for 90 minutes at 37°C,using [32P]NAD+ as 
substrate, as detailed in Chapter 2. ADP-ribosylated membranes were 
separated on SDS-PAGE, and western blotted onto nitrocellulose. The 
nitrocellulose was immunoblotted with antisera, as indicated below. The 
immunoblot was developed, dried and subsequently autoradiographed, as 
described in Chapter 2.
Lane A shows an autoradiograph of the region of the immunoblot 
encompassing proteins of the 35-45kDa range.
Lanes B-D show the region of the immunoblots encompassing 
proteins of the 35-45kDa range.
Lane B was immunoblotted with antiserum I3B, which 
recognises the a-subunit of Gi3.
Lane C was immunoblotted with antiserum AS7, which 
recognises the a-subunits of Gi2 and Gil.
Lane D was immunoblotted with antisemm IM1, which 
recognises the a-subunit of Go.
None of the proteins identified incorporated radioactivity in the 
absence of activated pertussis toxin.
Figure 3.3
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Figure 3.4
PERTIISSTS toxtn su b st r a t e s  in  m em br a n es  fro m  p e r t u s s is  
TOXIN PRETREATEP NG108-15 CELLS
NG108-15 cells were grown in the presence of pertussis toxin 
(50ng/ml) for 16 hours, and membranes prepared as described in Chapter
2. Membranes from control and pertussis toxin-pretreated NG108-15 cells 
(lOOpg) were ADP-ribosylated by thiol-activated pertussis toxin for 90 
minutes at 37°C, using [32P]NAD+ as substrate, as detailed in Chapter 2. 
Ribosylated membranes were separated on 10% SDS-PAGE, followed by 
drying of the gel, and subsequent autoradiography. This figure shows an 
autoradiograph of the region of the gel encompassing proteins of the 35- 
45kDa range.
Lane 1: Membranes (100jig) from untreated NG108-15 cells
Lane 2: Membranes (lOOjig) from pertussis toxin-treated NG108-15 
cells
None of the proteins identified incorporated radioactivity in the 
absence of activated pertussis toxin.
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Figure 3.5
C h o lera  t o x in  su b st r a t e s  in  m e m b r a n es  fr o m  N G 108-15
CELLS.
Membranes from NG108-15 cells (100jig) were ADP-ribosylated 
by thiol-activated cholera toxin for 90 minutes at 37°C, using [32P]NAD+ 
as substrate, as detailed in Chapter 2. ADP-ribosylated membranes were 
separated on SDS-PAGE, and western blotted onto nitrocellulose. The 
nitrocellulose was immunoblotted with antiserum CS1, which detects the a -  
subunit of Gs, as described in Chapter 2. The immunoblot was developed, 
dried and subsequently autoradiographed. This figure shows:
Lane A: an autoradiograph of the region of the immunoblot 
encompassing proteins of the 35-55kDa range.
Lane B: the region of the immunoblot encompassing 
proteins of the 35-55kDa range.
None of the proteins identified incorporated radioactivity in the 
absence of activated cholera toxin.
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F igure 3.6
Spe c ific it y  of  pr o t fjn -a  pu r ifie d  an tiser a
Protein-A purified antisera were prepared as detailed in Chapter 2, 
and used at a dilution of 1:200 in 1% gelatin in TBS. Crude antisera were 
used as described in the legend to Figure 3.1. Membranes from NG108-15 
cells (10, 50, and lOOjig) were separated on SDS-PAGE and western 
blotted as described in Chapter 2. Western blots were incubated with crude 
and protein-A purified antisera as illustrated.
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Figure 3.7
Spe c ific it y  of  p r o t e in -a  pijrtftep antiseriim  AS7
Protein-A purified antiserum AS7 was prepared as detailed in 
Chapter 2, and used at a dilution of 1:200 in 1% gelatin in TBS. Crude 
antiserum was used as described in the legend to Figure 3.1. Membranes 
from NG108-15 cells (10, 50, and 100jig) were separated on SDS-PAGE 
and western blotted as described in Chapter 2. Western blots were 
incubated with crude and protein-A purified antiserum AS7 as illustrated.
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Figure 3.8
TIME COURSE OF ASSOCIATION OF T3H1-YOHIMBINE SPECIFIC 
BINDING TO MEMBRANES FROM NG108-15 CEIXS
Specific [3H]-yohimbine (lOnM) binding to membranes (100jig) of 
NG108-15 cells at 30°C was assessed at the time points shown. Non­
specific binding was defined by parallel incubation with (-) noradrenaline 
(lOOjiM). Points shown are mean (± SD) of triplicate determinations from 
a single experiment, which was repeated twice using different NG108-15 
membrane preparations, with similar results being obtained.
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Figure 3.9
S p e c if ic  b in d in g  o f  r 3 H i- y o h im b in e  t o  in c r e a s in g
AMOUNTS OF MEMBRANES FROM NG108-15 CELLS
Specific pH]-yohimbine (lOnM) binding to increasing amounts of 
membranes of NG108-15 cells at 30°C was assessed as shown. Non-specific 
binding was defined by parallel incubation with (-) noradrenaline 
(IOOjiM). Points shown are mean (± SD) of triplicate determinations from 
a single experiment, which was repeated twice using different NG108-15 
membrane preparations, with similar results being obtained.
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Figure 3.10a
SPECIFIC BINDING OF INCREASING CONCENTRATIONS OF T3H1- 
YOHIMBINE TO MEMBRANES FROM NG108-15 CELLS
Membranes (lOOpg) of NG108-15 cells were incubated for 30 
minutes at 30°C with various concentrations of [3H]-yohimbine as shown. 
Non-specific binding was determined in the presence of lOOpM (-) 
noradrenaline, and increased in a linear fashion over the range of [3H]- 
yohimbine concentrations, being 35-50% of total binding (not shown). 
Points shown are means (± SEM) from 4 separate experiments using 
different membrane preparations.
Figure 3.10b
SCATCHARD TRANSFORMATION
Data from Figure 3.10a have been transformed by the method of 
Scatchard (Scatchard, 1949). Results suggested a Kd of 2.3 (±0.5) nM 
(mean ± SEM, n=4), and a mean Bmax of 93.6 (±9.4) fmoles/mg.
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Figure 3.11
D ispl a c e m e n t  of  l^ HI-y o h im b in e  b in d in g  to  m e m b r a n e s
FROM NG108-15 CELLS BY OXYMETAZOLINE AND PRAZOSIN
Displacement of [3H]-yohimbine (lOnM) to membranes (100jig) of 
NG108-15 cells by prazosin (♦ )  and oxymetazoline (□ ) was assessed at 
30°C for 30 minutes. Points shown are means of triplicate determinations 
(SD has been omitted for clarity, but was less than 10% of the mean in 
each case) from a single experiment which was repeated three times using 
different membrane preparations. For this experiment, IC5 0  for 
oxymetazoline was 0.12jiM, and for prazosin, 0.2jiM. 100% specific pH]- 
yohimbine binding was 88.4 (±4.3) fmoles/mg for prazosin, and 95.4 
(±9.4) fmoles/mg for oxymetazoline.
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Figure 3.12
E ffe c t  of oppnvrnp  o n  d ispl a c e m e n t  of l ih i-y o h t m b tn e
BINDING BY NORADRENALINE IN MEMBRANES FROM N G 108-15  
■CELLS.
Displacement of [3 H] -yohimbine (lOnM) binding by (-) 
noradrenaline in membranes from NG108-15 cells (lOOjig) was measured 
in the presence (♦ )  and absence (□ ) of IOOjiM Gpp(NH)p at 30°C for 30 
minutes. Points shown are means from four experiments using different 
membrane preparations. SEM has been omitted for clarity, but was less 
than 10% of the mean in all cases. 100% specific binding was 90.3 (±4.5) 
fmoles/mg for control, and 95.5 (±7.3) fmoles/mg for gpp(NH)p samples.
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Table 3.1
E f f e c t  o f  60 m in u te  p re tn c ijb a tto n  o f  m em branes f r o m  
NG108-15 CELLS AT 3QQ.C ON T3H1-YOHIMBINE BINDING
Membranes from NG108-15 cells (lOOjig) were incubated for 60 
minutes at 30°C, or at 0°C, or not preincubated before addition of (-) 
noradrenaline (lOOjiM) or buffer, and [3H]-yohimbine (lOnM). Incubation 
continued for a further 30 minutes before assessing specific binding by rapid 
filtration, as described in Chapter 2. Results are mean ± SEM, n=3.
[3H]-yohimbine binding (fmoles/mg) 
73.4 (±7.4)
74.3 (±6.5)
76.1 (±7.5)
Condition 
Not preincubated 
Preincubated 60 minutes, 30°C 
Preincubated 60 minutes, 0°C
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Figure 3.13
E f f e c t  o f  p r e in c u b a t io n  w it h  a n t is e r a  o r  g p p (N H )p o n
TOTAL T3H1-YOHIMBINE BINDING TO MEMBRANES FROM NG108- 
15 CELLS
Membranes from NG108-15 cells (lOOjig) were incubated for 60 
minutes at 30°C with protein-A purified antiserum (10p.g/sample) or 
lOOjiM 6;pp(NH)p as shown, before addition of buffer or (-) noradrenaline 
(lOOjiM), and pH]-yohimbine (2nM). Incubation continued for a further 
30 minutes before specific binding was assessed by rapid filtration, as 
described in Chapter 2. Points represent the means ± SEM of four 
experiments performed on different membrane preparations. 1 0 0 % 
specific binding was 23.9 (±0.7) fmoles/mg.
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Figure 3.14
E f f e c t  o f  p r e in c u b a t io n  w it h  a n t is e r a  o r  o p p n v m p o N
SPECIFIC T3H1-YOHIMBINE BINDING TO MEMBRANES F R O M  
NG108-15 CELLS
Membranes from NG108-15 cells (lOOjig) were incubated for 60 
minutes at 30°C with protein-A purified antiserum (10|xg/sample) or 
100|iM 6 pp(NH)p as shown, before addition of buffer or (-) noradrenaline 
(ljiM), and [3H]-yohimbine (2nM). Incubation continued for a further 30 
minutes before specific binding was assessed by rapid filtration, as 
described in Chapter 2. Points represent the means ± SEM of four 
experiments performed on different membrane preparations. 1 0 0 % 
specific binding was 24.6 (±1.4) fmoles/mg. *P<0.001 (Student’s t-test).
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Figure 3.15
E f f e c t  o f  cotnctjbatton  w it h  a n t is e r iim  AS7 a n d  
GPP f N H )P  ON SPECIFIC BINDING OF T3H1-YOHTMRTNE TO 
MEMBRANES FROM NG108-15 CEI/LS
Membranes from NG108-15 cells (lOOjig) were incubated for 
60 minutes at 30°C with protein-A purified AS7 (lOpg/sample) and/or 
&pp(NH)p (lOOjiM) as shown, before addition of buffer or (-) 
noradrenaline (lpM ), and [3H]-yohimbine (2nM). Incubation continued for 
a further 30 minutes before specific binding was assessed by rapid 
filtration, as described in Chapter 2. Points represent the means ± SEM of 
four experiments performed on different membrane preparations. 1 0 0 % 
specific binding was 25.0 (±2.4) fmoles/mg.
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Figure 3.16
E f f e c t  o f  AS7 o r  o p p n v m p  p re tn c t jb a t to n  o n  s p e c if ic  
BINDING OF_T3H1 - YOHIMBINE TO MEMBRANES OF PERTUSSIS 
TOXIN PRETREATED NG108-15 CELLS
Membranes from control or pertussis toxin pretreated (50ng/ml, 16 
hours) NG108-15 cells (lOOjig) were incubated for 60 minutes at 30°C 
with protein-A purified AS7 (lOpg/s ample) or gpp(NH)p (lOOpM) as 
shown, before addition of buffer or (-) noradrenaline (lpM ), and [3H]- 
yohimbine (2nM). Incubation continued for a further 30 minutes before 
specific binding was assessed by rapid filtration, as described in Chapter 2. 
Points represent the means ± SEM of three experiments performed on 
different membrane preparations. 100% specific binding was 25.1 (±1.7) 
fmoles/mg (control membranes) and 23.4 (±0.9) fmoles/mg (pertussis 
toxin treated membranes).
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DISCUSSION
NG108-15 is a commonly used cell line for the study of signal 
transduction in a “neuronal” type cell (Milligan et al, 1990, Hamprecht 
et al. 1985). It has proved useful for the study of 8 -opioid receptor 
coupling to G-proteins (McKenzie and Milligan, 1990), differentiation 
(Mullaney and Milligan, 1989) and calcium channel regulation by G- 
proteins (McFadzean et al. 1989). These studies have all taken 
advantage of the presence in NG108-15 cells of a range of receptor 
types and intracellular effectors. Most of these studies have been 
concerned with identifying the G-protein(s) responsible for mediating 
the intracellular effects of receptor activation.
One of the first receptors identified on the NG108-15 cell was 
an adrenergic receptor (Traber et al. 1975), which was shown to be 
coupled to inhibition of adenylyl cyclase (Sabol and Nirenberg, 1979). 
This inhibition was later shown to be pertussis toxin sensitive (Klee et 
al. 1985), indicating that a G-protein which was modified by this toxin 
was involved in the coupling of the adrenergic receptor to adenylyl 
cyclase inhibition. The generation of specific G-protein antipeptide 
antibodies (see Chapter 1) capable of both identifying specific G- 
proteins and interfering with receptor-G-protein coupling (McKenzie 
and Milligan, 1990; Simonds et al. 1989a, 1989b) suggested that it 
might be possible to use such antisera to identify the G-protein(s) 
responsible for coupling the adrenergic receptor to adenylyl cyclase 
inhibition in NG108-15 cells.
The method used in this study involved measuring changes in 
receptor affinity on uncoupling of receptor from G-protein. It is 
worth addressing the question of why this particular method was 
chosen. There are a number of consequences of receptor activation, as
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outlined in Chapter 1. Firstly, agonist occupation of receptor causes an 
increase in guanine-nucleotide exchange at the G-protein, resulting in a 
GTP-bound heterotrimer, which then dissociates into a - and py- 
subunits (Fung et al. 1981). The a-subunit is now activated, and can 
interact with its intracellular second-message generator -in the case of 
the adrenergic receptor in NG108-15 cells, this is an inhibitory action 
on adenylyl cyclase. After a period of time, an intrinsic GTPase 
activity of the a-subunit cleaves the terminal phosphate of GTP, 
restoring the GDP-bound form of the a-subunit (Cassel and Selinger, 
1977), which then reassociates with both the Py subunits and the 
receptor to return the cycle to the resting state. There are a number of 
points of this cycle which could be used directly to assess G-protein 
activation, notably the stimulation of GTPase activity on receptor 
activation, and also the direct measurement of adenylyl cyclase 
inhibition (Milligan, 1988). Both of these techniques have been used, 
in conjunction with specific anti-G-protein antisera, to identify G- 
protein coupling to receptors (Simonds etaL  1989a, 1989b; McKenzie 
and Milligan, 1990). Why were these, arguably more direct, 
measurements of G-protein activation not used here?
Preliminary experiments using NG108-15 membranes 
established that (-) noradrenaline and (-) adrenaline generated a small, 
but significant, increase in GTPase activity , of the order of 5-10% 
above basal (results not shown). However this GTPase activity was lost 
on the preincubation of the membranes for 60 minutes at 30°C 
required for antibody binding. Similarly, experiments using (-) 
noradenaline to inhibit adenylyl cyclase activity showed -30%  
inhibition of cyclase activity in membranes from NG108-15 cells 
(results not shown, and Sabol and Nirenberg 1979), but again, this 
inhibition was abolished on preincubation of membranes for 60
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minutes. The method using the change in receptor affinity as an assay 
for G-protein coupling to receptor was the only one robust enough to 
survive the preincubation period. To make a virtue of necessity, it 
should also be observed that, for a number of systems, the change of 
receptor affinity on uncoupling from a G-protein is the only method 
of detection of G-protein coupling, because either the stimulation of 
GTPase activity is undetectable, or (as in the case of receptors liked to 
phospholipase C) effector activity cannot usually be measured in 
membrane fractions, and we wished to demonstrate the applicability of 
the technique.
It is clear that, where a sufficiently large GTPase activity is 
obtained, this is the method of choice for assessing receptor-G-protein 
coupling. The reasons why GTPase stimulation is not always 
measurable are not clear. In some cases, this may be due to the 
relatively low numbers of activated G-proteins present, such that the 
signal-to-noise ratio is too low to allow assessment of stimulated 
activity over basal. If, as has been reported by Carty et al., (1990) 
different G-proteins have different activation rates, lack of detectable 
GTPase activity may simply be due to the kinetics of activation of the 
G-protein concerned. In other cases, there seems to be a relationship 
between the number of receptors interacting with a population of G- 
proteins, and the detectability of stimulated GTPase response. It is 
notable that McKenzie and Milligan (1990) were able to detect 8 - 
opioid stimulation of GTPase activity in NG108-15 cells of around 
50% above basal, where they reported a Bmax for [3H]-DADLE 
binding of 400 fmoles/mg, while the results reported here suggest a 
Bmax for [3H]-yohimbine binding of 93 fmoles/mg, this number of 
receptors producing a poorly detectable GTPase response of only 
~ 1 0 % above basal.
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The reasons for the loss of GTPase activity and adenylyl cyclase 
inhibition after preincubation are more obvious. Although it was clear 
that preincubation caused no loss of pH]-yohimbine binding to 
membranes from NG108-15 cells (Table 3.1), preliminary 
experiments using the tritiated adrenergic agonist, pH]-UK 14,304 
suggested a loss of some 20% of pH]-UK14,304 binding sites after 60 
minutes preincubation at 30°C (Control specific pH]-UK 14,304 
binding 76.6 (±3.5) fmoles/mg, incubated membranes specific pH]- 
UK14,304 binding 62.6 (±1.8) fmoles/mg, results are mean ± SEM, 
n=2 ). The implication of these data is that the receptors were being 
gradually uncoupled by the process of preincubation per se, adopting a 
low affinity state for their agonist which is detected as a reduction in 
pH]-UK14,304 binding. Despite this, there remained sufficient 
coupled receptors for the antibody incubation experiments to be 
successfully performed.
It has previously been reported that NG108-15 cells express the 
a-subunits of Gi2, Gi3, two forms of Gs, and Go (McKenzie et al.
1988). The results obtained here confirm this finding. The antiserum 
AS7, which was raised against a peptide sequence representing the C- 
terminal 10 amino-acids of bovine transducin (Falloon et al. 1986), 
detects not only transducin, but also Gil and Gi2, which share identical 
C-terminal sequences, differing in only a single amino acid to that of 
transducin (Itoh et al. 1986). In membranes from NG108-15 cells,
AS7 recognises only a single band on western blots, which appears to 
be Gi2 (Figure 3.1). Gil appears not to be expressed in NG108-15 
cells, as it is not detectable immunologically (Figure 3.1), and the 
mRNA for Gil is not detected in NG108-15 cells (McKenzie and 
Milligan, 1990).
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The pertussis toxin substrates of NG108-15 cells are shown in 
Figure 3.3 to be Gi2, Gi3, and Go. As adrenergic inhibition of 
adenylyl cyclase in NG108-15 cells is inhibited by pertussis toxin 
pretreatment (Klee et al. 1985), one or more of these G-proteins is 
responsible for coupling the receptor to adenylyl cyclase. Mullaney 
and Milligan (1990) have shown that isoforms of Go exist in 
membranes from NG108-15, however the separation technique used 
here does not allow detection of these two forms. Pertussis toxin 
pretreatment of NG108-15 cells for 16 hours (50ng/ml) completely 
ADP-ribosylates the group of pertussis toxin substrates, preventing 
subsequent ADP-ribosylation with p 2P]NAD+ as substrate (Figure 
3.4). The cholera toxin substrates of NG108-15 membranes are shown 
in Figure 3.5. Two forms of Gs are identified, with apparent Mr 42 
and 44kDa, with the 44kDa form predominating in both immunoblot 
and ADP-ribosylation study (Figure 3.5). Although 4 cDNA clones of 
Gs have been reported in human brain (Bray et al. 1986), it is not 
known which of these clones is expressed in NG108-15.
The 0C2 -adrenergic receptor in NG108-15 cells was 
characterised by radioligand binding using the tritiated antagonist, 
pH]-yohimbine (Figure 3.10). Previous studies of pH]-yohimbine 
binding to NG108-15 membranes have generated different Kd values. 
Kahn et al. reported a Kd of 9.1nM (Kahn et al. 1982), while Bylund 
et al. reported a Kd of 1.76nM (Bylund et al. 1988). The results 
obtained here suggested a Kd of 2.3nM, in close agreement with 
Bylund. The Bmax obtained in this study was, at 93.6fmoles/mg, 
significantly lower than that reported by both Kahn (258.4 fmoles/mg) 
and Bylund (153 fmoles/mg). The reason for this is likely to be that 
different clones of the cells , with different receptor numbers, have been 
used.
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The characterisation of the CC2  receptor subtype was on the basis 
of affinity of the receptor for oxymetazoline and prazosin, as 
suggested by Bylund (Bylund et al. 1988; Bylund, 1988). The (X2A 
adrenergic receptor, the prototype of which occurs on the human 
platelet, has been shown to possess a high affinity for oxymetazoline, 
and a low affinity for prazosin. The CC2B adrenergic receptor, the 
prototype for which occurs in neonatal rat lung tissue, has a high 
affinity for both prazosin and oxymetazoline. Displacement of pH]- 
yohimbine binding by oxymetazoline and prazosin in membranes from 
NG108-15 cells produced Ki values of 24.0nM and 33.1nM, 
respectively (Figure 3.11). These data suggest that the 0C2 -adrenergic 
receptor on NG108-15 cells is of the 0C2B subtype, which result is in 
agreement with that obtained by Bylund (Bylund et al. 1988).
The effect of guanine nucleotides and their analogues on agonist 
affinities of receptors was one of the first observations which led to 
the development of the idea that a guanine-nucleotide binding protein 
was required for the full functioning of many signal transduction 
systems (Rodbell et al. 1971; Rodbell, 1980). In membranes from 
NG108-15 cells, addition of lOOpM £pp(NH)p, a poorly hydrolysed 
analogue of GTP, caused a reduction in the ability of (-) noradrenaline 
to compete for pH]-yohimbine binding sites (Figure 3.12). IC50  values 
for (-) noradrenaline displacement of pH]-yohimbine increased from 
0.35jliM to 4.8jliM in the presence of £pp(NH)p. Similarly, pseudo-Hill 
slopes changed from 0.52 to 1.03, indicating a decrease in receptor 
cooperativity in the presence of the GTP analogue. These changes are
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consistent with the theory that the receptor affinity for agonist is 
governed by the coupling state of its G-protein. When the GDP- 
liganded G-protein is coupled to its receptor, the receptor has a high 
affinity for its agonist, however if the G-protein becomes activated by 
binding of GTP, or an analogue such as Grpp(NH)p, then the receptor 
adopts a low affinity state for its agonist (Wregget and De Lean,
1984). Similarly, agents which cause the uncoupling of the G-protein 
from its receptor, such as pertussis toxin-catalysed ADP-ribosylation 
of the C-terminus of the G-protein a-subunit, or preincubation with 
antisera which bind to the C-terminus, will cause the receptor to adopt 
a low affinity state for its agonist, resulting in a shift in apparent Kd 
for the agonist (Milligan eta l. 1990; McKenzie and Milligan, 1990).
A single concentration of ljiM(-) noradrenaline was chosen for use in 
subsequent “uncoupling” experiments, this concentration displacing 
«80% of specific pH ]-yohimbine binding in the absence of 6 ,pp(NH)p, 
but only displacing «30% of specific pH]-yohimbine binding in the 
presence of £pp(NH)p (Figure 3.12). Hence, it would be anticipated 
that agents which caused uncoupling of the receptor from its G-protein 
would cause a similar apparent increase in pH ]-yohimbine binding.
The first evidence that the C-terminus of the G-protein a -  
subunit was involved in coupling to receptors came from the 
observation that pertussis toxin-catalysed ADP-ribosylation of a 
cysteine residue 4 amino-acids from the C-terminus of the a-subunits 
of Td, G il, Gi2, Gi3 and Go prevented functional interaction between 
receptor and G-protein (Katada and Ui, 1979, 1982, West et al. 1985). 
This idea was supported by the observation that the lesion responsible 
for the unc mutant of S49 murine lymphoma cells, in which Gs is 
uncoupled from receptors which stimulate adenylyl cyclase, is the 
replacement of an Arg by a Pro residue near the extreme C-terminus
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of Gs (Sullivan et al. 1987). Furthermore, antisera which recognise the 
C-terminus of transducin prevented rhodopsin activation of transducin 
(Hamm and Bownds, 1984). Subsequent to this observation, (as has 
been detailed in Chapter 1) a number of groups have used anti-C- 
terminal antibodies to interfere with receptor-G-protein coupling in 
systems as diverse as human platelet, snail neurons, and S49 murine 
lymphoma cells. Hence it seemed likely that use of anti-C-terminal 
antisera would allow the identification of the G-protein which interacts 
with the 0C2B receptor in NG108-15 cells.
It was established that preincubation with an IgG fraction from 
normal rabbit serum, or with lOOjiM 6 pp(NH)p did not affect total 
[3H]-yohimbine binding in the absence of (-) noradrenaline (Figure 
3.13). However, in the presence of ljxM (-) noradrenaline, 
preincubation of membranes from NG108-15 cells with antisera raised 
against the C-teminal sequences of a range of G-protein oc-subunits 
showed that the antiserum AS7 caused a statistically significant 
increase (PcO.OOl, Student’s t-test) in measured pH]-yohimbine 
binding (Figure 3.14). Preincubation with lOOjiM 6pp(NH)p also 
caused this increase in pH]-yohimbine binding, however preincubation 
with an IgG fraction from normal rabbit serum, or with antisera 
raised against the C-terminal sequences of Go (OC1), Gs (CS1), and 
Gi3 (I3B) did not have this effect. The implication of this apparent 
increase in [3H]-yohimbine binding is that antiserum AS7 and lOOjiM 
gpp(NH)p are both able to uncouple the G-protein that interacts with 
the 0C2B-adrenergic receptor in NG108-15. In the case of 6 pp(NH)p, 
this is achieved by activation of the G-protein a-subunit, and in the 
case of antiserum AS7, by binding to the C-terminus of the a-subunit, 
preventing functional interaction between G-protein and receptor. As 
it has been established that, in membranes from NG108-15, antiserum
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AS7 recognises Gi2 only (Figure 3.1, and McKenzie et al. 1988), we 
can conclude that the OC2B-adrenergic receptor in NG108-15 cells 
interacts specifically with Gi2.
Two further experiments suggested that the CC2 B receptor 
interacts with Gi2 alone, and that no other G-protein is involved. Co­
incubation of antiserum AS7 and lOOjiM ^ pp(NH)p (Figure 3.15) 
produced no greater increase in pH]-yohimbine binding than either 
AS7 or§pp(NH)p alone. This indicated that antiserum AS7, at the 
concentration used (lOjig AS7 per lOOjig NG108-15 membranes), was 
able fully to uncouple the receptor from Gi2, producing the same 
degree of effect as lOOjiM §pp(NH)p, which would at this 
concentration completely uncouple all the G-proteins present. Finally, 
it was shown that no further increase in pH]-yohimbine binding was 
obtained when AS7 or gpp(NH)p were preincubated with membranes 
from NG108-15 cells which had been pretreated with pertussis toxin 
(Figure 3.16). This would be expected if pertussis toxin had already 
completely ADP-ribosylated Gi2 in vivo, making it impossible for 
further uncoupling to occur as a result of antibody preincubation. 
Hence these experiments indicated that Gi2 alone was coupled to the 
OC2B-adrenergic receptor in NG108-15 cells, and that antiserum AS7 
had completely uncoupled the G-protein from its receptor.
These results provide evidence that Gi2 acts as “Gi”, the 
inhibitory G-protein of adenylyl cyclase, for the adrenergic receptor 
of NG108-15. It has now been shown for a number of receptor 
systems that Gi2 acts as “Gi”, namely the 8 -opioid receptor in NG108- 
15 (McKenzie and Milligan, 1990), and the a 2 A-receptor in human 
platelets (Simonds et al. 1989a), so this may indicate that, where it is 
expressed, and where there is an inhibitory receptor for adenylyl 
cyclase, Gi2 has a general role as “Gi”.
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McFadzean et al. have shown that injection of NG108-15 cells 
with protein-purified antisera raised against the C-terminus of Go 
attenuated the adrenaline-induced reduction of calcium current 
(McFadzean et al. 1989), while injection of AS7 was without effect. 
These studies arose from the findings of Hescheler et al. , who 
reported 8 -opioid receptor-mediated inhibition of Ca2+ currents in 
NG108-15 which was pertussis toxin sensitive. The effect of pertussis 
toxin could be reversed, however, by subsequent injection of purified 
Gi and Go, Go being up to 10 times more potent than Gi (Hescheler et 
al. 1987). The results of McFadzean et al. suggest that the adrenergic 
receptor in NG108-15 is coupled to inhibition of Ca2+ currents via 
Go, and this supports the results of Hescheler in suggesting that Go is 
capable of the control of Ca2+ currents in NG108-15. The results 
reported herein have shown that AS7, which recognises Gi2 only, 
completely uncouples the OC2B receptor in NG108-15, and the 
coincubation experiment (Figure 3.15) and pertussis toxin experiment 
(Figure 3.16) suggested that no other G-protein was involved in 
coupling to this receptor. Hence there is an apparent contradiction 
between the results of McFadzean et al., and the findings reported 
here.
One possible explanation for this apparent contradiction is that 
there are separate, but pharmacologically similar adrenergic receptors 
in NG108-15 cells, each of which interacts with a different G-protein, 
and each of which is coupled to a different intracellular second- 
message generating system. Two results reported here argue against 
this interpretation. Firstly, the saturation binding isotherms of [3H]- 
yohimbine binding suggested a single-site binding affinity (Figure 
3.10). To date, only 3 well defined subtypes of the (X2 -adrenoceptor 
have been reported (Harrison et al. 1991), all of which can be
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The data presented in Figure 3.11 suggest that the Ki values for 
oxymetazoline and prazosin are similar to those observed previously for a 
receptor of the 0C2B subtype (Bylund et al. 1988). However, the slopes of
the displacement curves suggested that oxymetazoline and prazosin were 
binding to more than one receptor (see note to page 72). If this were the 
case, then it is possible that two receptors with similar affinities for 
yohimbine (ie. subtypes of the 0C2 -adrenergic receptor) exist on NG108-15
cells, and the corrollary of this would be that one receptor might couple 
exclusively to Go, while the other couples exclusively to Gi2.
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discriminated pharmacologically by their affinities for oxymetazoline 
and prazosin (Bylund, 1988). The assessment of these affinities in 
NG108-15 (Figure 3.11) clearly suggested an CC2B subtype 
adrenoceptor, so it seems unlikely that another receptor subtype is 
involved. The second piece of evidence against the “two receptors” 
hypothesis is the finding that preincubation of NG108-15 membranes 
with the antiserum OC1, raised against Go did not cause any apparent 
increase in pH]-yohimbine binding, as would be expected if the 
“other” a 2 -receptor were coupled to Go. If there were two receptors 
present with virtually identical affinities for pH]-yohimbine, (and for 
prazosin and oxymetazoline) it should have been possible to detect the 
increase in apparent pH]-yohimbine binding which accompanies 
uncoupling of the receptor. However, this was not detected.
It seems much more likely that the reason for the present failure 
to detect any coupling of the adrenergic receptor in NG108-15 to Go 
lies with the G-proteins themselves. It is customary, when measuring 
Ca2+ currents by electrophysiological methods, to first differentiate 
the cells in question, in order to maximise the currents (Hamprecht et 
al. 1985). Differentiation is usually achieved by preincubation of the 
cells with agents which raise levels of intracellular cAMP, such as 
dibutyryl cAMP, forskolin, and PGEi (Nirenberg et al. 1983). 
Accompanying this elevation in intracellular cAMP levels is a 
morphological change in the cells, resulting in the extmsion of 
neurite-like processes. It has also been shown by Mullaney that 
differentiation of NG108-15 cells results in changes in the levels of Gi 
and Go (Mullaney et al. 1988). Mullaney and Milligan noticed that 
levels of Go were low in comparison to those of Gi in undifferentiated 
cells, but that treatment with dibutyryl cAMP or forskolin resulted in 
an approximate doubling of the levels of Go (Mullaney and Milligan,
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1989). Concurrent with this increase in the level of Go, there was also 
a decrease in levels of the G-protein detected by the antiserum AS7 
(Mullaney et al. 1988).
From these data, it seems clear that the process of chemical 
differentiation results in an alteration in the levels of Gi2 and Go. The 
results obtained by McFadzean et al. showing coupling of the 
adrenergic receptor in NG108-15 to Go, and the results reported here, 
showing coupling of the same adrenergic receptor exclusively to Gi2, 
can therefore be compatible. In the undifferentiated state, NG108-15 
cells express higher levels of Gi2 than Go, and the 0C2B adrenergic 
receptor couples to inhibition of adenylyl cyclase via Gi2. However, 
on differentiation, NG108-15 cells express higher levels of Go, and the 
levels of Gi2 fall. Under these conditions, the CC2B receptor can be 
shown to couple to inhibition of voltage sensitive Ca2+ channels via 
Go. The corrollary of this hypothesis is that the CC2B adrenergic 
receptor in NG108-15 cells is physically capable of interacting with 
two different G-proteins, although it is not clear that these interactions 
ever occur simultaneously.
With reference to this point, it has been shown by Ashkenazi 
that the M2 muscarinic receptor can interact simultaneously with 
adenylyl cyclase and phospholipase C, ie. that a single receptor can 
interact at one time with different G-proteins to generate different 
intracellular effects (Ashkenazi et al. 1987). The results obtained here 
suggest that the adrenergic receptor in NG108-15 interacts specifically 
with only one G-protein at a time, the identity of which is dependant 
on the differentiation state of the cell. Hence the degree of specificity 
of coupling between G-protein and the adrenergic receptor in NG1 OS- 
15 is a property not of the sequence of the G-protein a-subunit, but of
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the prevalence of that G-protein, in terms of absolute amounts 
available for coupling to the receptor.
Mullaney and Milligan have shown recently that NG108-15 cells 
express two isoforms of Go, which they call Gol and Go2 (Mullaney 
and Milligan, 1990). They show that Gol is equivalent to one form of 
Go that is expressed in rat brain, but that Go2 is not equivalent to 
Go*,the other form of Go expressed in rat brain (Goldsmith et al. 
1988). Furthermore, chemical differentiation of NG108-15 cells 
results in an increase in the levels of Gol only, levels of Go2 being 
unaffected (Mullaney and Milligan 1990). These data again raise the 
question of why interaction of the 0C2B receptor with Go in 
undifferentiated NG108-15 cells was not detected. If control of 
voltage-operated calcium channels is mediated by only one form of Go 
(presumably Gol), then it is possible that the levels of Gol in 
undifferentiated NG108-15 cells are so low that interaction with the 
0C2B receptor does not occur, or occurs to such a small extent that it 
cannot be detected using the methods described here.
Despite the substantial degree of sequence homology between G- 
protein oc-subunits, it is clear that, in vivo, a high degree of specificity 
is obtained. Gi2 and Gi3 share 90% sequence homology, yet on the 
basis of the results obtained here, the OC2B-adrenergic receptor in 
NG108-15 cells is capable of discriminating between the two. This is 
also the case for the (X2A receptor in the human platelet, where again, 
the receptor can discriminate between Gi2 and Gi3 (Simonds et al. 
1989a). The interaction of the OC2B receptor in NG108-15 with Gi2 and 
Go under different conditions is therefore clearly a matter of interest. 
Since the receptor is capable of discriminating between two such 
similar a-subunits as those of Gi2 and Gi3 (90% sequence homology),
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and yet will interact under different conditions with Gi2 and Go, 
which share some 80% sequence homology, this raises the question: 
what is the determining factor of G-protein specificity ? The studies in 
Chapter 4 attempt to address this question by transfecting the 0C2A 
adrenergic receptor into a cell line which does not express an 
adrenergic receptor, in order to examine the specificity of coupling of 
G-proteins to this receptor in an “alien” environment.
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CHAPTER 4
INTERACTION OF THE a^-ClO ADRENERGIC
RECEPTOR IN RAT 1 FIBROBLASTS WITH
G-PROTEINS
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INTRODUCTION
The coupling of adrenergic receptors to their G-proteins has not been 
widely studied. The a i  adrenergic receptor has been shown in a number of 
systems to couple to stimulation of phospholipase C, although the identity of 
the G-protein responsible for this coupling is unclear, and its identification 
is made more difficult by its insensitivity to pertussis or cholera toxin 
(Berridge and Irvine, 1984; Burch et al. 1986). Both the 0C2A and 0C2B 
adrenergic receptors have been shown to couple to inhibition of adenylyl 
cyclase via a pertussis toxin sensitive G-protein (Jakobs et al. 1978; Klee et 
al. 1985), but there are several pertussis toxin substrates among the family 
of G-proteins, (Milligan, 1988) and the precise identity of these G-proteins 
remains to be established.
The a 2A-adrenergic receptor was the first 0C2 -adrenoceptor to be 
cloned. The clone identified was found to be localised to human 
chromosome 10 (Kobilka et al. 1987). This clone, designated OC2 -C1 0 , when 
expressed in COS cells showed identical characteristics to the 
pharmacologically defined (X2A adrenergic receptor, the prototype of which 
is found on human platelets, (Harrison et al. 1991) and which possesses a 
high affinity for the adrenergic agonist oxymetazoline and the antagonist 
yohimbine, but a low affinity for the antagonist prazosin (Murphy and 
Bylund 1988). Thus the pharmacological and molecular genetic definitions 
of the CC2 A receptor have converged.
The CC2A receptor in the human platelet has been shown to couple to 
inhibition of adenylyl cyclase via a pertussis toxin sensitive G-protein 
(Jacobs et al. 1978). Simonds et al. have used antisera raised against the C- 
terminal sequences of various G-protein a-subunits to study the specificity 
of coupling of the (X2A receptor to G-proteins (Simonds et al. 1989a). They 
showed that preincubation of platelet membranes with the antiserum AS7,
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which in the platelet recognises Gi2 only, resulted in abolition of the 
adrenaline-induced inhibition of PGEi-stimulated adenylyl cyclase activity. 
Antisera raised against Go, Gi3, Gs or Gz did not have this effect. They 
concluded that Gi2 was the principal transducer of the 0C2A receptor- 
mediated inhibition of adenylyl cyclase in human platelets. Clearly a high 
degree of specificity of coupling obtains here, as the receptor can 
discriminate between Gi2 and Gi3, which share some 90% sequence 
homology (Itoh et al. 1988).
The previous chapter has shown that the OC2B-adrenergic receptor in 
NG108-15 cells is also specifically coupled to Gi2, but that the receptor also 
has the potential to couple specifically to Go. The specificity of this 
coupling is shown by the fact that, like the 0C2 A receptor in human platelets, 
the receptor does not couple to Gi3. Go, on the other hand, has only -80%  
sequence homology to Gi2 (Van Meurs et al. 1987), and yet the 0C2B 
receptor can, under the right circumstances, also couple to this G-protein. 
The receptor therefore exhibits a high degree of discrimination between G- 
proteins, apparently regardless of their sequence similarity or dissimilarity. 
What, then is the factor which determines the specificity of G-protein 
coupling to receptors?
This chapter describes an attempt to examine this question by 
studying the specificity of coupling to G-proteins of the CC2A receptor in an 
“unnatural” environment. Milligan et al. have recently reported the 
transfection of the OC2A receptor clone (OC2-C10) into the Rat 1 fibroblast 
cell line (Milligan et al. 1991). Briefly, they constructed a transfection 
vector which contained the entire (X2A genomic DNA sequence together 
with a neomycin resistance gene, and transfected Rat 1 fibroblasts by 
calcium phosphate precipitation. They were then able to select clones which 
had been successfully transfected by growing them in G418 (geneticin 
sulphate)-supplemented medium. One clone, called 1C, was shown to
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express high levels of the 0C2 A receptor, and this clone was used here to 
study the coupling of this receptor to its G-proteins.
The identity of the adrenergic receptor transfected into the 1C clone 
was first confirmed by radioligand binding. It was found that the receptor 
bound pH]-yohimbine with high affinity, and displacement of yohimbine 
binding by oxymetazoline and prazosin suggested that the receptor was, 
indeed, of the 0C2 A subtype. The G-protein complement of clone 1C was 
assessed by immunoblotting membranes with antisera specific for various 
G-protein oc-subunits, and by pertussis and cholera toxin catalysed ADP- 
ribosylation. These data indicated that the 1C clone expressed G il, Gi2,
Gi3, and Gs. Coupling of the 0C2 A receptor to G-proteins in membranes 
from clone 1C was assessed by agonist-stimulated GTPase measurement. 
The 0C2-adrenergic agonist UK14,304 was shown to stimulate a high affinity 
GTPase activity in membranes from clone 1C which was sensitive to both 
yohimbine and pertussis toxin. It was shown that preincubation of 
membranes from clone 1C with antisera raised against the C-terminal 
sequences of G il, Gi2, and Gi3 caused a reduction of the UK14,304- 
stimulated GTPase activity. Finally it was shown that preincubation with 
antiserum AS7, which recognises Gil and Gi2, completely abolished the 
UK14,304 inhibition of forskolin stimulated adenylyl cyclase activity of 
membranes from clone 1C. The implications of these results will be 
discussed.
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RESULTS
1. THE ADRENERGIC RECEPTOR EXPRESSED IN CLONE 1C 
CELLS
The generation of the 1C clone has been described by Milligan and 
coworkers (Milligan et al. 1991). Radioligand binding with the CC2 - 
adrenergic ligand pH]-yohimbine (Daiguji et al. 1980) established that 
membranes from 1C cells bound pH]-yohimbine rapidly at 30°C, with 
equilibrium being attained after 10 minutes (Figure 4.1). Non-specific 
binding was assessed by co-incubation with the (X2 -adrenergic antagonist 
idazoxan (IOOjjM). This reached equilibrium within 1 minute (results not 
shown). Specific binding was linear over a range of 1C membrane 
concentrations from 10-150jig protein (Figure 4.2). Subsequent radioligand 
binding experiments were performed at 30°C for 30 minutes using 20-50jig 
protein.
Saturation binding isotherms indicated that, in the presence of 20mM 
Mg2+, pH]-yohimbine bound to a single site with high affinity (Figure 
4.3a). Scatchard transformation of these results (Figure 4.3b) suggested a 
Kd of 1.0(± 0.2) nM, and a Bmax of 3152 (± 310) fmoles/mg membrane 
protein (means ± SEM, n=4). Non-specific binding was typically 8-15% of 
total binding (results not shown).
Characterisation of the adrenergic receptor subtype was on the basis 
of differential affinities for the agonist oxymetazoline, and the antagonist 
prazosin, according to the scheme of Bylund (1988). Displacement of 
specific pH]-yohimbine binding to membranes of clone 1C cells (Figure 
4.4) produced IC50  values of 13.8 (± 5.6) nM and 4.8 (± 1.5) jliM  for 
oxymetazoline and prazosin respectively (means ± SEM, n=3 for both 
dmgs). Estimation of Ki by the method of Cheng and Prussoff (Cheng and
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Prussoff, 1973) gave values of 1.4nM and 0.9pM, respectively. The high 
affinity for oxymetazoline and low affinity for prazosin is typical of the 
0C2A-adrenergic subtype (Murphy and Bylund, 1988). These data confirm 
that the receptor expressed in the 1C clone is equivalent to an oc2A-receptor 
(Milligan et al. 1991).
2. THE G-PROTEIN COMPLEMENT OF CLONE 1C CELLS
Immunoblots of membranes from clone 1C cells with the antisera 
described in Table 1 of Chapter 2 demonstrated the presence of a range of 
G-protein a-subunits (Figure 4.5). Antiserum IIC, raised against a synthetic 
decapeptide representing amino acids 159-168 of G ila  recognised a single 
protein in membranes from clone 1C which comigrated with G ila  from rat 
cerebral cortex. Antiserum SGI, which was raised against the C-terminal 10 
amino acids from the a-subunits of G il and Gi2, demonstrated the presence 
of a single band on a 10% SDS-polyacrylamide gel (Figure 4.5) which 
comigrated with Gi2a from C6BU1 cells. Separation of membranes from 
clone 1C on 12% SDS-PAGE followed by immunoblotting with the 
antiserum AS7, which also recognises the C-terminal sequences of G il and 
Gi2a (Figure 4.7a) demonstrated that the single band recognised by 
antiserum SGI in Figure 4.5 is indeed a composite of the a-subunits of Gil 
and Gi2. Antiserum I3B, which was raised  ^a synthetic peptide 
corresponding to the C-terminal decapeptide of Gi3a, recognised a single 
protein on immunoblots of clone 1C membranes, which comigrated with 
Gi3a from rat C6BU1 cells (Figure 4.5). Antiserum IM1, which was raised 
against a synthetic peptide representing amino-acids 22-35 of Goa, 
recognised Goa from rat brain, but failed to detect any such protein in
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membranes from clone 1C. Antiserum CS1 recognised two proteins in 
membranes from clone 1C which comigrated with the two forms of Gsa 
from rat glioma C6BU1 membranes. These immunoblots suggested that 
membranes from clone 1C cells contained the a-subunits of G il, Gi2, Gi3, 
and Gs, but that they lack Goa. Figure 4.6 demonstrates the expression of 
the G-protein p-subunit in membranes from clone 1C cells.
Thiol-activated pertussis toxin-catalysed ADP-ribosylation of 
membranes from clone 1C cells in the presence of [32P]NAD+ followed by 
SDS-PAGE under conditions which allowed resolution of proteins in the 
35-45kDa range, and subsequent autoradiography, showed that pertussis 
toxin incorporated radiolabel into 2 bands (Figure 4.7a). These bands had 
apparent molecular weights of 40 and 41kDa, and were found to comigrate 
with proteins identified on immunoblots as G il, Gi2, and Gi3, the upper of 
the two ADP-ribosylated bands being a composite of Gil and Gi3 (Figure 
4.7a). Pertussis toxin catalysed ADP-ribosylation of membranes from 
NG108-15 and clone 1C cells (Figure 4.7b) showed that pertussis toxin 
failed to incorporate radiolabel in membranes from clone 1C cells into a 
band with apparent molecular weight of 39kDa, which has been shown to 
comigrate with Goa (Chapter 3, Figure 3.3). Hence the pertussis toxin 
substrates in membranes of clone 1C cells appear to be the a-subunits of 
G il, Gi2, and Gi3, while Goa appears to be undetectable by antibodies 
raised against Go, or by pertussis toxin-catalysed ribosylation. Pretreatment 
of clone 1C cells with pertussis toxin in vivo (50ng/ml, 16 hours) 
completely prevented subsequent in vitro pertussis toxin-catalysed 
incorporation of radiolabelled [32P]ADP-ribose (Figure 4.8).
Thiol-activated cholera toxin-catalysed ADP-ribosylation of 
membranes from clone 1C cells in the presence of [32P]NAD+ followed by 
SDS-PAGE under resolving conditions and subsequent autoradiography 
revealed that cholera toxin incorporated radioactivity into two bands of
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apparent molecular weight 42 and 44kDa. These bands comigrated with two 
proteins recognised on immunoblots by the antiserum CS1, raised against 
Gsa (Figure 4.9). Hence the cholera toxin substrates of membranes from 
clone 1C cells are two forms of Gsa.
As was described in Chapter 3, uncoupling experiments designed to 
investigate the identity of G-proteins coupling to the adrenergic receptor in 
clone 1C cells required the use of anti-G-protein antisera which had been 
protein-A purified to remove plasma proteins which might otherwise 
interfere with the action of the antisera. It was therefore necessary to 
demonstrate that protein-A purified antisera showed the same G-protein 
specificity as crude antisera. Figure 4.10 shows that the antisera AS7, CS1, 
and I3B when purified on protein-A sepharose, recognised the same G- 
protein a-subunits as crude antisera.
3. UNCOUPLING OF THE GTPASE ACTIVITY IN CLONE 1C 
CELLS
The a 2 -adrenergic agonist UK14,304 stimulated a high affinity 
GTPase activity at 37°C in membranes from clone 1C cells, with an EC50  
o f ^ . O  ±10.0nM (mean ±SEM, n=3) (Figure 4.11). This GTPase response 
was sensitive to the a 2 -adrenergic antagonist yohimbine (Figure 4.12), 
which inhibited the response with Ki=1.2 ±0.4nM (mean ±SEM, n=3). This 
high affinity GTPase response was also completely abolished by 
pretreatment of clone 1C cells with pertussis toxin (50ng/ml for 16 hours) 
(see Figure 4.19). Basal and UK14,304 (IOjiM) stimulated GTPase
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responses were found to be essentially linear over a range of clone 1C 
membrane concentrations from 2-10jig membrane protein (Figure 4.13).
In order to examine the identity of the G-protein(s) responsible for 
transducing this GTPase effect, a method similar to that outlined in Chapter 
3 was utilised, whereby membranes from clone 1C cells were incubated 
with anti-G-protein antisera for 60 minutes at 37°C, and then assayed for 
lOpM UK14,304 stimulated GTPase activity. The period of 60 minutes 
preincubation time has previously been shown to maximise the effects of 
added antisera (McKenzie and Milligan, 1990). It was first necessary to 
establish the effects of a 60 minute preincubation period at 37°C on the 
UK14,304 stimulated GTPase activity per se. Figure 4.14 shows that 
preincubation of membranes from clone 1C cells for various times at 37°C 
resulted in a reduction of lOpM UK14,304 stimulated GTPase activity. By 
60 minutes, there was a reduction in UK14,304 stimulated GTPase activity 
of -50%, with a similar reduction in basal GTPase activity also being 
observed (Figure 4.14).
Preincubation of membranes from clone 1C cells (5 jig) for 60 
minutes at 37°C with 10jig of protein-A purified antisera raised against the 
a-subunits of Gs (antiserum CS1), Go (antiserum OC1), Gil+Gi2 
(antiserum AS7) and Gi3 (antiserum I3B), resulted in a statistically 
significant reduction of lOjiM UK14,304 stimulated GTPase activity in the 
cases of AS7 and I3B (PcO.001, Student’s t-test). There was no such 
reduction in GTPase activity in the cases of antisera OC1 or CS1, and 
preincubation of clone 1C membranes with an IgG fraction from normal 
rabbit serum showed that antibody incubation per se did not affect basal or 
agonist stimulated GTPase activity (Figure 4.15). These results implied that 
antiserum AS7, which recognises Gil and Gi2,and antiserum I3B, which 
recognises Gi3, were inhibiting the the CC2A receptor-mediated UK14,304 
GTPase stimulation in clone 1C membranes by preventing the interaction of
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the C-termini of these G-proteins with the receptor, and therefore that Gil, 
Gi2, and Gi3 are all involved in coupling to this receptor.
Incubation of 5jig of clone 1C membranes with increasing 
concentrations of protein-A purified AS7 (Figure 4.16) or I3B (Figure 
4.17) showed that maximum inhibition of IOjiM UK14,304 stimulated 
GTPase occurred at around lOjig of antiserum per sample. This maximum 
inhibition was 35-40% for both antibodies, and did not increase at antibody 
concentrations up to lOOjig per sample (results not shown). Co-incubation 
of membranes from clone 1C cells with antisera AS7 and I3B caused a 
statistically significant greater reduction than incubation with antiserum 
AS7 or I3B alone, up to a maximum of 70-75% inhibition (Figure 4.18; 
PcO.OOl, Student’s t-test, comparing AS7+I3B with AS7 or I3B alone). In 
no case was complete abolition of the IOjiM UK14,304 stimulated GTPase 
observed, the stimulated GTPase response in the presence of antisera AS7 
and I3B together always being significantly greater than basal values 
(PcO.OOl, Student’s t-test, comparing AS7+I3B to basal). These results 
suggest that, while antisera AS7 and I3B are capable of substantially 
attenuating the (X2A-receptor mediated UK14,304 GTPase response in clone 
1C membranes, they are not capable of completely attenuating this response, 
and that some other G-protein may be involved in transducing a part of this 
GTPase response.
Pretreatment of clone 1C cells with pertussis toxin (50ng/ml for 16 
hours) resulted in complete abolition of the IOjiM UK14,304 stimulated 
GTPase response in membranes from pertussis toxin treated cells (Figure 
4.19). Hence any G-protein transducing this GTPase response other than 
G il, Gi2 or Gi3, must also be a substrate for pertussis toxin-catalysed ADP- 
ribosylation.
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4. UNCOUPLING OF ADENYLYL CYCLASE INHIBITION IN 
CLONE 1C CELLS
It has been shown that the (X2A receptor in the human platelet is 
coupled to inhibition of adenylyl cyclase, and that preincubation of platelet 
membranes with antiserum AS7, which recognises Gi2 only in the platelet, 
completely abolishes this inhibition (Simonds et al. 1989a). It was clearly of 
interest to examine the (X2A receptor expressed in clone 1C cells for any 
similar inhibition, and to determine whether Gi2 was also responsible for 
coupling this receptor to adenylyl cyclase. Figure 4.20 shows that forskolin 
(InM-lOOjiM) stimulated an adenylyl cyclase activity in membranes from 
clone 1C cells. This cyclase activity was inhibited by coincubation with the 
0C2 -adrenergic agonist UK14,304 (Figure 4.21), with maximal inhibition 
being 40% at a UK14,304 concentration of IOjiM. Pretreatment of clone 1C 
cells with pertussis toxin (50ng/ml for 16 hours) completely abolished the 
10|lM UK14,304 inhibition of IOjiM forskolin stimulated adenylyl cyclase 
activity (Figure 4.22).Thus, the OC2A receptor in clone 1C cells, like that in 
human platelets, couples to inhibition of forskolin stimulated adenylyl 
cyclase in a pertussis toxin-sensitive manner.
In order to determine which G-protein(s) were responsible for 
transducing this inhibition of stimulated adenylyl cyclase, the method of 
preincubation with anti-G-protein antisera was used, in a manner similar to 
that used earlier to examine the UK14,304 stimulated GTPase effect. Again, 
it was necessary first to establish the effect of a 60 minute preincubation 
period on adenylyl cyclase activity in membranes from clone 1C cells 
(Figure 4.23). Preincubation of clone 1C membranes at 37°C for periods up 
to 60 minutes resulted in reductions of basal, IOjiM forskolin stimulated 
adenylyl cyclase activity, and lOpM UK14,304 inhibition of forskolin
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stimulated activity (Figure 4.23). Mean percent inhibition remained constant 
throughout the preincubation, at 37.3 (±5.3)% (mean ±SEM, n=3).
Preincubation of membranes from clone 1C cells with protein-A 
purified IgG from normal rabbit serum, or with antisera against the C- 
terminal sequences of Gs (antiserum CS1), or Gi3 (antiserum I3B) did not 
cause any reduction in IOjiM UK14,304 inhibition of IOjiM forskolin 
stimulated adenylyl cyclase activity (Figure 4.24). However preincubation 
with protein-A purified antiserum AS7, which in clone 1C cells recognises 
G il and Gi2, caused complete abolition of the UK14,304 inhibition of 
forskolin stimulated adenylyl cyclase activity (Figure 4.24). These results 
suggest that the 0C2A receptor expressed in clone 1C cells , like that 
expressed in the human platelet, is coupled to inhibition of adenylyl cyclase 
activity via Gi2 and/or Gil.
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Figure 4.1
T im e  co urse  of associatio n  o f  f3Hl- y o h im b in e  spec ific
BINDTNO TO MEMBRANES FROM CLONE 1C CELLS
Specific pH]-yohimbine (lOnM) binding to membranes (50jig) of 
clone 1C cells at 30°C was assessed at the time points shown. Non-specific 
binding was defined by parallel incubation with idazoxan (lOOpM). Points 
shown are mean (± SD) of triplicate determinations from a single 
experiment, which was repeated twice using different clone 1C membrane 
preparations, with similar results being obtained.
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Figure 4.2
Spe c ific  binding  o f r3Hi-y o h im b in e  to  in c r ea sin g
AMOUNTS OF MEMBRANES FROM CLONE 1C CELLS
Specific pH]-yohimbine (lOnM) binding to increasing amounts of 
membranes of clone 1C cells at 30°C was assessed as shown. Non-specific 
binding was defined by parallel incubation with idazoxan (lOOpM). Points 
shown are mean (± SD) of triplicate determinations from a single 
experiment, which was repeated twice using different clone 1C membrane 
preparations, with similar results being obtained.
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Figure 4.3a
SPECIFIC BINDING OF INCREASING CONCENTRATIONS OF T3H1- 
YOHIMBTNE TO MEMBRANES FROM CLONE 1C CELLS
Membranes (17pg) of clone 1C cells were incubated for 30 minutes 
at 30°C with various concentrations of [3H]-yohimbine as shown. Non­
specific binding was determined in the presence of lOOpM idazoxan, and 
increased in a linear fashion over the range of pH]-yohimbine 
concentrations, being 8-15% of total binding (not shown). Points shown 
are means (± SEM) from 4 separate experiments using different 
membrane preparations.
Figure 4.3b
SCATCHARD TRANSFORMATION
Data from Figure 4.3a have been transformed by the method of 
Scatchard (Scatchard, 1949). Results suggested a Kd of 1.0 (±0.2) nM 
(mean ± SEM, n=4), and a mean Bmax of 3152 (±310) fmoles/mg.
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Figure 4.4
D ispla c em en t  of h h i -y o h im bin e  binding  to  m e m b r a n e s  
fr o m  Cl o n e  1C cells by  o xym etazo lin e  and pr a zo sin
Displacement of [3H]-yohimbine (5nM) to membranes (50jig) of 
clone 1C cells by prazosin (□) and oxymetazoline (♦ ) was assessed at 
30°C for 30 minutes. Points shown are means of triplicate determinations 
(SD has been omitted for clarity, but was less than 10% of the mean in 
each case) from a single experiment which was repeated three times using 
different membrane preparations. For this experiment, IC50  for 
oxymetazoline was 31.0 nM, and for prazosin, 5.0 pM. 100% specific 
pH]-yohimbine binding was 2830 (±211) fmoles/mg for prazosin, and 
2894 (±187) fmoles/mg for oxymetazoline.
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Figure 4.5
IMMIJNOBLOT ANALYSTS OF MEMBRANES FROM CLONE 1 C
CELLS
Membranes from clone 1C cells were separated on SDS-PAGE as 
described in Chapter 2, and western blotted onto nitrocellulose sheets. 
Western blots were incubated with anti-G-protein antisera as described in 
Chapter 2. Samples were incubated with 1:200 dilutions of:
A: antiserum IIC (1; 25 jig rat cerebral cortex membranes, 2; 50 jig 
clone 1C membranes)
B: antiserum SGI (1; 25jig rat glioma C6BU1 membranes, 2; 50 jig clone
1C membranes)
C: antiserum I3B (1; 25jig rat glioma C6BU1 membranes, 2; 50 jig clone
1C membranes)
D: antiserum IM1 (1; 10 pg rat cerebral cortex membranes, 2; 50 jig 
clone 1 C membranes).
E: antiserum CS1 (1; 25jig rat glioma C6BU1 membranes, 2; 50 jig clone
1C membranes)
Primary antisera were detected by incubation with a donkey-anti- 
rabbit horseradish peroxidase-linked second antiserum, as detailed in 
Chapter 2. The substrate for the enzyme was o-dianisidine.
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Figure 4.6
IMMUNOBLOT DETECTION OF P-SIJBIJNIT IN MEMBRANES FROM 
CLONE 1C CELLS.
Membranes from clone 1C cells (lOOjig) were separated on SDS- 
PAGE and western blotted onto nitrocellulose as described in Chapter 2. 
Western blots were then incubated with a 1:200 dilution of antiserum 
BN1, which detects the G-protein p-subunit. Blots were developed as 
described in the legend to Figure 4.5. Lanes are:
A: molecular weight standards
B. clone 1C membranes (lOOjig)
C. rat brain membranes (100 jig)
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Figure 4.7a
PERTUSSIS TOXIN SUBSTRATES IN MEMBRANES FROM CLONE 1C 
CELLS
Membranes from clone 1C cells (50pg) were ADP-ribosylated by 
thiol-activated pertussis toxin for 90 minutes at 37°C,using [32P]NAD+ as 
substrate, as detailed in Chapter 2. ADP-ribosylated membranes were 
separated on SDS-PAGE, and western blotted onto nitrocellulose. The 
nitrocellulose was immunoblotted with a 1 :2 0 0  dilution of antisera, as 
indicated below. The immunoblot was developed, dried and subsequently 
autoradiographed, as described in Chapter 2. Lanes A-C show the region 
of the immunoblots encompassing proteins of the 35-45kDa range.
Lane A was immunoblotted with antiserum I3B, which recognises 
the a-subunit of Gi3.
Lane B was immunoblotted with antisemm AS7, which recognises 
the a-subunits of Gi2 and G il.
Lane C was immunoblotted with antisemm IIC, which 
recognises the a-subunit of G il.
Lane D shows an autoradiograph of the region of the immunoblot 
encompassing proteins of the 35-45kDa range.
None of the proteins identified incorporated radioactivity in the 
absence of activated pertussis toxin.
Figure 4.7a
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Figure 4.7b
PERTUSSIS TOXIN SUBSTRATES IN MEMBRANES FROM CLONE 1C 
'CELLS AND NG108-15 CELLS
Membranes from clone 1C cells (50jig) and NG108-15 cells (50jig) 
were ADP-ribosylated by thiol-activated pertussis toxin for 90 minutes at 
37°C, using [32P]NAD+ as substrate, as detailed in Chapter 2. Ribosylated 
membranes were separated on SDS-PAGE, followed by drying of the gel, 
and subsequent autoradiography. This figure shows an autoradiograph of 
the region of the gel encompassing proteins of the 35-45kDa range.
Lane A: NG108-15 membranes (50jig)
Lane B: Clone 1C membranes (50pg)
None of the proteins identified incorporated radioactivity in the 
absence of activated pertussis toxin.
Figure 4.7b
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Figure 4.8
Per t u ssis  toxtn su b st r a t e s  in  m em br a n es  fro m
PERTUSSIS TOXIN PRETREATED CLONE 1C CELLS
Clone 1C cells were grown in the presence of pertussis toxin 
(50ng/ml) for 16 hours, and membranes prepared as described in Chapter 
2. Membranes from control and perussis toxin-pretreated clone 1C cells 
(50pg) were ADP-ribosylated by thiol-activated pertussis toxin for 90 
minutes at 37°C, using [32P]NAD+ as substrate, as detailed in Chapter 2. 
Ribosylated membranes were separated on SDS-PAGE, followed by 
drying of the gel, and subsequent autoradiography. This figure shows an 
autoradiograph of the region of the gel encompassing proteins of the 35- 
45kDa range.
Lane 1: Membranes (50pg) from untreated clone 1C cells 
Lane 2: Membranes (50pg) from pertussis toxin-treated clone 1C 
cells
None of the proteins identified incorporated radioactivity in the 
absence of activated pertussis toxin.
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Figure 4.9
C h o lera  t o x in  substrates  tn  m em branes fro m  clo ne  1C
CELLS.
Membranes from clone 1C cells (50pg) were ADP-ribosylated by 
thiol-activated cholera toxin for 90 minutes at 37°C, using [32P]NAD+ as 
substrate, as detailed in Chapter 2. ADP-ribosylated membranes were 
separated on SDS-PAGE, and western blotted onto nitrocellulose. The 
nitrocellulose was incubated with a 1:200 dilution of antiserum CS1, 
which detects the a-subunit of Gs, as described in Chapter 2. The 
immunoblot was developed, as described in the legend to Figure 4.5, 
dried and subsequently autoradiographed. This figure shows:
Lane A: an autoradiograph of the region of the immunoblot 
encompassing proteins of the 35-55kDa range.
Lane B: the region of the immunoblot encompassing 
proteins of the 35-55kDa range.
None of the proteins identified incorporated radioactivity in the absence 
of activated cholera toxin.
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F igure 4.10
Spe c ific it y  of  pr o t e in -a  pu r ifie d  antisera
Protein-A purified antisera were prepared as detailed in Chapter 2, 
and used at a dilution of 1:200 in 1% gelatin in TBS. Crude antisera were 
used as described in the legend to Figure 1. Membranes from clone 1C 
cells (50, and 100jig) were separated on SDS-PAGE and western blotted 
as described in Chapter 2. Western blots were incubated with crude and 
protein-A purified antisera as illustrated. Blots were developed as 
described in the legend to Figure 4.5.
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Figure 4.11
UK14.304 STIMULATED HIGH AFFINITY GTPASE ACTIVITY IN 
MEMBRANES FROM CLONE 1C CELLS
Membranes from clone 1C (lOpg/sample) were assessed for high 
affinity GTPase activity for 20 minutes at 37°C as described in Chapter 2. 
Points are mean (+SEM) of three separate experiments using different 
clone 1C membrane preparations. EC5o=2£0.0 (±W-&) nM.
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Figure 4.12
YOHIMBINE SENSITIVITY OF UK14.304 STIMULATED GTPASE 
ACTIVITY IN MEMBRANES FROM CLONE 1C CELLS
Membranes (lOjig/sample) from clone 1C cells were incubated with 
yohimbine (0.1-50jiM) before assessment of lOpM UK14,304 stimulation 
of GTPase activity at 37°C for 20 minutes, as described in Chapter 2. 
Results are mean (±SD) of triplicate determinations from a single 
experiment, which was repeated twice, using different membrane 
preparations, with similar results. For this experiment, IC50  = 150.0 
(±9.3) nM.
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Figure 4.13
UK14.304 STIMULATION OF GTPASE ACTIVITY IN INCREASING 
AMOUNTS OF CLONE 1C MEMBRANES
Membranes from clone 1C cells, at the concentrations shown, were 
assessed for IOjiM UK14,304 stimulation of GTPase activity for 20 
minutes at 37°C, as described in Chapter 2. Results are means of triplicate 
determinations from a single experiment, which was repeated using a 
different membrane preparation, with similar results. SD has been 
omitted for clarity, but was less than 5% of the mean for all points. 
(□)=basal GTPase, (■)=stimulated GTPase, (0)=GTPase increase/ basal.
Figure 4.13
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Figure 4.14
E ffect  of 37&C preincijbatio n  on  UK14.304 s t im u l a t e d  
GTPase  activity  in  m em bra nes  fro m  clone  1C cet,t,s
Membranes from clone 1C cells (lOjig) were incubated at 37°C for 
the times shown before addition of GTPase reaction mixture and 
assessment of lOpM UK14,304 stimulated GTPase activity for 20 minutes 
at 37°C, as described in Chapter 2. Results are means (±SEM) of three 
experiments, performed using different membrane preparations. Data are 
expressed as % of basal (■ ) or of total (ie. basal + UK14,304 stimulated) 
response (□). 100% was 42.3 ± 2.2 pmol/min/mg membrane protein for 
basal GTPase samples, and 87.3 ± 5.6 pmol/min/mg membrane protein 
for total IOjiM UK14,304 stimulated samples (means ±SEM, n=3).
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Figure 4.15
E f f e c t  o f  p r e t n c u b a t io n  w it h  a n t i-G -p r o t e in  a n ttser a
ON U K l4.304 STIMULATED GTPASE IN MEMBRANES FROM 
CLONE 1C CELLS
Membranes from clone 1C cells (5pg/sample) were preincubated 
for 1 hour at 37°C with protein-A purified IgG (lOjig) from normal 
rabbit semm or from anti-G-protein antisera (lOjig) as shown, in GTPase 
assay mix without [y-32P]GTP. After preincubation, [y-32P]GTP and 
lOpM UK14,304 were added and incubation continued for a further 20 
minutes. Points are means (± SEM) from four experiments performed 
using different membrane preparations. Results are expressed as increases 
over basal GTPase. Basal GTPase activity was 20.8 ±4.0 pmoles/ 
minute/mg membrane protein preincubated with H2 O, and 22.3 ±1 .4  
pmoles/minute/mg membrane protein preincubated with IgG (means 
±SEM, n=4). * significantly different from IgG samples, PcO.OOl 
(Student’s t-test).
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Figure 4.16
E f f e c t  o f  p r e in c ijb a t io n  w i t h  in c r e a s in g  
CONCENTRATIONS OF AS7 ON UK14.304 STIMULATED GTPASE 
ACTIVITY IN MEMBRANES FROM CLONE 1C CELLS
Membranes from clone 1C cells (5jig) were preincubated for 1 
hour at 37°C with protein-A purified antiserum AS7 at the concentrations 
shown, before assessment of lOpM UK14,304 stimulated GTPase activity, 
as described in the legend to Figure 4.15. Points are means ± SEM from 
three experiments performed using different membrane preparations. 
100% represented an increase over basal GTPase of 41.2 (±1.7) 
pmoles/min/mg membrane protein.
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Figure 4.17
E f f e c t  o f  p re tn c ijb a t io n  w i t h  in c re a s in g  
CONCENTRATIONS OF I3B ON UK14.304 STIMULATED GTPASE 
ACTIVITY IN MEMBRANES FROM CLONE 1C CELLS
Membranes from clone 1C cells (5jig) were preincubated for 1 
hour at 37°C with protein-A purified antiserum I3B at the concentrations 
shown, before assessment of lOjiM UK14,304 stimulated GTPase activity, 
as described in the legend to Figure 4.15. Points are means ± SEM from 
three experiments performed using different membrane preparations. 
100% represented an increase over basal GTPase of 42.0 (±2.0) 
pmoles/min/mg membrane protein.
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Figure 4.18
E ffect  of c o -incijbatton w it h  AS7 and I3B on  U K 14.304  
STIMULATED GTPASE ACTIVITY IN MEMBRANES FROM CLONE 
1C CELLS
Membranes from clone 1C cells (5jig) were preincubated with 
protein-A purified IgG from normal rabbit serum, or from antiserum 
AS7 and/or antiserum I3B (lOjig), as shown, for 1 hour at 37°C, before 
assessment of lOpM UK14,304 GTPase activity, as described in the legend 
to Figure 4.15. Points are means ± SEM from six experiments, 
performed using different membrane preparations. Results are expressed 
as increases over basal GTPase, which was 24.5 (±3.0) pmoles/minute/mg 
membrane protein. * significantly different from IgG samples, PcO.OOl.
**significantly different from AS7 or 13 B samples alone, PcO.OOl, 
Student’s t-test.
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Figure 4.19
UK14.304 STIMULATED GTPASE ACTIVITY IN MEMBRANES 
FROM PERTIJSSTS TOXIN PRETREATED CLONE 1C CELLS
Membranes (5pg) from control and pertussis toxin (50ng/ml) 
treated clone 1C cells were preincubated for 1 hour at 37°C with protein- 
A purified IgG from normal rabbit serum (lOjig) , or from antiserum 
AS7 (lOjig), before assessment of IO j iM  UK14,304 stimulatedGTPase 
activity, as described in the legend to Figure 4.15. Results are means 
±SEM from three experiments performed on different membrane 
preparations. Results are expressed as increases over basal GTPase, which 
were 25.8 (±2.3) pmol/min/mg membrane protein for control 
membranes, and 13.7 (±1.1) pmol/min/mg membrane protein for 
pertussis toxin treated membranes.
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Figure 4.20
FORSKOLTN STIMULATED ADENYLYL CYCLASE ACTIVITY IN 
MEMBRANES FROM CLONE 1C CELLS
Forskolin stimulated adenylyl cyclase activity in membranes from 
clone 1C cells (5jig) was assayed at 30°C for 15 minutes, as described in 
Chapter 2. Results are mean (±SEM) of three experiments performed on 
different membrane preparations. ECso= 59.2 (±2.0) nM.
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Figure 4.21
UK14.304 INHIBITION OF FORSKOLIN STIMULATED ADENYLYL 
CYCLASE ACTIVITY IN MEMBRANES FROM CLONE 1C CELLS
UK14,304 inhibition of lOjiM forskolin-stimulated adenylyl cyclase 
activity in membranes (5jxg) from clone 1C cells was assayed at 30°C for 
15 minutes, as described in Chapter 2. Results are means (±SEM) from 
three experiments performed using different membrane preparations. 
IC5o=0.12 (±0.1 )jiM.
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Figure 4.22
UK14.304 INHIBITION OF FORSKOLIN STIMULATED ADENYLYL 
CYCLASE ACTIVITY IN MEMBRANES FROM PERTUSSIS TOXIN 
TREATED CLONE 1C CELLS
Membranes (5pg) from clone 1C cells grown in pertussis toxin 
(50ng/ml), or control membranes were assayed for lOpM UK 14,304 
inhibition of lOpM forskolin stimulated adenylyl cyclase activity as 
described in Chapter 2. Results are means ±SEM from three experiments 
performed on different membrane preparations. 1 0 0 % adenylyl cyclase 
activity was 476 (±33) pmoles/minute/mg membrane protein (control 
membranes) and 520 (±55) pmoles/minute/mg membrane protein 
(pertussis toxin treated membranes), ^significantly reduced compared to 
control forskolin stimulated samples, Student’s t-test.
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Figure 4.23
E ffect  of  30&C preincijbatio n  on  u k i  4.304 in h ib it io n  o f
FORSKOLIN STIMULATED ADENYLYL CYCLASE ACTIVITY IN 
MEMBRANES FROM CLONE 1C CELLS
Membranes from clone 1C cells (5jig) were incubated at 30°C for 
the times shown in adenylyl cyclase mixture without added a [32P]ATP. 
After the preincubation, oc[32P]ATP, lOjiM forskolin and 10]iM 
UK14,304 were added, and incubation continued for a further 15 minutes. 
Assay of adenylyl cyclase activity was as described in Chapter 2. Results 
are means of triplicate determinations from a single experiment which 
was repeated twice using different membrane preparations, with similar 
results. SD has been omitted for clarity, but was less than 10% of the 
mean in all cases. Symbols are: basal adenylyl cyclase (□), lOjiM 
forskolin (A), lOjiM UK14,304 (■ ). Mean UK14,304 inhibition over the 
preincubation period was 37.3(±5.3) pmoles/minute/mg membrane 
protein.
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Figure 4.24
Effe c t  of preincijbatio n  w it h  a n t i-G-pr o t e in  antisera
ON UK14.304 INHIBITION OF FORSKOLIN-STIMIJLATED 
ADENYLYL CYCLASE ACTIVITY IN MEMBRANES FROM CLONE 1C 
CELLS
Membranes from clone 1C cells (5jng) were preincubated for 1 
hour at 30°C with protein-A purified anti-G-protein antisera 
(10{ig/sample) in adenylyl cyclase mixture without a [32P]ATP. After 
preincubation, ocp2P]ATP, lOjiM forskolin and lOjiM UK14,304 were 
added, and incubated for a further 15 minutes. Assay of adenylyl cyclase 
activity was as described in Chapter 2. Results are means (±SEM) from 
four experiments performed using different membrane preparations. 
Basal adenylyl cyclase activity was 67.5 (±3.3) pmoles/minute/mg, 
forskolin stimulated activity was 257.3 (±25.2) pmoles/minute/mg (mean 
±SEM). *significantly different from IgG samples, P<0.001 (Student’s t- 
test).
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DISCUSSION
The Rat 1 fibroblast is a clonal cell line which has been shown to 
express receptors for endothelin, bradykinin, and platelet-derived growth 
factor, all coupled to stimulation of phospholipase C (Muldoon et al. 1989; 
Parries et al. 1987). Rat 1 fibroblasts do not appear to express an 0C2 - 
adrenergic receptor in vivo (Milligan et al. 1991). The Rat 1 fibroblast 
clone used in these studies (clone 1C) was transfected with the genomic 
DNA for the human platelet CC2A receptor (clone oc2-C10) by Milligan et 
al. in order to examine the specificity of coupling of this receptor to its 
G-proteins (Milligan etal. 1991).
In their initial report on clone 1C, Milligan et al. measured agonist 
activation of the 0C2A receptor by using a method of [32P]NAD+ dependant 
[32P] ADP-ribosylation of “Gi”, wherein G-proteins which are normally 
pertussis toxin substrates are ADP-ribosylated by cholera toxin. This 
method arose from the observation that, in the absence of added guanine 
nucleotides, cholera toxin could catalyse the ADP-ribosylation of a 40kDa 
protein in a mouse macrophage cell line - ie. that it could ADP-ribosylate 
substrates other than Gsoc (Aksamit et al. 1985). All G-protein oc-subunits 
possess an arginine residue equivalent to that which is the substrate for 
cholera toxin-catalysed ADP-ribosylation, however, in the case of “Gi”- 
like G-proteins (ie. the class of G-proteins which are pertussis toxin 
substrates) it is believed that some conformational change, dependant on 
the presence of guanine nucleotide, hides this residue, making it 
inaccessible to cholera toxin under conventional ADP-ribosylation 
conditions (Milligan, 1988). It has been shown that in the absence of 
guanine nucleotide, and in the presence of agonists which activate the 
receptors coupled to “Gi”-like G-proteins, there is an enhancement of
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cholera toxin-catalysed ADP-ribosylation of these “Gi”-like G-proteins 
(Giershik and Jacobs, 1987; Milligan and McKenzie 1988). The 
explanation of this enhancement of ADP-ribosylation in the presence of an 
agonist was that receptor activation catalysed GDP release in the normal 
manner (see Chapter 1), but that the lack of added guanine nucleotides 
resulted in an a-subunit without any bound guanine nucleotide, thus 
exposing the arginine residue which is the site for cholera toxin action 
(Milligan, 1988).
Milligan et al. used this method to demonstrate that, in the absence 
of guanine nucleotides, and in the presence of lOpM UK14,304, cholera 
toxin catalysed the incorporation of radiolabelled [32P] ADP-ribose into a 
40kDa protein, as well as the 45 and 42kDa forms of Gsa (Milligan et al. 
1991). Using the antisera SGI and I3B, which identify the a-subunits of 
Gil+Gi2, and Gi3, respectively, they found that it was possible to 
immunoprecipitate two radiolabelled proteins in a manner dependant on 
UK14,304 activation of the 0C2A receptor; these proteins were identified as 
Gi2 and Gi3a. It was concluded that the CC2A receptor that had been 
transfected into the Rat 1 fibroblast clone 1C must therefore be coupled to 
Gi2 and Gi3 (Milligan et al. 1991).
The results of Milligan et al. have essentially been confirmed here, 
although the measurement of UK14,304 stimulated high affinity GTPase 
activity allows a more precise quantification of receptor activation than 
does the use of UK14,304 stimulation of cholera toxin p 2P] ADP- 
ribosylation of “Gi”. Furthermore, the GTPase results reported here 
suggest that Gi2 and Gi3 alone do not account for the full extent of (X2A 
receptor-stimulated GTPase activity in clone 1C cells, and that another G- 
protein may therefore be involved in coupling to this receptor.
The identity of the receptor expressed in clone 1C cells was 
confirmed by radioligand binding. [3H]-yohimbine binding suggested the
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presence of a single high affinity binding site in membranes from clone 1C 
cells (Figure 4.3a, 4.3b) with a Kd of InM, and a Bmax of some 
3pmoles/mg membrane protein. The (X2 -receptor subtype was 
characterised by displacing pH]-yohimbine with oxymetazoline and 
prazosin, which allows discrimination of the CC2A and &2B subypes (Bylund 
1988). The Ki values obtained (Figure 4.4) indicated a receptor with high 
affinity for oxymetazoline (Ki=1.4nM) but a substantially lower affinity 
for prazosin (Ki=900nM). These data are characteristic of a receptor of 
the (X2A subtype, and confirm the identity of the receptor transfected into 
this cell line (Milligan et al. 1991).
The G-protein complement of clone 1C cells was assessed by 
immunoblotting membranes from cells with antibodies raised against 
specific G-proteins, as described in Chapter 2 (Figures 4.5, 4.6). The 
presence of three forms of “Gi” was demonstrated by immunoblotting 
membranes from clone 1C cells with the antisera raised against G il, Gi2, 
and Gi3 (Figure 4.5). Antiserum AS7, which was raised against the C- 
terminus of transducina , and which also recognises the C-termini of G ila  
and Gi2a , therefore recognises the a-subunits of both Gil and Gi2  in 
membranes from clone 1C cells. This contrasts with the findings for 
NG108-15 cells (Chapter 3, and McKenzie et al. 1988), where antiserum 
AS7 recognises Gi2a only, as Gil appears not to be expressed in NG108- 
15 cells (McKenzie and Milligan, 1990). The presence of Gil and Gi2 in 
clone 1C cells limits the conclusions that can be drawn from the use of 
antiserum AS7 in “uncoupling” experiments with membranes from these 
cells, however the use of antiserum AS7 cannot be avoided or improved 
upon in these circumstances, because it is the C-teiminus of the G-protein 
a-subunit which is thought to be responsible for coupling to the receptor 
(Chapter 1), and it is this part of Gil and Gi2 which is recognised by 
antiserum AS7.
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The pertussis toxin substrates from membranes of clone 1C cells are 
shown in Figure 4.7a to be G il, Gi2, and Gi3. Go was not detected on 
immunoblots (Figure 4.7a) and comparison of pertussis toxin-catalysed 
[32P]ADP-ribosylated membranes from clone 1C cells with those from 
membranes of NG108-15 cells, which do express Go (Figure 4.7b), also 
failed to detect the a-subunit of Go. These results suggested that, in clone 
1C cells, Go was either expressed at levels not detectable by 
immunoblotting or radiolabelled ADP-ribosylation, or that Go was not 
expressed at all.
It was a notable feature of membranes from clone 1C cells that the 
relative levels of Gil,Gi2 and Gi3, as assessed by immunoblotting, 
appeared to be markedly different (Figure 4 .5 ). Gi2 levels appeared to be 
much higher than those of either Gil or Gi3, and Gil levels appeared to be 
the lowest of the three pertussis toxin substrates. The relative levels of all 
the pertussis toxin substrates were compared with those from NG108-15 
cells both by immunoblotting (results not shown) and by pertussis toxin- 
catalysed [32P]ADP-ribosylation (Figure 4.7b). These data indicated that 
levels of Gi2, in particular, were greater in membranes from clone 1C 
cells than in equivalent amounts of NG108-15 cells. This fact may be of 
importance in the discussion of the relative abilities of anti-G-protein 
antibodies to uncouple adrenergic receptors from functional responses in 
NG108-15 and clone 1C cells (see below).
Immunoblotting with the antisemm CS1, which recognises Gsa, and 
cholera toxin-catalysed [32P] ADP-ribosylation of membranes from clone 
1C cells, both suggested that two forms of Gsa with apparent molecular 
weights of 44 and 42kDa were expressed in clone 1C cells (Figures 4.5, 
4.9). The higher molecular weight form appears to be predominant. As 
with NG108-15 cells, it is not clear which of the four isoforms of Gsa  
known to date are expressed in clone 1C cells (Bray et al. 1986).
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Incubation of membranes from clone 1C cells with the OC2- 
adrenergic full agonist UK14,304 (bromoxidine) resulted in a substantial 
stimulation of high affinity GTPase activity (Figure 4.11). The magnitude 
of this GTPase stimulation (an increase over basal activity of some 60 
pmoles/minute/mg of membrane protein) may be compared with that 
obtained using the 8 -opioid receptor agonist, [D-Ala-D-Leu]enkephalin 
(DADLE), in membranes from NG108-15 cells, where a stimulation over 
basal of approx. 10  pmoles/minute/mg membrane protein was obtained 
(McKenzie et al. 1988). The stimulated GTPase response in the clone 1C is 
therefore of an exceptional size. The magnitude of stimulation appears to 
be related to receptor number; this was discussed in Chapter 3 with 
reference to the adrenergic receptor in NG108-15, where it was observed 
that the OC2A receptor in human platelets mediated a detectable GTPase 
response while the CC2B receptor in NG108-15 cells did not, and it was 
speculated that the difference in receptor number was an important factor. 
Further evidence in favour of this suggestion came from another clone of 
the Rat 1 fibroblast transfected with the oc2-C10 receptor which was 
isolated at the same time as the 1C clone. This clone, called ID, showed 
specific [3H]-yohimbine binding of -810 fmoles/mg membrane protein and 
IOjiM UK14,304 stimulated a high affinity GTPase activity of some 20 
pmoles/minute/mg membrane protein over basal activity (data from 
C.Carr, personal communication). Hence a clone with a lower receptor 
number showed a lesser UK14,304 stimulated GTPase response. While it is 
likely that other factors will play a part in determining the size of a 
GTPase response, such as the levels of expression of the G-proteins 
coupling to these receptors, it seems that the level of receptor number is an 
important factor.
The UK14,304 stimulated GTPase response was sensitive to the 0C2 - 
adrenergic antagonist yohimbine (Figure 4.12), and was completely
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abolished by prior treatment of 1C cells with pertussis toxin (Figure 4.19). 
From these results it can be inferred that the UK14,304 GTPase effect was 
due to activation of an 0C2 -adrenergic receptor (presumably the 0C2A 
receptor), and that this subsequently resulted in a GTPase response via 
activation of a pertussis toxin substrate or substrates.
The identity of the pertussis toxin substrates coupling to the OC2A 
receptor in clone 1 C cells was examined by use of “uncoupling 
experiments”, in which antibodies raised against the C-terminal region of 
the various G-proteins present in clone 1C cells were incubated with 
membranes from these cells and then assayed for UK14,304 stimulated 
GTPase activity. It was reasoned that antibodies which bound to the G- 
protein which normally couples to the <X2A receptor would prevent 
interaction of receptor and G-protein, thus preventing receptor-mediated 
stimulation of high affinity GTPase activity. The C-terminus of the cc- 
subunit has been implicated as the likely site of interaction of the G-protein 
with its receptor (the evidence for this suggestion has been discussed in 
Chapter 1 and Chapter 3), and the functional use of antibodies raised 
against synthetic peptides representing the C-terminus of various G-protein 
a-subunits (as discussed in Chapter 1 and Chapter 3) has been validated in 
a number of different systems (Hamm and Bownds, 1984; Harris-Warrick 
et al. 1988; Simonds et al. 1989a, 1989b; McKenzie and Milligan 1990).
As a prelude to these uncoupling experiments it was necessary to 
establish the effect of the preincubation phase on UK14,304 stimulated 
GTPase activity (Figure 4.14). Preincubation of clone 1C membranes for 
1 hour at 37°C resulted in the loss of -50% of both stimulated and basal 
GTPase activity. This effect has been noted before, (McKenzie et al. 1988) 
and is usually attributed to a gradual uncoupling of the receptor from its 
G-protein during the preincubation phase. Radioligand binding has shown 
that antagonist binding to receptors under these conditions is unchanged,
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yet agonist binding gradually decreases during the preincubation, this 
change in receptor affinity for agonist suggesting uncoupling of the G- 
protein(s) interacting with the receptor (see comments on this phenomenon 
in NG108-15 cells in the Discussion of Chapter 3). Nevertheless, despite 
this loss of receptor-stimulated GTPase response, sufficient activity 
remained to allow assessment of uncoupling in the clone 1C membranes by 
using GTPase activity as the measure of receptor-G-protein coupling.
Preincubation of 5jig of clone 1C membranes for 1 hour with 
protein-A purified IgG from normal rabbit serum or from antisera OC1 
or CS1 (lOpg) did not affect basal or IOjiM UK14,304 stimulated high 
affinity GTPase activity, however preincubation with protein-A purified 
IgG from antisera AS7 or I3B resulted in a statistically significant 
reduction of IOjiM UK14,304 stimulated GTPase activity (Figure 4.15). 
Basal GTPase activity was unaffected by preincubation with antibody AS7 
or I3B (results not shown). The implication of these results is that the 
protein-A purified antisera AS7 (which was raised against the a-subunits 
of Gil and Gi2) and I3B (raised against Gi3oc) had bound to their target a -  
subunits, preventing interaction of these a-subunits with the a 2 A receptor 
in clone 1C membranes. This interference subsequently prevents the 
receptor-mediated stimulation of high affinity GTPase activity, and hence 
it may be concluded that the a 2A receptor in membranes from clone 1C 
cells interacts with G il, Gi2, and Gi3. In order to assess the maximum 
extent of inhibition of UK14,304 stimulated GTPase activity, membranes 
(5jig) from clone 1C cells were incubated with increasing amounts of the 
antisera AS7 and I3B (Figures 4.16 and 4.17). It was found that both 
antisera were maximally effective at concentrations of lOjig per assay. 
Antiserum AS7 appeared to be more potent, since it showed 90% of its 
maximum efficacy at a concentration of 5jig per assay, and it has already 
been suggested that the levels of Gi2 were higher in clone 1C cells than
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those of Gi3 (Figure 4.5 and Figure 4.7b, lane 2). The antiserum I3B was 
less potent than antiserum AS7, becoming maximally effective only at 
concentrations of 10jig per assay (Figure 4.17). Despite this, both antisera 
at 10|ig inhibited IOjiM UK14,304 stimulated GTPase activity in clone 1C 
cells by a similar proportion, and even at antibody concentrations up to 
lOOjig per sample, inhibition by antiserum AS7 or I3B did not exceed 
40%.
These results raise a number of questions of interpretation. Firstly, 
as was mentioned earlier, the use of antiserum AS7 in this context limits 
the conclusions that can be drawn, since this antiserum recognises the C- 
teiminal regions of the a-subunits of both G il and Gi2 (Spiegel, 1990), 
both of which are expressed in clone 1C cells (Figure 4.5). Although both 
immunoblotting and pertussis toxin-catalysed [32P] ADP-ribosylation 
(Figure 4.7a, 4.7b) suggest that the levels of Gil in clone 1C cells are low 
(and substantially lower than those of Gi2) it cannot be assumed from these 
results that G il does not play a role in transducing the a 2 A-receptor- 
mediated high affinity GTPase response observed here. It might be 
supposed that only a G-protein present in high amounts would be capable 
of generating the substantial UK14,304 GTPase response, and indeed Gi2 
is present in high amounts, both relative to G il and Gi3, and also relative 
to Gi2 levels in NG108-15 cells (Figure 4.7b). Despite this, the possibility 
exists that a fraction of this GTPase response is due to G il. However, the 
data of Carty et al. (1990) showed that different G-protein a-subunits have 
different activation kinetics, and that Gi2 in particular bound GTP7S and 
released GDP more rapidly than either Gil or Gi3. As it is the release of 
GDP that is the rate-limiting-step in the GTPase reaction (Ferguson et al. 
1986), this evidence would lend more weight to suggestions that G il, if 
involved at all, plays only a small role in transducing the UK14,304- 
stimulated GTPase effect. The initial study by Milligan et al. on the 1C
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clone showed that agonist-driven cholera toxin [32P]ADP-ribosylation of 
1C membranes (see above) followed by immunoprecipitation with antisera 
AS7 and I3B resulted in precipitation of two bands, which corresponded to 
Gi2 and Gi3 (Milligan et al. 1991). Immunoprecipitation of G il was not 
observed, however the authors were careful not to conclude that Gil was 
therefore not involved in coupling to the 0C2A receptor in clone 1C cells, as 
it was possible that due to the low level of expression of G il, its 
immunoprecipitation might not be detected.
Another problem attendant on the interpretation of the “GTPase 
uncoupling” results is the question of relative levels of antibody required 
to account for all the G-proteins in clone 1C membranes, and whether 
sufficient antibody had been added to abolish completely the lOpM 
UK14,304 stimulated GTPase effect. The data in Figure 4.18 are relevant 
to this point. Co-incubation of membranes from clone 1C cells with 
antisera AS7 and I3B showed that their effects were additive (Figure 
4.18), but complete inhibition of IOjiM UK14,304 stimulated GTPase 
activity was never observed. There always remained a statistically 
significant UK14,304 stimulated GTPase response (in Figure 4.18, Column 
AS7+I3B was significantly different from basal GTPase, PcO.OOl, 
Student’s t-test). There are a number of possible reasons for this. The 
simplest is to suggest that insufficient antibody had been added to the 
reaction to uncouple all the receptors. The 1C clone expresses, as has been 
observed previously, a high number of OC2A receptors, and a high level of 
Gi2. It is difficult using the methods available here, to quantitate the levels 
of antibody necessary to uncouple all the G-proteins from all the 
receptors, except by trial and error, however increasing the antibody 
concentration up to 100jig per sample, and decreasing the 1C membrane 
concentration to 2 jig per sample (the lowest concentration giving linear 
stimulated increases over basal, see Figure 4.13) did not produce any
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greater inhibition of stimulated GTPase, the results being essentially the 
same as those in Figure 4.18 (data not shown). This contrasts with the 
results of uncoupling experiments in membranes from NG108-15 cells, 
where antiserum AS7, at a concentration of lOpg per sample, was able 
completely to uncouple the 0C2B receptor from Gi2 (Chapter 3, Figures 
3.12-3.14), however NG108-15 cells express lower levels of both 0C2B 
receptor and Gi2 (Chapter 3, and Chapter 4 figure 4.7b). It is clear that 
the use of antibodies in uncoupling experiments of this kind has 
limitations, particularly as the antisera used here form only a part of an 
IgG fraction obtained from rabbit , and it is difficult to assess in a 
manner other than the purely qualitative, what proportion of the total IgG 
is the anti-G-protein IgG.
The second possible interpretation of the results indicating an 
incomplete antibody-attenuation of IOjiM UK14,304 stimulated GTPase 
activity is that clone 1C cells express another G-protein besides G il, Gi2, 
and Gi3, which is responsible for transducing a part of the GTPase effect. 
This G-protein would have to be a pertussis toxin substrate, since the 
UK14,304 GTPase stimulation is completely pertussis toxin sensitive 
(Figure 4.19). It would also have to be undetected by any of the antibodies 
so far raised against G-protein a-subunits. Most of the known pertussis 
toxin sensitive G-proteins have had antibodies raised against them, these 
include Tdl, Td2, G il, Gi2, Gi3 and Go (Spiegel, 1990). If another 
pertussis toxin substrate exists in clone 1C cells, then it must be completely 
novel. One thing is clear: this result was not anticipated by the use of 
UK14,304-driven cholera toxin-catalysed [32P]ADP ribosylation of 
pertussis toxin substrates (Milligan et al. 1991), and if another pertussis 
toxin substrate is found in clone 1C cells, then this will be as the result of 
the application of a quantitative assessment of receptor-G-protein coupling, 
rather than a qualitative one.
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The work of Simonds et al. on the coupling to G-proteins of the OC2A 
receptor in the human platelet involved using antibodies raised against 
synthetic decapeptides corresponding to the C-termini of various G- 
proteins in a similar manner to that reported here (Simonds et al. 1989a). 
Platelet membranes were preincubated with the antisera and then assayed 
for noradrenaline inhibition of PGEi-stimulated adenylyl cyclase activity. 
It was found that preincubation with the antiserum AS7 resulted in 
attenuation of the noradrenaline-induced inhibition of PGEi stimulated 
adenylyl cyclase activity, and that this effect was not produced by antisera 
against the other G-proteins detected in platelets. Antiserum AS7 is 
specific for Gi2 alone in platelet membranes, as G il appears not to be 
expressed (Simonds et al. 1989a). From these results, it was concluded that 
Gi2 mediates 0C2 -adrenergic inhibition of adenylyl cyclase in platelet 
membranes.
Hence it seems clear that the 0C2A receptor expressed in vivo 
interacts specifically with Gi2 to inhibit adenylyl cyclase. It was therefore 
of interest to examine the 0C2A receptor expressed in the “unnatural” 
environment of the Rat 1 fibroblast clone 1C for a similar effect. 
Membranes from clone 1C cells were shown to possess a forskolin- 
stimulated adenylyl cyclase activity (Figure 4.20) which could be inhibited 
by the (X2 -adrenergic agonist UK14,304 (Figure 4.21). This a 2 -adrenergic 
inhibition of adenylyl cyclase activity was pertussis toxin sensitive (Figure 
4.22). Preincubation of membranes from clone 1C cells with protein-A 
purified IgG from normal rabbit serum, or from antisera CS1 or I3B 
(which recognise the C-termini of Gs and Gi3, respectively), did not affect 
UK14,304 inhibition of forskolin-stimulated adenylyl cyclase. However 
preincubation with protein-A purified IgG from antiserum AS7 
completely abolished lOpM UK 14,304 inhibition of IOjiM forskolin 
stimulated adenylyl cyclase activity (Figure 4.24). Hence it appears that
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antiseram AS7, which in clone 1C cells recognises the C-termini of both 
Gil and Gi2, completely uncouples the CC2A receptor from inhibition of 
adenylyl cyclase, presumably by binding to Gil and Gi2 and preventing 
their interaction with the receptor.
The caveats that applied to the interpretation of the GTPase 
uncoupling results (above) apply here, ie. that antiserum AS7 recognises 
both G il and Gi2, but the arguments against the role of Gil also apply, 
and it is probably safe to infer that these results suggest that Gi2 in clone 
1C cells is the primary mediator of the oc2A-receptor-induced inhibition of 
adenylyl cyclase activity. Unlike the data obtained for GTPase stimulation, 
these data show that Gi3 has no role in the inhibition of adenylyl cyclase 
activity. In this respect, these results show that the OC2A receptor retains its 
specificity of inhibitory coupling to adenylyl cyclase, since both in vivo, in 
the human platelet (Simonds et al. 1989a), and now in the unnatural 
environment of the rat fibroblast clone 1C, the 0C2A receptor only couples 
to inhibition of adenylyl cyclase via Gi2. As was noted of the CC2B receptor 
in NG108-15, which also couples to inhibition of adenylyl cyclase via Gi2 
(Chapter 3 Discussion), this is a considerable degree of specificity, since 
the amino acid sequences of Gi2 and Gi3 are 90% homologous (Itoh et al. 
1988).
Yet it has also been shown here that Gi3 is activated by the OC2 A 
receptor in clone 1C cells, as an antiserum against the C-terminal region of 
Gi3 attenuates the UK14,304-stimulated high affinity GTPase activity 
(Figure 4.15, Figure 4.17). Simonds et al. did not assess receptor 
stimulated GTPase activity, which would have indicated whether the (X2A 
receptor in the human platelet showed some interaction with Gi3, hence it 
is impossible to state categorically that there has been a loss of specificity 
of G-protein coupling to the OC2A receptor, but their results suggested that, 
despite the presence of Gi3 in platelet membranes, Gi2 alone mediated the
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functional response of the 0C2A receptor. This would imply that there has 
indeed been a loss of specificity of G-protein coupling to the OC2A receptor 
when expressed in the 1C clone. If the process of transfection and 
expression has not modified the receptor structure, how is the OC2 A 
receptor now able to interact with a different G-protein? If there has 
genuinely been a loss of integrity of receptor-G-protein interaction in 
clone 1C cells, then the results reported here might be construed as 
evidence that within the membrane there is some degree of 
compartmentalisation of G-proteins, or that some post-translational 
modification of the various G-proteins plays a role in determining the 
specificity of receptor coupling in vivo. As to the cause of the loss of 
specificity in clone 1C cells, it is possible that the high level of receptor 
expression is important here. It may be speculated that, in vivo, receptors 
are localised to the cell membrane in the presence of a select surrounding 
of G-protein types, thus ensuring that the receptor only interacts with 
particular G-proteins. The over-expression of the CC2A receptor in clone 
1C cells may result in the placing of receptors in “inappropriate” areas, 
where it can now interact with novel G-proteins.
The function of the activated Gi3 in clone 1C cells is also a matter 
for speculation. The results of the adenylyl cyclase uncoupling experiments 
(Figure 4.24) seem quite conclusive: Gi3 does not mediate the interaction 
of the OC2A receptor in clone 1C cells with adenylyl cyclase. However, it 
has recently been shown that UK14,304 stimulates a pertussis toxin 
sensitive phospholipase D activity in clone 1C cells, but not in parental Rat 
1 fibroblasts (E. MacNulty, personal communication). It is tempting to 
speculate that this PLD activity might be transduced by Gi3, but this will 
be difficult to prove until a method of assessing PLD activity in 
membranes or broken cells is obtained, or until a method of introducing 
antibodies into whole cells is obtained.
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Finally, the results obtained from the clone 1C cells suggest that the 
OC2A receptor interacts simultaneously with multiple pertussis toxin 
substrates. This is not the first report of multiple interaction between 
receptor and G-protein. Gierschik et al. noted the interaction of the fMet- 
Leu-Phe receptor in human leukemia HL-60 cells with Gi2 and Gi3 
(Gierschik et al. 1989). By using the method of agonist-driven cholera 
toxin-catalysed [32P] ADP-ribosylation of pertussis toxin substrates 
(Giershik and Jacobs,1987) they were able to demonstrate the 
incorporation of radiolabelled [32P]ADP-ribose into two protein bands, 
and on the basis of relative mobilities on SDS-polyacrylamide gels 
identified them as Gi2 and Gi3. It has already been noted that this method 
suffers from the drawback that the results can only demonstrate 
qualitative, and not quantitative interaction. Hence it is likely that the 
results reported here give the first quantitative assessment of receptor- 
activation of multiple G-proteins.
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The initial observations of the effects of guanine-nucleotides on 
adenylyl cyclase activity were treated in some quarters with skepticism (see 
Gilman, 1989). Nowadays it is accepted, and indeed expected, that most 
receptors will be coupled to intracellular second-message-generating 
systems via the actions of one or more members of the signal-transducing 
class of guanine-nucleotide binding proteins. The scheme of G-protein 
activation proposed by Cassel and Selinger wherein G-proteins are 
activated by binding GTP and inactivated as the result of the intrinsic 
GTPase activity of the G-protein a-subunit (Cassel and Selinger, 1977) has 
been found to be widely applicable. Examination by X-ray crystallography 
of the structures of the p2 1 ras protein and of bacterial elongation factor 
EF-Tu (de Vos et al. 1988; Jumak, 1985) has shown that certain structural 
features are common to most guanine-nucleotide binding proteins, 
particularly with respect to the guanine nucleotide binding domains 
(Halliday, 1984; Masters et al. 1986). The allocation of functions to parts 
of the G-protein molecule is well advanced, with general acceptance for the 
idea that the C-terminus of the a-subunit represents the site of receptor 
interaction (Ui et al 1984; Sullivan et al. 1987), and that the N-terminus of 
the a-subunit represents the site of py-interaction (Navon and Fung, 1987; 
Osawa et al. 1990). The use of molecular biological techniques has allowed 
the isolation of novel G-proteins, including recently the long-awaited 
discovery of a G-protein mediating receptor interaction with phospholipase 
C (Pang and Stemweis, 1990; Taylor et al. 1991). Undoubtedly, more new 
G-protein subunits will be isolated, adding to the already extensive family 
of heterotrimeric signal-transducing G-proteins (see Chapter 1, Table 1.1).
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Increasingly, the focus of research has shifted from examination of 
the structural or functional features of G-protein subunits to addressing 
questions relating to the function of the heterotrimer within the cell 
membrane, ie how it interacts with its receptor, or with its second 
message-generating effector. The work reported in this thesis has attempted 
to address the question of specificity of interaction of G-proteins. Although 
there is a large family of G-proteins, their structures, and in particular the 
sequences of the a-subunits, are all remarkably similar. The degree of 
sequence similarity extends from around 50% (for Gi2a and Gsa) to 82% 
(for Gi2 and Go), to 95% (for G ila  and Gi3a) (Itoh et al. 1988; Van 
Meurs et al. 1987). If the a-subunits are so homologous in sequence, is it 
reasonable to expect any degree of specificity of interaction between G- 
protein a-subunits and receptors, and if such specificity exists, how can it 
be accounted for?
There is a body of conflicting evidence on the question of the 
existence of specificity of interaction between G-protein and receptor. 
Yatani et al. (1988) used purified, recombinant forms of G il, Gi2, and 
Gi3, and found that they were all capable of opening excised atrial K+ 
channels. Moving to the model system under investigation here, namely the 
a 2 -adrenergic receptor system, it was shown that the a 2 -adrenergic 
receptor purified from human platelets, when inserted into phospholipid 
vesicles, was capable of interacting with both Gi and Go, but was much less 
effective in interacting with Gs (Cerione et al. 1986). One interesting 
finding reported by this group was that Gi copurified with the a 2 - 
adrenergic receptor through the initial steps of receptor purification 
(Cerione et al. 1986). More recently the a 2 -C1 0  and a 2 -C4  adrenergic 
receptor clones were overexpressed in COS-7 cells, purified and inserted 
into phospholipid vesicles with recombinant forms of Gs, G il, Gi2, Gi3, 
and Go (Kurose et al. 1991). Again, both the a 2 -receptors were found to
160
Chapter 5
interact with all the “Gi” like G-proteins (order of specificity 
Gi3>Gil>Gi2>Go), but not with Gs. It seems clear from these observations 
that a basic level of specificity of interaction between receptors and G- 
proteins obtains. Receptors may appear to interact with closely related 
members of the G-protein family (such as the different members of the 
“Gi” group of pertussis toxin substrates, or the different forms of Gs), but 
are unlikely also to interact with G-proteins significantly different in 
sequence, hence a receptor which will interact with Gi will not interact 
with Gs, which is much less similar in sequence to Gi.
As was observed by Kurose et al in their discussion, these 
reconstitution experiments demonstrate the potential for interaction of 
adrenergic receptors with multiple G-proteins, however they do not 
exclude the possibility of specific interaction of receptors and G-proteins. 
Indeed, one reconstitution study using the purified dopamine D2  receptor 
from bovine pituitary and resolved G-proteins from bovine brain 
demonstrated that the D2  receptor interacted with a 1 0  fold higher affinity 
with Gi2 than with G il, Gi3, or Go (Senogles et al. 1990). However, it is 
usually studies of receptor-G-protein specificity using native membranes, 
or whole cells, which tend to report a high degree of specificity of 
interaction. McKenzie and Milligan showed that the 8 -opioid receptor in 
the NG108-15 cell line was coupled specifically to inhibition of adenylyl 
cyclase activity via Gi2 (McKenzie and Milligan, 1990). Simonds et al. 
showed that the (X2 -adrenergic receptor in human platelets was coupled to 
inhibition of adenylyl cyclase activity, also via Gi2 alone (Simonds et al. 
1989a). It was also shown by Simonds et al. that Gs alone mediated 
receptor-activated stimulation of adenylyl cyclase in S49 cells (Simonds et 
al. 1989b). The data reported in Chapter 3 suggested that the CC2 B 
adrenergic receptor in the NG108-15 cell line was coupled specifically to 
Gi2, although it was clear that the specificity of this coupling was
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dependant on the differentiation state of the cell, and that the same receptor 
could, under different circumstances, couple to Go (Chapter 3; McClue and 
Milligan 1990).
So there is evidence that specificity of interaction of receptors with 
G-proteins occurs in vivo, even though the potential exists for the 
interaction of some receptors with multiple G-proteins, as demonstrated by 
reconstitution experiments, and by the work reported in Chapter 3 on the 
adrenergic receptor in NG108-15 cells. If it is accepted, then, that 
specificity of interaction does occur, this raises the question of how it 
occurs. This leads us to consider the work reported in Chapter 4. The CC2 A 
receptor in the human platelet has been shown in native membranes to 
couple to inhibition of adenylyl cyclase via Gi2 (Simonds et al 1989a). The 
reconstitution experiments of Cerione et al indicated that the receptor has 
the potential to couple to Gi and Go (Cerione et al. 1986), this finding 
being supported by the results of Kurose et al., which suggested that the 
(X2-C10 receptor could couple to G il, Gi2, Gi3, and Go (Kurose et al. 
1990). It has been shown in Chapter 4 that transfection of this receptor into 
the Rat 1 fibroblast cell line results in the expression of an 0C2A receptor 
which can interact with Gi2 and Gi3, possibly with G il, and possibly with 
another pertussis toxin substrate (Chapter 4, Results). Once again, this 
receptor was able to interact only with G-proteins which have a high 
degree of sequence homology {ie. the members of the class of pertussis 
toxin substrates), but not with G-proteins possessing a substantially 
different sequence {ie. Gs). It was also shown in Chapter 4 that inhibition 
of adenylyl cyclase activity in the 1C clone was mediated solely via Gi2, 
and that Gi3, although activated by the 0C2A receptor, does not participate 
in inhibition of adenylyl cyclase (Chapter 4, Figure 23).
These data, examining the specificity of coupling of the CC2 A receptor 
in the clone 1C cells, indicate a “half-way house” between the results from
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reconstitution experiments, which generally report a low level of receptor- 
G-protein specificity, and the results from native membranes, which tend 
to show a high degree of receptor-G-protein specificity. It is clear that the 
0C2A receptor, when transfected into an unnatural environment, can interact 
with multiple G-proteins, however it is also apparent that the specificity of 
the G-protein coupling to its intracellular effector is tightly maintained. In 
a similar way, the 0C2B receptor in NG108-15 cells can, under different
circumstances, activate both Gi2 and Go, however the activated Gi2 will
h
only interact with adenylyl cyclase, and activated Go only with Ca2+ 
channels (see Discussion in Chapter 3). Does this imply that receptors 
interact with G-proteins with a relatively low degree of specificity, but that 
subsequent G-protein interaction with intracellular second-message 
generators has a high degree of fidelity?
There are some problems with this hypothesis, notably the 
assumption that specific G-proteins interact only with specific intracellular 
effectors. For example, while it has been shown for a number of systems 
that Gi2 is the G-protein responsible for mediating the inhibition of 
adenylyl cyclase (McKenzie and Milligan 1990; Simonds et al. 1989a; 
Chapter 3), it has also been shown that Gi2 is capable of transducing signals 
to other effectors, notably to stimulation of a phospholipase C in the human 
monoblastic U937 cells (F.M.Mitchell, personal communication) and in the 
human leukemia HL-60 cell line (Gierschik et al. 1989). If this is so, then 
the reason for the specificity of Gi2 in each situation cannot lie in its 
primary sequence, ie not in the fact that it is Gi2. This suggests that 
specificity of G-protein interaction has more to do with differential or 
tissue specific expression, or with membrane compartmentation, and that 
particular G-proteins interact with specific receptors and intracellular 
effectors simply because they happen to be the only ones expressed in a 
particular tissue, or because they happen to be the only G-proteins that a
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receptor has access to. This may explain the apparent anomaly of results 
(from native membranes) which suggest specificity of coupling (eg. 
Chapter 3), while other results (including reconstitution experiments, and 
Chapter 4) suggest G-protein promiscuity of interaction.
Evidence for G-protein compartmentalisation is scarce, however one 
group has shown differential localisation of Gi2 and Gi3 in a kidney 
epithelial cell line LLC-PKi (Ercolani et al. 1990). The LLC-PKi cell line
is polarised, ie the cells have a distinct orientation which is required for 
proper functioning. By using anti-G-protein antibodies and 
immunofluorescence it was shown that Gi2 was localised to the basolateral 
membrane of this polar cell line, while Gi3 was localised to the apical 
membrane and the Golgi. Transfection of the LLC-PKI cells with the gene 
for Gi2 resulted in an increase in Gi2 levels, which was still found to be 
localised only to the basolateral membrane. While it is difficult to 
extrapolate these results in a cell line which depends for its function on 
having a “top” and a “bottom” to other cells which are not thus polarised, 
these results do set a precedent, and indicate that the concept of G-protein 
compartmentalisation can be supported by experimental evidence.
Tissue-specific expression of G-proteins has been noticed since the 
beginning of G-protein research (see Chapter 1), and if 
compartmentalisation of G-proteins can be shown to be more widely 
applicable, then it may be possible to explain the specificity of interaction 
of G-proteins with receptors and intracellular effectors as being due to the 
availability to receptors of only certain G-proteins, which, in turn, are able 
to interact only with specific effectors in the locale. The results described 
in Chapter 4 for the interaction of the OC2A adrenergic receptor with G- 
proteins in the 1C clone could than be interpreted in a similar manner. 
While in the human platelet the OC2A receptor may only interact with Gi2, 
on transfection into the Rat 1 fibroblast the receptor is now expressed in
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areas where it has access to Gi3 as well as Gi2. The similarity of sequence 
of the two G-proteins allows the receptor now to interact with Gi3 as well 
as Gi2. In any event, the apparent loss of specificity of G-protein coupling 
to the (X2A receptor in the 1C clone suggests that results arising from the 
use of recombinant G-proteins and transfected receptors to attribute 
receptor-G-protein specificity must be interpreted with caution.
The results of the experiments on adenylyl cyclase activity in the 1C 
clone also deserve some comment (Chapter 4, Figures 4.20-4.24). It is 
interesting to note that, despite the expression of some 3000 fmoles/mg of 
CC2A receptor in the clone 1C cells (as measured by specific [3H]-yohimbine 
binding, Chapter 4 Figure 4.3a), the degree of adenylyl cyclase inhibition 
by UK14,304 is over the range 37-50%, which compares with 0C2B- 
receptor mediated inhibition of adenylyl cyclase activity in NG108-15 cells 
of 35-60% (Sabol and Nirenberg, 1979). These levels of inhibition are not 
dissimilar, despite the findings that NG108-15 cells express the CC2B 
receptor in the much lower range of 100-250 fmoles/mg (as measured by 
specific [3H]-yohimbine binding, Chapter 3 Figure 3.10, and Murphy and 
Bylund, 1988). It may be that the <X2A receptor interacts less efficiently 
with Gi2 to produce inhibition of adenylyl cyclase activity than does the 
0C2B receptor, but this extreme difference in receptor number might still 
have been anticipated to produce a greater degree of cyclase inhibition. 
Although GTPase activity appears to be closely linked to receptor number 
(see Discussions to Chapter 3 and Chapter 4), it would appear that 
inhibition of adenylyl cyclase activity is not. Also, the presence of 
substantially higher levels of Gi2 in clone 1C cells by comparison with 
those in NG108-15 cells (Chapter 4, Figure 4.7b) has not resulted in any 
greater inhibition of adenylyl cyclase activity. It may be that the important 
factor here is the balance in the levels of Gs and Gi2, ensuring that
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adenylyl cyclase inhibition is not more than -40%. What is not clear, 
however, is how a 40% inhibition of stimulated adenylyl cyclase activity 
can affect the cell, and why 100% inhibition of stimulated adenylyl cyclase 
activity is not observed.
One further question remains to be addressed with respect to 
adenylyl cyclase inhibition in the clone 1C cells. Do the results from 
Chapter 4 shed any light on the question of which G-protein subunit, a - or 
(3y-, is responsible for mediating inhibition of adenylyl cyclase activity (see 
Chapter 1 for a discussion of the evidence for and against Py-subunit 
mediated inhibition of adenylyl cyclase)? The use of antibodies directed 
against the a-subunit of Gil/Gi2 alone has been shown to attenuate 
receptor-mediated inhibition of adenylyl cyclase activity in the clone 1C 
cells (Chapter 4, Figure 4.24). Unfortunately, no conclusions can be drawn 
from these results about the moiety responsible for mediating adenylyl 
cyclase inhibition, since prevention of receptor-G-protein contact by the 
antibodies also prevents the subsequent dissociation of the G-protein which 
might give rise to activated Ga or free py, the two species which are 
thought, variously, to be responsible for inhibition of adenylyl cyclase. 
Considering Levitzki’s hypothesis (see Chapter 1) that it is the heterotrimer 
which is the active body in cyclase inhibition (Marbach et al. 1990), once 
again no conclusions may be drawn, since the interference of G-protein 
contact with receptor prevents the stimulation of guanine-nucleotide 
exchange which results in the GTP-bound, activated form of the G-protein 
heterotrimer which is proposed as the transducer of cyclase inhibition. 
However, application of Occam’s Razor would lead one to favour the 
simplest conclusion, ie. that it was, in this system, the a-subunit of Gi2 
which was responsible for mediating inhibition of adenylyl cyclase.
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